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ABSTRACT 
 
Introduction: Defining the neurophysiological features of the peripheral neuropathy 
associated with childhood mitochondrial disease, including the neuropathy/neuronopathy 
associated with Brown-Vialetto-Van Laere syndrome (BVVL), will aid in classifying the 
mitochondrial syndrome, directing genetic testing and instituting therapy.  
 
Methods: Nerve conduction studies and clinical assessments were performed on children 
with nuclear or mitochondrial genome mutations. The clinical and genetic profile, 
neurophysiology, histopathology, audiology and response to riboflavin therapy of nine 
children with BVVL due to RFVT2 deficiency were evaluated.  
 
Results: Peripheral neuropathy was more frequent with nuclear gene mutations. SURF1 was 
associated with a demyelinating neuropathy while PDHc deficiency caused an axonal 
neuropathy. POLG mutations caused a sensory axonal neuropathy. The neuropathy associated 
with mitochondrial disease was not length-dependent. Children with RFVT2 deficiency 
presented with an auditory neuropathy and sensory ataxia, and developed upper limb 
weakness. Nerve excitability studies showed an increase in myelin permeability.  Riboflavin 
therapy caused partial reversal of these changes and improvement in strength, audiology and 
respiratory function.  
 
Conclusions: Nerve conduction studies should be part of the initial assessment of children 
with suspected mitochondrial disease. Clinicians need to be familiar with the unique 
phenotype of RFVT2 deficiency so that affected children are diagnosed early and 
commenced on appropriate therapy.
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This literature review has been modified from a published article (Menezes MP & Ouvrier 
RA, DMCN 2012). It is a comprehensive review of the characteristics of peripheral 
neuropathy in childhood mitochondrial disease. A literature review of Brown-Vialetto-Van 
Laere syndrome, a neurodegenerative syndrome that resembles mitochondrial disease, is 
provided separately in Chapter 2. 
 
INTRODUCTION 
Mitochondria are subcellular organelles whose most important function is oxidative 
phosphorylation for the generation of cellular ATP. This is accomplished through four 
transmembrane respiratory chain complexes that create an electron gradient between them to 
drive the final complex (ATP synthase) to make ATP. The components of the oxidative 
phosphorylation pathway are encoded by mitochondrial DNA (mtDNA) or by nuclear genes, 
and mutations in these genes may result in mitochondrial disease.
1,2
 Mitochondrial respiratory 
chain enzyme disorders have a minimum birth prevalence of 1/7634 live births and the onset 
occurs in childhood in around half of affected individuals.
3
 Because of the varied and 
overlapping clinical features, respiratory chain enzyme analysis on an affected tissue is 
usually used to confirm a biochemical abnormality and direct genetic testing. However, these 
tests are invasive and not always abnormal or diagnostic.
2
 
 
Mitochondrial diseases are often associated with peripheral nerve dysfunction and neuropathy 
in adults with mitochondrial disease has been well described.
4,5
 While mitochondrial diseases 
in children are often associated with, and occasionally present as, a peripheral neuropathy, the 
presence of a neuropathy is frequently under-recognised because of the overwhelming central 
nervous system involvement. Colomer et al. reported a peripheral neuropathy in 37% of 25 
children with mitochondrial disorders.
6
 A peripheral neuropathy occurring as part of the 
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syndrome complex in an individual with a clinical profile, biochemical abnormality or 
genetic mutation suggestive of mitochondrial disease may be broadly classified as a 
mitochondrial neuropathy. Such mitochondrial neuropathies are heterogeneous in their 
clinical, neurophysiological and histopathological characteristics.  This chapter provides a 
comprehensive review of childhood mitochondrial neuropathy. The peripheral neuropathy 
syndromes caused by different nuclear and mitochondrial DNA mutations have been 
classified according to the age of onset and clinical phenotype to provide a diagnostically 
useful guide (Table 1). These childhood mitochondrial neuropathies can also be classified 
according to whether the neuropathy is a predominant part of the presentation (neuropathy, 
ataxia, and retinitis pigmentosa [NARP], ataxia neuropathy spectrum [ANS] , sensory ataxic, 
neuropathy, dysarthria, and ophthalmoparesis [SANDO], mitochondrial neurogastrointestinal 
encephalopathy [MNGIE], Friedreich ataxia, Charcot–Marie–Tooth disease [CMT] 
associated with MFN2 and GDAP1 mutations) or occurs as part of a more complex 
phenotype (mitochondrial depletion syndromes, MTP deficiency, Leigh syndrome, 
leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation 
[LBSL], Kearns–Sayre syndrome, mitochondrial myopathy, encephalopathy, lactic acidosis, 
and stroke-like episodes [MELAS], myoclonic epilepsy with ragged red fibres [MERRF], 
Leber hereditary optic neuropathy). 
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Table 1. Classification of childhood mitochondrial neuropathy 
Mitochondrial syndromes with an onset in infancy or early childhood 
            Mitochondrial depletion syndromes (MDS) 
         Hepatocerebral MDS:  POLG1, PEO1, DGUOK, MPV17 
         Encephalomyopathic MDS:  SUCLA2 
 Complete MTP deficiency: HADHA, HADHB 
 Leigh syndrome:  Various nuclear and mtDNA mutations including SURF1, MTATP6  
                                           and PDHA1 
 NARP:  MT-ATP6 
 LBSL:  DARS2 
 Kearns–Sayre syndrome:  single large mtDNA deletions 
Mitochondrial syndromes with an onset in late childhood 
 MELAS:  various mtDNA mutations, most commonly in MT-TL1 
 MERRF: various mtDNA mutations, most commonly in MT-TK 
 Late-onset syndromes due to POLG1 (ANS, MEMSA, and arPEO) 
 MNGIE:  TYMP 
Mitochondrial optic neuropathies  
 Leber hereditary optic neuropathy:  various mtDNA mutations 
 Dominant optic atrophy:  OPA1 
 Friedreich ataxia:  FXN 
Mitochondrial neuropathies presenting as CMT 
 MFN2, GDAP1 
MDS - mitochondrial depletion syndrome, MTP - mitochondrial trifunctional protein, NARP 
- neuropathy, ataxia, and retinitis pigmentosa, LBSL - leucoencephalopathy with brainstem 
and spinal cord involvement and lactate elevation, MELAS - mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke-like episodes, MERRF - myoclonic epilepsy with 
ragged red fibres, ANS - ataxia neuropathy spectrum, MEMSA - myoclonus, epilepsy 
myopathy, sensory ataxia, arPEO - autosomal recessive progressive external 
ophthalmoplegia, MNGIE - mitochondrial neurogastrointestinal encephalopathy, CMT - 
Charcot–Marie–Tooth disease. 
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Mitochondrial syndromes with an onset in infancy or early childhood 
 
Mitochondrial Depletion Syndromes (MDS) 
Mitochondrial DNA depletion syndromes are disorders of oxidative phosphorylation 
characterised by a reduction in mtDNA copy number in the affected tissues and caused by 
mutations in genes associated with mitochondrial nucleotide metabolism. The early onset 
MDS syndromes may be hepatocerebral (POLG1, PEO1, DGUOK, MPV17) or 
encephalomyopathic (RRM2B, TK2, SUCLA2, SUCLG1).  
 
Hepatocerebral MDS 
Alpers-Huttenlocher syndrome (AHS) is a hepatocerebral mitochondrial DNA depletion 
syndrome, often with an infantile or early childhood onset, characterised by refractory 
seizures, psychomotor delay or regression and progressive liver dysfunction. AHS is most 
commonly caused by recessive POLG1 mutations but mutations in PEO1 have also been 
implicated. When seizures are not a prominent feature and POLG1 and PEO1 sequencing are 
negative, mutations in DGUOK and MPV17 should be looked for.
1
 
 
POLG1 
A peripheral neuropathy is only infrequently described in children with AHS and AHS-like 
syndrome with homozygous or compound heterozygous POLG1 mutations, possibly due to 
overwhelming progressive encephalopathy, hepatic failure and early death.
7-9
 
 
PEO1 
Recessive mutations in PEO1, a gene that codes for mitochondrial Twinkle helicase, result in 
two similar syndromes: an early-onset encephalopathy resembling AHS with symptom onset 
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at around 6 months of age and an infantile-onset spinocerebellar ataxia with symptom onset 
at an average age of 14 months.
10
  Reported with both homozygous and compound 
heterozygous PEO1 mutations, the early onset syndrome is characterised by psychomotor 
regression, truncal hypotonia, growth failure, ophthalmoparesis, epileptic encephalopathy, 
lactic acidosis and elevation of liver transaminases with mtDNA depletion in the brain and 
liver. Affected children have an axonal sensory neuropathy with absent SNAPs on nerve 
conduction studies and loss of large myelinated fibres on sural nerve biopsy.
10,11
 
 
Infantile-onset spinocerebellar ataxia is characterised by ataxia, hypotonia, athetosis, hearing 
loss, ophthalmoplegia and a predominantly sensory axonal neuropathy. The onset of epilepsy 
is usually beyond the second decade of life. Children with infantile-onset spinocerebellar 
ataxia have loss of touch, proprioception and vibration sense with preserved pain and 
temperature responses and may develop distal weakness and pes cavus.
12
 SNAPs usually 
become unrecordable between five and 15 years of age. The motor conduction velocities in 
the lower limbs are normal initially but show a gradual decline in the second decade of life. 
The sural nerve biopsy shows an axonal neuropathy with pronounced loss of large myelinated 
fibres.
13
 MtDNA depletion is limited to the CNS in infantile-onset spinocerebellar ataxia.
14
 In 
both syndromes, difficulties with micturition, urinary incontinence, constipation and dry eyes 
indicate the presence of an autonomic neuropathy.
10,12
 
 
DGUOK 
Children with homozygous or compound heterozygous deoxyguanosine kinase (DGUOK) 
mutations have progressive liver failure and variable neurological involvement. A 
sensorimotor neuropathy was identified in two of nine children in a case series of children 
with DGUOK mutations.
15
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MPV17 
Homozygous or compound heterozygous mutations in MPV17 have been described in 
affected children with an infantile onset of progressive liver failure, ataxia, hypotonia, 
dystonia and psychomotor regression. Also referred to as Navajo neurohepatopathy, the 
syndrome is characterised by a severe sensorimotor neuropathy with severe anaesthesia, 
corneal ulceration, painless fractures, acral mutilation and distal weakness. Nerve conduction 
studies show reduced motor conduction velocities, with ulnar motor nerve conduction 
velocities of 28-36m/s reported in two patients aged 8 and 6 years. Sural nerve biopsies show 
complete loss of myelinated fibres and degeneration and regeneration of unmyelinated fibres. 
MPV17 encodes for a protein of unknown function located on the inner mitochondrial 
membrane.
16-18
  
 
Encephalomyopathic MDS 
SUCLA2 
Succinyl-coenzyme A ligase (SUCL) is a mitochondrial enzyme associated with the Krebs 
cycle that catalyses the conversion of succinyl-CoA to succinate. Patients with recessive 
mutations in SUCLA2 and SUCLG1, encoding the β2 and α subunits of SUCL, have an 
encephalomyopathy and mild methylmalonic aciduria with mitochondrial DNA (mtDNA) 
depletion in muscle and to a lesser extent in the liver.
19
 There are multiple reports of children 
with homozygous or compound heterozygous SUCLA2 mutations, but a peripheral 
neuropathy has been described in only two children from a consanguineous family from the 
Faroe Islands, while other affected individuals in the family had normal nerve conduction 
studies.
20,21
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Complete Mitochondrial Trifunctional Protein (MTP) Deficiency  
MTP is a multienzyme complex bound to the inner mitochondrial membrane that is involved 
in the β-oxidation of long-chain fatty acids. Homozygous or compound heterozygous 
mutations in HADHA or HADHB, encoding the α and β-subunits respectively of the 
Hydroxyacyl-CoA Dehydrogenase/3-Ketoacyl-CoA Thiolase/Enoyl-CoA Hydratase 
(Trifunctional Protein),  have been identified in complete mitochondrial trifunctional protein 
deficiency. Complete MTP deficiency may present in an early-onset rapidly progressive form 
with hypoketotic hypoglycaemia and cardiomyopathy, with high mortality due to metabolic 
decompensation and cardiac failure, or in an insidious neuromyopathic form. In the series 
described by den Boer et al., 11 of 14 children had a peripheral neuropathy at diagnosis.
22
 In 
the later onset neuromyopathic form, the chronic neuropathic weakness often precedes 
episodes of recurrent myoglobinuria and can cause distal weakness, foot deformity and loss 
of ambulation.  Nerve conduction studies reveal an axonal sensorimotor neuropathy.
23
  
 
Leigh Syndrome/ Neurogenic muscle weakness, Ataxia and Retinitis Pigmentosa 
(NARP) 
Leigh syndrome (subacute necrotising encephalopathy) is a clinically and genetically 
heterogeneous group of neurodegenerative disorders that have similar features on central 
nervous system imaging and histopathology. The onset of symptoms is usually in infancy or 
early childhood and children may have progressive psychomotor retardation, hypotonia, 
weakness, ataxia, optic atrophy, ophthalmoplegia, nystagmus, dystonia, evidence of 
brainstem dysfunction and lactic acidosis.
24
 Neuroimaging demonstrates high T2 signal, most 
frequently in the caudate nucleus and putamen, but sometimes involving the thalamus, 
periaqueductal grey matter, tegmentum, red nuclei and dentate nuclei.
25,26
 A large number of 
different mitochondrial and nuclear gene mutations have been reported in Leigh syndrome, of 
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which SURF1 is the most common nuclear gene involved, and MT-ATP6 the most common 
mitochondrial gene.
24
 
 
NARP syndrome is characterised by neuropathy, ataxia with cerebellar atrophy on MRI, and 
pigmentary retinopathy and optic atrophy on ophthalmologic examination. MT-ATP6 is the 
only gene reported to be mutated in this syndrome, with the 8993T>G mutation being the 
most common, though 8993T>C and 9185T>C mutations have also been described.
27
 
 
SURF1 
SURFEIT1 or SURF1 is the most commonly mutated nuclear gene in Leigh syndrome, with 
both homozygous and compound heterozygous mutations being reported.
24
 Two case reports 
of children (16 months and 3 years of age) with Leigh syndrome due to SURF1 mutations 
described a demyelinating neuropathy with motor conduction velocities in the median and 
peroneal nerves of 20-27m/s.
28,29
 Sural nerve biopsy in one child showed reduced myelinated 
fibres with a complete absence of fibres of larger diameter and thin myelin sheaths in the 
remaining fibres. Schwann cell mitochondria were enlarged with rounded cristae.
29
 
 
MT-ATP6 
In a small case series that included both children and adults with MT-ATP6 mutations, the 
median age of onset of symptoms was four to five months for those with a 8993T>G 
mutation compared to four years for the 8993T>C mutation. Around 30% of individuals with 
8993T>G and 8993T>C mutations in MT-ATP6 were found to have a peripheral 
neuropathy.
30
 The peripheral neuropathy presents with ataxia, pes cavus and absent ankle 
jerks. Diminished responses to pinprick and vibration have been described. An axonal 
sensory neuropathy is described in adults with the 8993T>G mutation, but reports with well 
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characterised nerve conduction studies in children with this mutation are lacking, probably 
due to the early onset and prominent central nervous system involvement
31,32
. An axonal 
neuropathy has been reported in children and adults with the 8993T>C and 9185T>C 
mutations. Sural nerve biopsy shows active Wallerian degeneration of both myelinated and 
unmyelinated fibres.
33-36
 Childs et al. described a family with the 9185T>C mutation with 
affected individuals having either an axonal or demyelinating neuropathy, but the nerve 
conduction velocities were not reported.
37
 
 
PDHA1 
The pyruvate dehydrogenase complex (PDHc) is a multi-enzymatic complex with three 
catalytic subunits. PDHc deficiency is most frequently caused by a deficit in the α subunit of 
E1, due to  mutations in the E1 α subunit gene, PDHA1.38 Affected children may present 
acutely with weakness and motor regression. Symptoms and nerve conduction velocities may 
improve after treatment with thiamine in deficiency of the PDHc E1subunit, a thiamine-
pyrophosphate dependent decarboxylase.
39,40
 Seven percent of reported cases with PDHc 
deficiency had an associated peripheral neuropathy.
38
 PDHc deficiency is associated with an 
axonal sensorimotor neuropathy, with normal or mildly reduced motor conduction velocity 
(>= 30m/s), low amplitude or absent SNAPs and evidence of denervation distally on 
electromyography.
40-45
 The sural nerve biopsy usually shows only a mild reduction in 
myelinated fibre density.
42,45
 Di Rocco et al. reported a five-year-old male with more 
significant reduction in motor conduction velocity (19.8m/s in the median nerve) which 
improved to 37.9m/s after treatment with thiamine. 
 
 
                                                                                                                         Literature Review 
 21 
Leukoencephalopathy with Brainstem and Spinal cord involvement and Lactate 
elevation (LBSL) 
LBSL is characterised by a childhood onset of slowly progressive cerebellar ataxia, spasticity 
and dorsal column dysfunction. Mild cognitive decline is seen in some affected individuals. 
The MRI shows signal changes in the cortical white matter and in specific tracts through the 
brainstem and spinal cord. LBSL occurs due to compound heterozygous, and rarely 
homozygous, mutations in DARS2 that encodes mitochondrial aspartyl-tRNA synthetase.
46,47
 
A neuropathy, often subclinical, is associated with LBSL though it may be symptomatic with 
pes cavus and distal weakness. Nerve conduction studies show an axonal neuropathy with 
preserved or mildly reduced SNAPs, reduced CMAPs and preserved or mildly reduced 
conduction velocities with denervation in distal muscles on EMG.
48,49
 Interestingly, 
mutations in genes encoding cytoplasmic aminoacyl-tRNA synthetases have been reported to 
cause CMT, of which only KARS, a lysyl-tRNA synthetase, appears to have an additional 
role in mitochondrial protein translation.
50
 
 
Kearns–Sayre Syndrome (KSS) 
KSS is a multi-system disorder caused by single, large deletions in mtDNA and is associated 
with retinitis pigmentosa and progressive external ophthalmoplegia developing before the age 
of twenty years. In addition, affected individuals have at least one of the following: cardiac 
conduction block, cerebrospinal fluid protein concentration greater than 100 mg/dL or 
cerebellar ataxia. Cognitive impairment, sensorineural deafness, cardiomyopathy, short 
stature, endocrinopathies and dysphagia are associated features.
2
  
 
Reports in adults with KSS document either normal nerve conduction studies or an axonal 
peripheral neuropathy.
51,52
  An axonal sensorimotor peripheral neuropathy has been described 
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in childhood with gait ataxia, glove and stocking paresthesia, distal weakness and areflexia. 
The muscle biopsy may show evidence of denervation with type 2 atrophy, and sural nerve 
biopsy in severe neuropathy shows prominent endoneurial collagen with few remaining 
axons. In sural nerve biopsies in adults, enlarged mitochondria with abnormal cristae may be 
seen on electron microscopy in the Schwann cells as well as in endoneurial capillaries and 
small arterioles of the sural nerves.
53-55
 
 
MITOCHONDRIAL SYNDROMES WITH AN ONSET IN LATE CHILDHOOD 
Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes 
(MELAS) 
While 80% of patients with MELAS have the 3243A>G mutation in the mtDNA MT-TL1 
gene, encoding mitochondrial tRNA for leucine, mutations in several other mitochondrial 
genes have also been described as causing this syndrome characterised by stroke-like 
episodes with seizures, intermittent episodes of encephalopathy, vomiting, migraine like 
headaches, ataxia and cognitive impairment.
2
 Between 22 and 77% of adults with the 
3243A>G mutation have neurophysiological evidence of a peripheral neuropathy which is 
predominantly axonal.
56,57
 Stickler et al. reported that children with MELAS commonly had a 
mixed neuropathy.
58
 
 
Myoclonic Epilepsy and Ragged Red Fibres (MERRF) 
MERRF is caused most commonly by an 8344A>G point mutation in the mtDNA MT-TK 
gene, encoding mitochondrial tRNA for lysine, though mutations in several other 
mitochondrial genes can be associated with this progressive neurodegenerative disorder 
characterised by myoclonic seizures among other seizure types, myopathy with ragged red 
fibres on muscle biopsy, ataxia, optic atrophy, pyramidal signs and hearing loss.
2
 An axonal 
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or mixed neuropathy is most commonly reported in adults.
59
 Erol et al. reported a child with 
the 8344A>G mutation and combined central and peripheral demyelination, with reduced 
motor conduction velocities (31m/s in the peroneal and 41m/s in the median nerves) and 
absent SNAPs.
60
 
 
Late-onset syndromes associated with POLG1 mutations  
Homozygous or compound heterozygous mutations in DNA polymerase-γ (POLG1) have 
been identified as causing varied late-onset disease phenotypes that include: (1) Ataxia 
neuropathy spectrum (ANS) disorders that include the mitochondrial recessive ataxia 
syndrome (MIRAS) and spinocerebellar ataxia and epilepsy (SCAE), (2) Myoclonus, 
epilepsy, myopathy, sensory ataxia (MEMSA) and (3) autosomal recessive progressive 
external ophthalmoplegia (arPEO) that includes the sensory ataxia, neuropathy, dysarthria, 
and ophthalmoparesis (SANDO) syndrome.
61
 POLG1 is required for the genetic stability of 
mtDNA, and its exonuclease domain increases the fidelity of mtDNA replication by 
conferring a proofreading activity on the enzyme.
62
 
 
A peripheral neuropathy is commonly described as a component of the clinical phenotype in 
a number of overlapping syndromes including ANS, MEMSA and arPEO.
61,63-65
 These 
syndromes with predominant ataxia and peripheral neuropathy have an onset in late 
adolescence or adulthood, while those with a prominent encephalopathy or hepatopathy 
usually have a much earlier onset in infancy or early childhood.
61,66,67
 Older children and 
young adults with recessive POLG1 mutations present with deterioration of their gait and 
progressive unsteadiness and demonstrate loss of kinesthetic and vibration sensation, positive 
Romberg sign, ataxia and areflexia on examination, consistent with a sensory ataxic 
neuropathy. Nerve conduction studies show a predominantly sensory axonal neuropathy. 
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Sural nerve biopsy shows loss of large and small myelinated and unmyelinated fibres. Most 
patients have progressive ataxia due to a combination of cerebellar and sensory deficits and 
this results in significant disability and wheelchair dependence.
63,64
 
 
Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE) 
MNGIE is caused by homozygous or compound heterozygous mutations in TYMP encoding 
thymidine phosphorylase and is associated with multiple deletions and depletion of mtDNA 
in skeletal muscle.
68-70
 MNGIE is characterised clinically by severe gastrointestinal 
dysmotility, cachexia, ptosis, ophthalmoparesis, peripheral neuropathy and 
leukoencephalopathy. The thymidine phosphorylase enzyme catabolizes thymidine to 
thymine and 2-deoxy-D-ribose 1-phosphate. In patients with MNGIE, reduced thymidine 
phosphorylase activity alters deoxynucleoside and nucleotide pools and consequently impairs 
mtDNA replication and repair.
71
 Recently, mutations in RRM2B, encoding cytosolic p53-
inducible ribonucleoside reductase small subunit (RIR2B), have been described as causing 
the MNGIE-like phenotype.
72
  
 
The age of onset of symptoms is usually in the 2
nd
 decade of life (median 18.7 years) and 
commonly with gastrointestinal symptoms, though a small number may have a peripheral 
neuropathy as the first symptom. All patients will ultimately develop a peripheral 
neuropathy.
71
 Patients often present with numbness, paresthesiae and a burning pain in their 
feet and toes. Deterioration in gait and hand weakness may also be presenting symptoms or 
develop soon afterwards. Examination reveals distal weakness and atrophy, areflexia and 
sensory loss, including pain and vibration, in a glove-stocking distribution.
71,73-75
. 
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On nerve conduction studies, a demyelinating sensorimotor neuropathy is seen.
73-75
 
Prolongation of F-waves and presence of conduction block may lead to a misdiagnosis of 
chronic inflammatory demyelinating neuropathy.
73,75
 Biopsies from the lumbar and brachial 
plexus show lost or markedly attenuated myelin sheaths with comparatively little axonal loss. 
Sural nerve biopsy shows thin myelin sheaths around axons and axonal loss. While 
ultrastructural mitochondrial abnormalities have not been reported in the peripheral nerve 
biopsy, the cytoplasm of ganglion cells on rectal biopsy may show numerous 
megamitochondria with an expanded matrix and reduced cristae.
74,75
 Sustained biochemical 
and clinical improvement has been described after allogeneic bone marrow transplantation 
for MNGIE.
76
 It is recommended that transplantation be carried out early in the disease 
course where the potential for optimum recovery may be higher.
77
  
 
3. Mitochondrial Optic Neuropathies 
 
3.1. Leber Hereditary Optic Neuropathy (LHON) 
LHON usually has an onset between 15 and 30 years of age and is characterised by bilateral 
acute or subacute visual loss. Ninety-five percent of cases of LHON are caused by the 
3460G>A, 11778G>A and 14484T>C mutations in mtDNA. Cardiac arrhythmias, postural 
tremor, myopathy and movement disorder may be associated.
78
 A peripheral neuropathy with 
mild to moderate reduction of motor conduction velocities may be seen in up to 20% of 
adults with LHON but is often mild or subclinical.
79,80
 
 
3.2. Dominant Optic Atrophy (OPA1 gene) 
Dominant mutations in OPA1, encoding a dynamin-related ATPase, are a common cause of 
autosomal dominant optic atrophy. Affected patients present with visual loss in the first two 
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decades of life, and have abnormalities in colour vision, central or paracentral scotomas and 
optic disc pallor.
78,81
 Yu-Wai-Man et al. reported an axonal sensory and/or motor neuropathy 
in 31 out of 104 individuals with OPA1. In this cohort, one-third of children below 18 years 
of age had evidence of a neuropathy. 
82
 
 
3.3. Friedreich Ataxia  
Friedreich ataxia is caused by hyperexpansion of GAA repeats in the first intron of the FXN 
gene that codes for frataxin, a protein that is a component of iron-sulphur clusters and 
involved in mitochondrial respiratory chain activity.
83
 Friedreich ataxia is characterised by 
ataxia, sensory neuropathy, muscle weakness, scoliosis, hypertrophic cardiomyopathy, optic 
atrophy, sensorineural hearing loss and diabetes.
84
 Though onset is commonly in the second 
decade, onset before the age of 10 years is well described.
85
 Nerve conduction studies reveal 
an axonal sensory neuropathy with severely reduced or absent SNAPs, and sural nerve biopsy 
shows loss of myelinated fibres, particularly those of large diameter. Santoro et al. have 
shown that, on multiple regression analysis, the number and percentage of sural myelinated 
fibres as well as the sural and tibial SAP are significantly related  to the size of the GAA 
repeats but not to disease duration.
86
 
 
4. Mitochondrial neuropathies presenting as Charcot-Marie-Tooth disease (CMT) 
The characteristics of the peripheral nerve disorders associated with abnormalities of genes 
that are known to be important for mitochondrial aggregation provide a framework to 
understand peripheral nerve dysfunction in mitochondrial disease. The coordinated action of 
the mitofusins, mfn1 and mfn2, located on the outer mitochondrial membrane and OPA1, 
located on the inner mitochondrial membrane, is required for mitochondrial fusion.
87,88
 
Dominant mutations in the gene encoding mitofusin 2 (MFN2), a large transmembrane 
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GTPase, are the most common cause of Charcot-Marie-Tooth disease type 2, an axonal 
sensorimotor peripheral neuropathy.
89
 Some individuals with MFN2 mutations have 
associated optic atrophy.
90
 Abnormal small, round and aggregated mitochondria have been 
demonstrated on electron microscopy of sural nerve biopsies of children with MFN2 
mutations.
91
   
 
Mutations in the ganglioside-induced differentiation-associated protein 1 gene (GDAP1) are 
associated with both axonal and demyelinating types of autosomal recessive CMT (CMT4A) 
and are also a rare cause of autosomal dominant axonal CMT (CMT2H/K).
92,93
 GDAP1 is 
located on the outer mitochondrial membrane and expressed by both neurons and myelinating 
Schwann cells. It promotes mitochondrial fission and over-expression results in 
mitochondrial fragmentation. Fibroblasts from patients with GDAP1 mutations show reduced 
complex 1 activity, a fragmented mitochondrial network and abnormally large 
mitochondria.
94
 MFN2 and GDAP1 thus have opposing effects on mitochondria and their 
equilibrium is necessary for normal mitochondrial dynamics.
95
 The clinical features and 
neurophysiological abnormalities associated with these two mutations have been well 
described and will not be repeated here. 
 
CONCLUSION 
Peripheral nervous system involvement has been described in a number of mitochondrial 
syndromes and may be a significant part of the presenting phenotype. However, the clinical, 
neurophysiological and histopathological characteristics of these mitochondrial neuropathies 
are poorly described, often only in the form of individual case reports and occasional children 
in mainly adult cohorts. The quality of the studies in this cohort of children is poor, with level 
3 studies (non-random sample) available for children with IOSCA, MTP deficiency, MT-
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ATP6 mutations, PDHc deficiency, LHON and Friedreich Ataxia, and only case series or case 
reports (level 4 studies) being available for other mutations. Early recognition of the 
associated neuropathy (in NARP, ANS, MNGIE and the optic neuropathies) may help 
identification of the mitochondrial syndrome. The characteristics of the neuropathy may help 
direct genetic testing without the requirement for invasive skin, muscle and liver biopsies in 
mitochondrial syndromes where a common phenotype is caused by different mutations. This 
could be useful in Leigh syndrome, where the common nuclear SURF1 mutation causes a 
demyelinating neuropathy while mtDNA MT-ATP6 mutations cause an axonal neuropathy. 
POLG1 mutations, especially when associated with late-onset phenotypes, cause a 
predominantly sensory neuropathy with prominent ataxia. The identification of the peripheral 
neuropathy also helps target genetic testing in the mitochondrial optic neuropathies. Though 
often subclinical, the peripheral neuropathy associated with mitochondrial disease may 
occasionally be symptomatic and cause significant disability. Recognition of the neuropathy, 
where symptomatic, will help early institution of rehabilitative therapy. I also suggest that 
nerve conduction studies should be a part of the early evaluation of children with suspected 
mitochondrial disease.  
 
This literature review indicates that there is a need for a systematic study investigating the 
characteristics of the peripheral neuropathy in children with different genetic changes causing 
mitochondrial disease, to determine more accurately the different characteristics of the 
peripheral neuropathy associated with each of these genetic changes. This thesis presents the 
results of such a study with data from patients at three tertiary level paediatric hospitals.  
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Hypotheses 
1. The peripheral neuropathies associated with the common genetic causes of childhood 
mitochondrial disease have unique neurophysiological characteristics that help direct 
genetic testing. 
2. Brown-Vialetto-Van Laere syndrome (BVVL) due to RFVT2 deficiency has a unique 
clinical, audiological, neurophysiological and biochemical profile that resembles 
mitochondrial disease and is different from that of RFVT3 deficiency. 
3. Treatment with high-dose riboflavin is effective in stabilising or reversing the 
progress of auditory neuropathy and peripheral neuropathy in Brown-Vialetto-Van 
Laere syndrome due to RFVT2 deficiency. 
 
Structure of this thesis 
Hypothesis 1 
I performed prospective nerve conduction studies and reviewed previously performed nerve 
conduction studies in a total of 26 children with mitochondrial disease with identified nuclear 
or mitochondrial mutations. The results were classified according to the underlying genetic 
cause before assessment. The results of this study are detailed in Chapter 1. 
 
Hypothesis 2 
BVVL is a neurodegenerative syndrome with a motor and sensory neuropathy. The 
introduction to Chapter 2 provides a literature review on BVVL. I studied the clinical 
phenotype, audiology, neurophysiology, biochemical defect and histopathology of 9 children 
from 4 families with BVVL with mutations in SLC52A2. This phenotypic characterisation is 
detailed in Chapter 2, and the audiological profile in Chapter 3. 
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Hypothesis 3 
As SLC52A2 encodes a neuronal riboflavin transporter RFVT2, it has been suggested that 
high-dose riboflavin may be beneficial in BVVL due to RFVT2 deficiency, and there have 
been reports of benefit with riboflavin on short-term follow-up. I treated seven of the affected 
children with high-dose riboflavin over a 2-year period. Clinical, audiological, 
neurophysiological and biochemical assessments were performed at baseline and after 12 and 
24 months of therapy. The neurophysiological assessments included the use of novel nerve 
excitability techniques. The nerve excitability tests at baseline helped understand the 
pathophysiological basis of motor nerve dysfunction in BVVL, and this study, including the 
change after riboflavin therapy, is detailed in Chapter 4. Chapter 5 details the change in 
clinical, audiological and biochemical parameters after therapy, including assessments on the 
validated CMT Pediatric Scale (CMTPedS). 
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Subjects in the mitochondrial neuropathies study were confirmed to have mitochondrial 
disease by the identification of pathogenic nuclear or mitochondrial genome mutations on 
genetic testing or, in the case of pyruvate dehydrogenase complex (PDHc) deficiency, by the 
identification of a biochemical defect on PDHc enzyme assay that was consistent with PDHc 
deficiency. The diagnosis of Brown-Vialetto-Van Laere syndrome due to RFVT2 deficiency 
in the study subjects was confirmed by the identification of homozygous or compound 
heterozygous mutations in the SLC52A2 gene.  
 
All subjects and/or their parental guardian gave informed consent to the study and 
procedures, which were approved by the relevant human research ethics committee. Details 
of specific ethics approvals are noted in the individual chapters. The information sheet and 
consent forms for the neuropathy in children with mitochondrial disease study are available 
in the Appendix. Other consents were taken as part of larger genetic, natural history and 
nerve excitability studies. 
 
NEUROPHYSIOLOGICAL ASSESSMENTS 
Nerve conduction tests  
Nerve conduction tests were performed using a Viking™ On Nicolet™ EDX 
Electrodiagnostic System from CareFusion Nicolet with surface electrodes. Sedation with 
nitrous oxide was used in some children above the age of 12 months. For the motor studies, a 
supramaximal rectangular pulse direct current stimulus was delivered using a two-prong 
stimulator, to elicit a compound muscle action potential (CMAP).  The median nerve was 
stimulated at the wrist and elbow, and the CMAP was recorded over the bulk of the abductor 
pollicis brevis (APB) muscle. The ulnar nerve was stimulated over the wrist and behind the 
elbow, and the CMAP was recorded over the bulk of the abductor digiti minimi (ADM) 
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muscle. The common peroneal nerve was stimulated over the ankle and knee, and the CMAP 
was recorded over the bulk of the extensor digitorum brevis (EDB) muscle. The tibial nerve 
was stimulated over the ankle and behind the knee, and the CMAP was recorded over the 
bulk of the abductor hallucis (AH) muscle. The sweep speed and sensitivities were 5 
ms/division and 5 mV/division respectively. The duration of the stimulus was 0.1ms.  
 
The sensory nerve action potential (SNAP) was recorded by an orthodromic technique for the 
upper limb (median and ulnar) nerves and by an antidromic technique for the lower limb 
(sural) nerve. For the median nerve, the stimulus was delivered by ring electrodes over the 
index finger (digital branch of the median nerve) and SNAPs were recorded over the wrist. 
For the ulnar nerve, the stimulus was delivered by ring electrodes over the little finger (digital 
branch of the ulnar nerve) and SNAPs were recorded over the wrist. For the sural nerve, the 
stimulus was delivered above the lateral malleolus, approximately 14 cm from the proximal 
recording electrode which was placed on the lateral border of the foot. All sensory potentials 
were recorded using a recurrent stimulus and with averaging using a supramaximal stimulus. 
The stimulus duration was 0.1ms and the sweep speed and sensitivities were 1 ms/division 
and 10 µV/division respectively. 
 
The distal motor latencies, CMAP amplitudes and conduction velocities were recorded using 
conventional methods. CMAP and SNAP amplitudes were measured from baseline to the 
negative peak of the action potential. The distal motor latency was calculated from the 
stimulus artefact to the initial negative deflection from the baseline.  
 
Audiological tests 
The methodology of the audiological tests is detailed in Chapter 3. 
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Nerve excitability studies 
The methodology of the nerve excitability studies is detailed in Chapter 4. 
 
CMT PAEDIATRIC SCALE (CMTPedS) 
The Charcot-Marie-Tooth Paediatric Scale (CMTPedS) is a reliable, valid and sensitive 
global measure of function and disability for children with CMT. The CMTPedS was 
developed by Prof Joshua Burns at The Children’s Hospital at Westmead and The University 
of Sydney, Australia, through the Inherited Neuropathies Consortium and has undergone a 
rigorous process of development and validation.
96
 Most forms of CMT have an onset in 
childhood and this scale was devised because of the need for a clinical tool to measure 
impairment in affected children. The scale includes test items relevant to neuropathy and 
disability that are sensitive to change.  
 
The test items in the CMTPedS include 
1. Functional dexterity test 
2. Nine hole peg test 
3. Grip strength 
4. Plantarflexion strength 
5. Dorsiflexion strength 
6. Pinprick 
7. Vibration 
8. Balance: Bruininks-Oseretsky Test of Motor Proficiency, 2nd Ed (BOT-2)  
9. Gait  
10. Long jump  
11. Six-minute walk test 
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The CMTPedS scale has test items that measure function (upper limb - functional dexterity 
test and nine hole peg test; lower limb - balance, gait, long jump and six-minute walk test), 
strength (upper limb – grip strength; lower limb – plantarflexion and dorsiflexion strength) 
and sensation (pinprick and vibration). All items are measured in the dominant limb only, as 
item analysis has shown that left and right paired items are highly correlated. In order to rate 
performance across age and gender, item scores are converted to dimensionless z-scores  
based on age and gender-specific normative reference values. This offsets the improvement 
in strength and function seen with increasing growth and development. Based on z-scores, 
each item is thus scored between 0 and 4. The 11-item CMTPedS total score has a possible 
range of 0 (unaffected) to 44 (severely affected).  
 
CMTPedS equipment and training resource kit is available from a link in the article detailing 
the validation of the CMTPedS scale 
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335189/). An online calculator that 
calculates the individual item z-score, individual item category score and total CMTPedS 
score is available at https://www.cmtpeds.org/. Prior to use in study subjects, I was trained in 
the application of the individual test items by Prof Joshua Burns. Reliability for the test items 
was compared with other trained users and found to be excellent. 
 
The CMTPedS scale has been shown to have excellent inter-rater reliability. Rasch analysis 
has shown that the CMTPedS is a viable global measure of disability in children with CMT.
96
 
Since its validation, the CMTPedS has been used by the Inherited Neuropathies Consortium 
as the primary measure for the measurement of disability in children aged 3-20 years with 
CMT, in natural history studies as well as intervention trials. Analysis of longitudinal data 
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has shown that the CMTPedS is sensitive to change in children with CMT aged 3-20 years 
over a 2-year period.
97
 
 
The CMTPedS scale can be used to (1) measure baseline disability (2) perform longitudinal 
measurements as part of a natural history study or to determine response to an intervention, in 
children with CMT. I have used the CMTPedS to measure baseline disability and response to 
treatment with riboflavin in children with BVVL due to RFVT2 deficiency. The phenotype of 
BVVL due to RFVT2 includes generalised abnormality in sensation, differential motor 
involvement in upper and lower limb strength, and significant functional abnormalities. The 
CMTPedS has items that are able to measure each of these deficits. As discussed in Chapter  
3, the CMTPedS is not currently validated as an outcome measure in BVVL.  
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SECTION I 
 
Peripheral neuropathy associated with 
mitochondrial disease in children 
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Chapter 1 
 
Neurophysiological profile of peripheral 
neuropathy in childhood mitochondrial 
disease 
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INTRODUCTION 
Childhood mitochondrial diseases have a heterogeneous phenotype with many different 
systems being affected including the peripheral nervous system. Around 30% of children 
with a mitochondrial disease have an associated peripheral neuropathy, 
6
 but the neuropathy 
is often unrecognised due to the overwhelming central nervous system manifestations. 
Mutations in nuclear genes responsible for mitochondrial fission, fusion and axonal transport, 
including MFN2 and GDAP1, are recognised causes of Charcot-Marie-Tooth disease 
(CMT).
89,95
 Recently, mutations in MT-ATP6 and SURF1, genes known to cause Leigh 
syndrome and other multisystemic mitochondrial diseases, have been shown to cause 
phenotypes characterised predominantly by a peripheral neuropathy.
98,99
  
 
As evident from the literature review, the neurophysiological characteristics of the associated 
peripheral neuropathy often differ among the various mitochondrial syndromes. Identifying 
the presence of a peripheral neuropathy and defining its characteristics may help with 
classifying the mitochondrial syndrome and targeting genetic testing. The associated 
peripheral neuropathy may be symptomatic and disabling, and specific treatments and 
rehabilitative interventions may be useful.  
 
METHODS 
(a) Children with mitochondrial disease and an identified genetic mutation who had 
previously undergone nerve conduction studies were identified from the mitochondrial 
diseases database at the Murdoch Childrens Research Institute, Melbourne, Australia, the 
records of the Metabolic Diseases Clinic at the Children’s Hospital at Westmead and the 
Neurophysiology Department at the Great Ormond Street Children’s Hospital. The Metabolic 
Diseases Clinic is the primary clinic for children with mitochondrial disease at The 
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Children’s Hospital at Westmead. The Murdoch Childrens Research Institute is the premier 
diagnostic and research institute for mitochondrial disease in Australia, and almost all 
diagnostic testing for mitochondrial disease (muscle enzymology and genetic testing) on 
samples from patients in Australia takes place at this institute. The institute maintains a 
clinical database on samples referred from all over Australia. I was working as an Honorary 
Fellow at the National Hospital for Neurology and Neurosurgery at Queens Square and Great 
Ormond Street Children’s Hospital in 2011-2012 as part of the Churchill Fellowship. The 
Great Ormond Street Children’s Hospital has a clinic and research program for childhood 
mitochondrial disease. The Neurophysiology Department has a database of previously 
performed nerve conduction studies and I compared this database to the patient list from the 
GOSH mitochondrial disease clinic to identify those affected children who had nerve 
conduction studies. 
 
(b) Prospective nerve conduction studies were performed on children from the Metabolic 
Diseases Clinic at the Children’s Hospital at Westmead who had an identified mitochondrial 
mutation and consented to inclusion in the study. Both studies were approved by the Sydney 
Children’s Hospital ethics committee (10/56). 
 
The methodology of the prospective nerve conduction studies is detailed in the Methodology 
section on page 13. Normative data was sourced from Cai et al.
100
  The neuropathy was 
designated as demyelinating when the nerve conduction velocity was reduced to < 70% of the 
lower limit for that age range (lower limit = mean-2SD). The neuropathy was designated as 
axonal when there was a reduction in the CMAP amplitude and there was no reduction in the 
conduction velocity, or the reduction did not satisfy criteria for demyelinating neuropathy. 
Care was taken when the CMAP amplitude was <1mV as it is known that measures of 
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conduction velocity in this setting can be erroneous and appear pseudo-demyelinating due to 
preferential loss of faster conduction fibres. 
 
All prospective nerve conduction studies (designated with P in column 5 of the tables 1.1 – 
1.3 and column 6 for table 1.4) were performed by me according to a previously defined 
protocol (see Methodology section). I also reviewed, tabulated and compared all nerve 
conduction study results with age matched norms. 
 
RESULTS 
Nerve conduction data was available from 27 studies on 26 children with a genetically 
identified mitochondrial disease. This included retrospective nerve conduction study data on 
20 children and prospectively performed nerve conduction studies on seven children. One 
child in the prospective study also had data included from another nerve conduction study 
performed four years prior. The results were classified according to the underlying genetic 
abnormality. 
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PDHC Deficiency 
The pyruvate dehydrogenase complex (PDHc) is a mitochondrial complex that catalyzes the 
rate-limiting step in aerobic glucose oxidation and is made up of three enzymatic subunits, all 
of which are nuclear encoded. Most affected individuals have a mutation in the PDHA1 gene 
on the X-chromosome, encoding the E1 α subunit. Diagnosis is established by showing 
reduced overall PDHc activity or reduced activity of one of its component parts in muscle, 
skin fibroblasts, lymphoblasts or other tissues.
38
  
 
Review of five nerve conduction studies (3 prospective, 2 retrospective) from three children 
with PDHc deficiency showed the presence of a patchy axonal, non-length dependent 
sensorimotor neuropathy. CMAP amplitudes were low in the upper and lower limbs with 
mild or no slowing of the nerve conduction velocity, consistent with axonal loss.  
Sensory responses were universally absent, even in studies done at a young age. There was 
no clear correlation of severity of motor neuropathy with increasing age or disease duration, 
and nerve conduction studies performed 4 years apart in patient 1 did not show a significant 
deterioration. The study in patient 4 was performed 8 weeks into an episode of acute 
weakness.   
 
Previously published reports of children with PDHC deficiency and a neuropathy show a 
predominantly axonal neuropathy with significantly reduced CMAP amplitudes and mildly 
reduced nerve conduction velocities (32-38m/s).
39-43,101
 In these reports, the axonal 
neuropathy was recognised in both those investigated prior to institution of treatment with 
thiamine as well as those on treatment. Only a single individual had a more significant 
reduction of median motor conduction velocity, which improved from 19.8m/s to 37.9m/s 
following treatment with thiamine.
39
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Table 1.1: Neurophysiological profile of children with PDHc deficiency 
Pt./Sex Mutation 
Age at 
presentation 
Possible 
neuropathic 
features 
Age at NCS, 
Retrospective
/Prospective  
Median 
CMAP 
(mV) 
Median 
CV           
(m/s) 
Ulnar 
CMAP 
(mV) 
Ulnar            
CV               
(m/s) 
Peroneal 
CMAP 
(mV) 
Peroneal    
CV                      
(m/s) 
Tibial 
CMAP 
(mV) 
Tibial                  
CV                    
(m/s) 
Median 
SNAP 
(µV) 
Ulnar 
SNAP 
(µV) 
Sural 
SNAP 
(µV) 
1/M c.787C>G 11 m 
mild generalised 
weakness, areflexia, 
acute episodic 
weakness 
1 yr/R 3.7 39 4.0 52 2.1 52 3.9 42 NR NR NR 
5 yrs/P 4.8 52 2.7 58 1.6 52 4.9 47 - NR NR 
6 yrs/P 6.9 50 3.8 55 1.9 47 2.5 37 NR - NR 
2/M NT 5 m - 7 yrs/P 4.9 43 5.4 47 1.9 35 4.4 35 NR NR NR 
3/M NT 3 yrs 
generalised distal 
predominant 
weakness, areflexic 
during acute 
episode 
11 yrs/R                      
(8 weeks into 
acute 
episode) 
0.7 57 5.5 51 NR NR 0.2 36 NR - NR 
 
Abnormal results (< 2SD) in bold. Reference values from Cai et al.
100
 R – retrospective, P – prospective, CMAP – compound muscle action 
potential, CV – conduction velocity, SNAP – sensory nerve action potential, m – months, NR – not recordable, NT – not tested 
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SURF1 
Leigh syndrome is a neurodegenerative condition characterised by progressive psychomotor 
deterioration, characteristic basal ganglia and brainstem changes on neuroimaging or 
neuropathology, and raised CSF or serum lactate. Leigh syndrome can be caused by 
mutations in the nuclear or mitochondrial genomes. The SURF1 (surfeit-1) gene encodes one 
of the assembly factors of COX, the terminal component of the mitochondrial respiratory 
chain, and mutations in SURF1 can cause Leigh syndrome.  
 
I reviewed 11 nerve conduction studies from 10 children with homozygous or compound 
heterozygous SURF1 mutations. All SURF1 mutations identified in my study have been 
previously reported except for the c.792_793delAG mutation seen in patient 13. Seven 
children had a demyelinating sensorimotor neuropathy, while three showed predominantly 
axonal changes with a mild reduction in motor conduction velocity. The cohort had a median 
CV of 28m/s (range 14-43m/s). Unlike typical forms of CMT, the nerve conduction 
abnormalities were not length-dependent. Three children had only motor involvement on 
nerve conduction studies, while both sensory and motor nerves were involved in the rest. 
Ataxia is a prominent feature of children with Leigh syndrome due to SURF1 deficiency, and 
these nerve conduction studies indicate a neuropathic component to the ataxia. 
 
Six of the children described here (patients 5,6,7,8,9,11) were also included in a description 
of 44 individuals with SURF1 mutations by Wedatilake et al.
102
 In that report, 13 of 16 
individuals undergoing nerve conduction studies had a neuropathy, which was demyelinating 
in seven cases.  
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Table 1.2: Neurophysiological profile of children SURF1 mutations 
Pt./     
Sex 
Mutation 
Age at 
presentation 
Possible 
neuropathic 
features 
Age at NCS, 
Retrospective/  
Prospective  
Median 
CMAP 
(mV) 
Median 
CV                
(m/s) 
Ulnar 
CMAP 
(mV) 
Ulnar 
CV 
(m/s) 
Peroneal 
CMAP 
(mV) 
Peroneal                
CV                  
(m/s) 
Tibial 
CMAP 
(mV) 
Tibial 
CV 
(m/s) 
Median 
SNAP 
(µV) 
Ulnar 
SNAP 
(µV) 
Sural 
SNAP 
(µV) 
4/M 
c.312_320del10insAT/                 
c.532_535delAATA 
10 m areflexia 12 m/R - 28.4 - - - - - 22.2 17.1 - NR 
5/M Hz c.516-2A>G 10 m ataxia, tremor 14 m/R - - - - - - 4.1 21 - - 14 
6/M Hz c.324-11T>G 9 m ataxia, hypotonia 18 m/R - - - - - - 1.5 14 - - NR 
7/M 
Hz 
c.312_320del10insAT 
10 m 
ataxia, hypotonia, 
tremor 
18 m/R - - - - - - 4.5 43 - - 3 
8/M Hz c.516-2A>G 4 m ataxia, hypotonia 21 m/R - - - - - - 5.4 35.8 - - 9.2 
9/F Hz c.751C>T 9 m 
ataxia, hypotonia, 
tremor 
2 yrs/R - - - - - - 7.5 22 NR - - 
7 yrs/R 0.6 - 0.6 19.5 - - 4 - NR - NR 
10/M 
Hz 
c.312_320del10insAT 
18 m 
ataxia, tremor, 
areflexia 
2 yrs/R 9.4 36.9 - - - - - - 6.8 - NR 
11/F 
c.240+1G >T, 
c.575G>A 
18 m 
ataxia, hypotonia, 
tremor 
2 yrs/R - - 4.7 43 - - 5.3 26 
23 
(radial) 
- 
21 
(medial 
plantar) 
12/M Hz c.516-2A>G 3 d 
 
4 yrs/R - - 4.9 28 3.5 28 3.9 18 
24 
(radial) 
- NR 
13/F Hz c.792_793delAG 5 yrs 
ataxia, tremor, 
areflexia 
5 yrs/R 5.6 31.9 - - 1.4 31.3 - - 6 7.6 - 
Abnormal results (< 2SD) in bold. Reference values from Cai et al.
100
 R – retrospective, P – prospective, CMAP – compound muscle action 
potential, CV – conduction velocity, SNAP – sensory nerve action potential, Hz – homozygous, m– months, NR – not recordable 
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Echaniz-Laguna and colleagues have reported three individuals from two families presenting 
with a childhood-onset demyelinating sensorimotor neuropathy, initially diagnosed as CMT, 
in whom recessive mutations in SURF1 were identified.
99
 The individuals also had 
nystagmus, hearing loss, lactic acidosis and MRI brain lesions suggestive of Leigh syndrome, 
and developed cerebellar ataxia with disease progression. 
 
POLG1 
DNA polymerase-γ (POLG1) mutations in children have a wide spectrum of onset and 
phenotype, ranging from infantile hepato-encephalopathy [including the Alpers-Huttenlocher 
syndrome and childhood myocerebrohepatopathy (MCHS)], to syndromes with an onset in 
young adulthood including MEMSA (myoclonic epilepsy, myopathy, sensory ataxia), ANS 
(ataxia neuropathy spectrum) and recessive and dominantly inherited PEO (progressive 
external ophthalmoplegia).
61
 In my study, previously performed nerve conduction studies in 
six children with compound heterozygous and homozygous mutations in POLG1 showed a 
severe axonal sensory neuropathy, irrespective of the age at which nerve conduction studies 
were performed. Additional axonal motor involvement was seen in older children. 
 
While hypotonia and areflexia are listed as features of POLG1 mutations in the first year of 
life, there are very few reports of the nerve conduction findings of affected children in this 
age-group. My study included a 2-week old term infant in whom the nerve conduction 
velocities were significantly reduced (8-10m/s). In a cohort of eight children with Alpers 
syndrome, Ferrari et al. reported two infants with neurophysiological or biopsy evidence of a 
demyelinating neuropathy.
9
 One five-month-old had a demyelinating neuropathy with nerve 
conduction velocities of 3.4 – 6m/s, while another had a marked reduction of myelinated 
fibres. 
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Table 1.3: Neurophysiological profile of children with POLG1 mutations 
Pt./     
Sex 
Mutation 
Age at 
presentation 
Possible neuropathic 
features 
Age at NCS, 
Retrospective/
Prospective  
Median 
CMAP 
(mV) 
Median 
CV 
(m/s) 
Ulnar 
CMAP 
(mV) 
Ulnar 
CV 
(m/s) 
Peroneal 
CMAP 
(mV) 
Peroneal 
CV                
(m/s) 
Tibial 
CMAP 
(mV) 
Tibial 
CV 
(m/s) 
Median 
SNAP 
(µV) 
Ulnar 
SNAP 
(µV) 
Sural 
SNAP 
(µV) 
21/M c.1399G>A/c.695G>A 2 weeks - 2 weeks/R - - - 8 - - - 10 - - - 
22/F Hz c.911T>G 4 yrs ataxia, areflexia 10 yrs/R 8.8 56 - - 4.0 49 9.0 47 NR NR NR 
23/F Hz c.1399G>A 7 yrs ataxia, tremor, areflexia 13 yrs/R 10.4 48 - - 2.7 45 - - 20 - 
NR                                                       
NR (sup 
peroneal) 
24/M c.1943C>G/c.926G>A 12 yrs - 16 yrs/R - - - 23 - - NR - NR - - 
25/M c.2551A>G/c.3140G>A 17 yrs - 17 yrs/R - - - 47.8 NR NR - - 6.7 6.1 NR 
26/F Hz c.1399G>A 15 yrs - 19 yrs/R 14.1 46.8 6.1 49.4 3.0 45 2.7 39.3 NR NR 
NR                                                        
NR (sup 
peroneal) 
 
Abnormal results (< 2SD) in bold. Reference values from Cai et al.
100
 R – retrospective, P – prospective, CMAP – compound muscle action 
potential, CV – conduction velocity, SNAP – sensory nerve action potential, Hz – homozygous, m– months, NR – not recordable, sup - 
superficial 
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While a ‘sensory ataxic neuropathy’ almost universally develops in individuals with late-
onset POLG syndromes, its onset is usually in the late second decade or beyond,
103-105
 though 
an earlier onset has rarely been described.
61,63
 Isohanni and colleagues sequenced POLG1 in 
136 children with varying central and peripheral nervous system features and found 
mutations in seven children, all of whom had an encephalopathy.
7
 A peripheral neuropathy 
was not listed as a feature in any of these seven children, though nerve conduction study 
results were not specifically reported as part of this study.  
 
The neuropathy associated with the late-onset POLG1 syndromes is often a severe axonal 
sensory neuropathy, with motor studies varying from normal to showing a motor axonal 
neuropathy predominantly affecting the lower limbs,
104,106
 similar to the findings from the 
children with POLG1 mutations in this study. As suggested by the single neonate in my 
cohort and the previously published by Ferrari et al., very young children with POLG1 
mutations may have a demyelinating neuropathy. 
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Mitochondrial genome mutations 
Neurophysiologic findings in seven children with mutations in the mitochondrial genome 
were evaluated. Three had Leigh/NARP syndrome due to 8993T>C mutation in MT-ATP6, 
two had MELAS due to the 3243A>G mutation in MT-TL1, and two individuals had single 
large mitochondrial deletions. When compared to the prominent nerve conduction study 
abnormalities in children with nuclear mutations affecting mitochondrial function, this group 
of children had normal studies or mild abnormalities, usually in the form of an axonal 
sensorimotor neuropathy.  
 
The 3243A>G mutation in MT-TL1 is the most common cause of MELAS syndrome. 
Between 22 and 77% of individuals with MELAS have a peripheral neuropathy
56,107
 and the 
incidence of a peripheral neuropathy is likely to be lower in children. Out of the nine children 
in the cohort of adults and children with MELAS described by Kaufmann et al., five had 
normal nerve conduction studies while another three had only borderline reductions in 
peroneal CMAP amplitudes.
107
 
 
This study included two siblings with MELAS, and nerve conduction tests in one sibling 
were done when he was admitted with an acute stroke-like episode with acute sensorineural 
hearing loss, ataxia, bilateral intention tremor and reduced reflexes in the lower limbs. Nerve 
conduction studies during that acute episode showed an axonal predominantly motor 
neuropathy. The studies were repeated a year later, when he was well, and showed almost 
complete resolution of neuropathy with only borderline reduction of lower limb motor 
amplitudes. 
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Table 1.4: Neurophysiological profile of children with mitochondrial genome mutations 
Pt./    
Sex 
Syndrome Mutation 
Age at 
presentation 
Possible 
neuropathic 
features 
Age at NCS, 
Retrospective/
Prospective  
Median 
CMAP 
(mV) 
Median 
CV 
(m/s) 
Ulnar 
CMAP 
(mV) 
Ulnar 
CV 
(m/s) 
Peroneal 
CMAP 
(mV) 
Peroneal 
CV       
(m/s) 
Tibial 
CMAP 
(mV) 
Tibial 
CV 
(m/s) 
Median 
SNAP 
(µV) 
Ulnar 
SNAP 
(µV) 
Sural 
SNAP 
(µV) 
14/M Leigh MTATP6 8993T>C 2 yrs - 5 yrs/R 14.2 54 - - 1.7 46 1.4 38 25 - 38 
15/F Leigh MTATP6 8993T>C 12 yrs - 12 yrs/P 4.9 52 - - 3.5 43 - - 16 - NR 
16/F NARP MTATP6 8993T>C 16 yrs - 16 yrs/R - 46 - - - 46 - - 15 - 10 
17/M MELAS MTTL1 3243A>G 9 yrs - 11 yrs/P 9 54 9.6 60 5.3 46 17.3 49 26 20 5 
18/M MELAS MTTL1 3243A>G 10 yrs 
mild ataxia 
during acute 
episode 
 
12 yrs/P 2.7 56 NR NR NR NR NR NR 23 15 NR 
13 yrs/P 10.3 59 9.5 59 2.0 47 8.7 51 26 12 NR 
19/M Pearson 
single mtDNA 
deletion 
7 m - 4 yrs/P 7.6 45 6.7 62 - - 9.9 48 35 - 9 
20/M 
Kearns-
Sayre 
single mtDNA 
deletion 
11 yrs - 15 yrs/P 14.8 68 13.9 65 5.1 58 23.2 58 10 11 16 
 
Abnormal results (< 2SD) in bold. Reference values from Cai et al.
100
 R – retrospective, P – prospective, CMAP – compound muscle action 
potential, CV – conduction velocity, SNAP – sensory nerve action potential, m – months, NR – not recordable 
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Of the three children in this study with MT-ATP6 mutations, one child had an absent sural 
SNAP and otherwise normal study, while another had an axonal motor neuropathy affecting 
the lower limbs.  
 
30% of cases of Leigh syndrome are associated with a mutation in the mitochondrial genome 
(mitochondrial (mt)-DNA associated Leigh syndrome or maternally inherited Leigh 
syndrome [MILS]). A third of those with mt-DNA associated Leigh syndrome have an 
8993T>C or 8993T>G mutation in MT-ATP6. 
108,109
 Mt-DNA associated Leigh syndrome 
usually has an onset in the first year of life. Of the 67 individuals with Leigh and Leigh-like 
syndrome described by Rahman et al, only four had a peripheral neuropathy (one each with 
PDHC deficiency, Complex-I deficiency, Complex-IV deficiency and no defect identified).
109
 
None of 12 individuals with a mutation involving the mitochondrial genome had a peripheral 
neuropathy. 
 
In contrast to Leigh syndrome, NARP (neurogenic muscle weakness, ataxia, and retinitis 
pigmentosa) usually presents in young adulthood, though childhood onset is known. 
Presentation in childhood is usually with ataxia and learning difficulties. The neurogenic 
muscle weakness is often seen only in adulthood and with disease progression,
31
 though those 
with the 9185T>C mutation may have a neuropathy at presentation or in the first two decades 
of life.
37
 MT-ATP6 is the only gene associated with NARP, with more than half of those with 
NARP having the 8993T>C or 8993T>G mutations. 
 
Recently, the 9185T>C mutation in MT-ATP6, usually associated with NARP and Leigh 
syndrome, has been reported to cause CMT, with 1.1% of a cohort of undiagnosed CMT 
shown to have the mutation.
98
 Affected individuals were all homoplasmic for the mutation; 
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most had a pure motor or motor-predominant neuropathy with onset often in the first or 
second decade of life and variable sensory involvement with disease progression. In addition 
to a peripheral neuropathy, learning difficulties, sensorineural hearing loss, retinal 
degeneration and Leigh syndrome-like acute deteriorations with intercurrent illness were seen 
in some affected individuals. None of the 442 probands with CMT screened in this published 
report by Pitceathly et al. had the 8993T>C mutation. Similarly, in another study of 96 
individuals with CMT, none was found to have the 8993T>C mutation.
34
 Overall, it appears 
that presentations predominantly with a peripheral neuropathy or the presence of a peripheral 
neuropathy in the first two decades of life in individuals with the NARP phenotype are 
specific to the 9185T>C mutation, and the occurrence of a neuropathy in childhood is rare 
with the 8993T>C mutation. 
 
Single large mitochondrial deletions usually cause three overlapping syndromes, 
progressive external ophthalmoplegia (PEO), Kearns-Sayre syndrome (onset before age 20, 
pigmentary retinopathy and PEO, often with cardiac arrhythmias and cerebellar involvement) 
and Pearson syndrome (sideroblastic anemia and exocrine pancreatic insufficiency). A 
peripheral neuropathy in childhood has been described with the Kearns-Sayre syndrome in 
only a single case report.
53
  This study includes prospective nerve conduction studies in two 
individuals with single large mitochondrial deletions, neither of whom had 
neurophysiological evidence of a peripheral neuropathy. 
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DISCUSSION 
The characteristics of the mitochondrial disease- associated peripheral neuropathies differ 
depending on the underlying genetic defect 
Previous investigations and prospectively performed nerve conduction studies in a total of 27 
children with mitochondrial disease and an identified molecular genetic defect were reviewed as 
part of this study. As the retrospective group included only those known to have a peripheral 
neuropathy, this study was not designed to characterise the frequency of peripheral neuropathy in 
different mitochondrial diseases. Studies data collected in the retrospective group were 
performed at different centres and hence there was variation in the protocol used. It is, however, 
the largest study to date of peripheral neuropathy in childhood mitochondrial disease and 
provides valuable data on the characteristics of the peripheral neuropathy associated with 
different mitochondrial diseases. SURF1 mutations are associated with a predominantly 
demyelinating sensorimotor neuropathy.  MNGIE (mitochondrial neurogastrointestinal 
encephalomyopathy) due to mutations in the TYMP gene is also reported to be associated with a 
childhood-onset demyelinating neuropathy.
71,110
 PDHc deficiency is characterised by axonal 
sensorimotor neuropathy. POLG1 mutations are associated with a axonal sensory neuropathy 
with variable motor involvement. Recessive mutations in PEO1, the gene encoding 
mitochondrial Twinkle helicase, present with a similar phenotypic spectrum to POLG1 and are 
also associated with an early-onset sensory neuropathy.
14
 In this study, children with a 
mitochondrial genome mutation had either normal studies or a mild neuropathy when not acutely 
ill. Similar to the findings in our cohort, Horga et al. found that peripheral neuropathy had the 
highest specificity (91%), negative predictive value (83%) and positive likelihood ratio (5.87) for 
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the diagnosis of a nuclear DNA defect as opposed to a mitochondrial gene defect, in individuals 
with mitochondrial ophthalmoplegia.
111
 
 
The neuropathy associated with CMT is usually length-dependent, with weakness starting and 
being more pronounced distally, and the lower limbs being earlier and more severely affected 
than the upper limbs.
112-114
 In contrast, the nerve conduction abnormalities in this cohort of 
children with mitochondrial disease did not show a length-dependent pattern.  
 
Acute neuropathy in mitochondrial disease 
An acute neuropathy, either as a presenting feature or during the disease course, has only rarely 
been described with mitochondrial disease.
45,115,116
 Acute weakness associated with 
mitochondrial disease appears to be predominantly myopathic in origin. Aure et al. described 
acute weakness in a cohort of individuals with MT-ATP6/8 mutations, who also had evidence of 
a late-onset distal motor neuropathy.
117
  The acute weakness was triggered by prolonged sitting 
or rest after exercise, lasted less than 24 hours and resolved with acetazolamide, resembling the 
periodic paralysis seen with a channelopathy.  
 
In this study, one of the children with MELAS due to 3243 A>G mutation in MT-TL1 developed 
an acute axonal neuropathy during an acute stroke-like episode. An acute axonal neuropathy has 
previously been reported in a 30 year-old who presented with acute weakness, leading to the 
diagnosis of MELAS.
116
 As seen in the child in this study, it is possible that an acute neuropathy 
accompanies stroke-like episodes with MELAS but is under-recognised due to the prominent 
central nervous system features. 
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Debray et al. provided a summary of individuals with PDHc deficiency and acute weakness, 
describing 13 individuals (11 of whom had previously been reported). Of the seven who had 
undergone nerve conduction studies, five had neurophysiological evidence of a peripheral 
neuropathy.
118
 However, the lack of studies in these individuals before the onset of weakness or 
after recovery makes it difficult to determine if the neuropathy was chronic and unrelated to the 
episode of muscle weakness or if an acute metabolic neuropathy or worsening of a pre-existing 
neuropathy was responsible for the acute weakness. Two children in this study (patients1 and 2) 
with PDHc deficiency had evidence of an axonal sensorimotor neuropathy on studies performed 
when they were not acutely ill or weak. Patient 4 had very low CMAP amplitudes while 
recovering from an episode of acute weakness, raising the possibility that a worsening of a pre-
existing neuropathy may have contributed to the acute symptomatology. 
 
Mechanism of peripheral nerve dysfunction in mitochondrial disease 
 Normal mitochondrial function is essential for neuronal growth, survival and function.
119
 The 
genes that affect mitochondrial function may cause a peripheral neuropathy by alteration in the 
mitochondrial dynamics of fusion, fission and axonal transport, or due to abnormalities in energy 
production. Our understanding of the pathophysiology of peripheral neuropathy caused by genes 
associated with CMT and known to be associated with maintaining mitochondrial function 
(MFN2, OPA1, GDAP1), provides a template for explaining this dysfunction. Dominant and 
recessive mutations in mitofusin 2 (MFN2), encoding the outer mitochondrial membrane GTPase 
mfn2, cause CMT2A, the most common form of inherited axonal neuropathy.
90
 Some affected 
individuals with MFN2 mutations also have acute or chronic optic atrophy. Dominant mutations 
in OPA1 cause inherited optic atrophy, and a third of affected individuals have an axonal 
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peripheral neuropathy.
82
 The coordinated function of the mitofusins (mfn1 and mfn2) and 
OPA1(located on the inner mitochondrial membrane) is required for mitochondrial fusion.
87,88
 
Small, rounded and abnormally aggregated axonal mitochondria are seen in sural nerve biopsies 
of individuals with MFN2 mutations.
91
 Mutations in the ganglioside-induced differentiation 
associated protein 1 gene (GDAP1) cause recessive (CMT4A) and dominant (CMT2H/K) forms 
of axonal and demyelinating neuropathy. GDAP1 is an outer mitochondrial membrane protein 
expressed in both myelinating Schwann cells and axons and known to play a role in 
mitochondrial fission. Fibroblasts from individuals with GDAP1 mutations show abnormally 
large mitochondria, a fragmented mitochondrial network and reduced complex I activity.
94
 
 
In addition to abnormalities with mitochondrial fission, defective mitochondrial axonal transport 
has been demonstrated in cultured neurons from MFN2 knock-out mice or neurons with MFN2 
disease mutants.
120
 Mitochondria supply the vast axonal energy requirement for maintaining the 
axonal gradient required for impulse transmission and are known to be positioned at areas of 
high energy demand along the axon.
121
 Mitochondria move both anterogradely and retrogradely, 
predominantly along the axonal microtubules using kinesin and cytoplasmic dynein motors and 
for short distances along actin filaments using myosin motors.
121
 Mfn2 interacts with the 
molecular complex (Milton/Miro) that links mitochondria to the kinesin motors. Disruption of 
this interaction impairs transport of mitochondria along the axon and this may be the cause of the 
length-dependent nature of neuropathy due to MFN2 mutations.   
 
Mitochondrial ATP production supports synapse assembly, action potential generation and 
synaptic transmission in peripheral nerves.
122
 Another hypothesis for the nerve dysfunction 
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associated with mitochondrial diseases is energy failure due to the failure of the Na
+
/K
+
-ATPase 
pump. Because of their long axons, peripheral nerves are especially susceptible to energy failure. 
Nerve excitability studies during an acute stroke-like episode in MELAS are consistent with 
membrane depolarisation, possibly due to dysfunction of the  Na
+
/K
+
-ATPase pump 
123
. 
However, nerve excitability testing in the non-acute setting, in a cohort of adults with either 
MELAS 3243A>G mutation or muscle biopsy evidence of a mitochondrial myopathy, did not 
show an abnormality, indicating that this is unlikely to be the cause of the chronic neuropathy in 
mitochondrial disease.
124
 In a mouse model where mitochondrial metabolism was disrupted 
solely in Schwann cells, there was activation of an abnormal integrated stress response through 
actions of heme-regulated inhibitor kinase (HRI). This resulted in a shift of lipid metabolism 
away from fatty acid synthesis towards oxidation, causing depletion of myelin lipid components 
and accumulation of acylcarnitines which can cause axonal degeneration.
125
 
 
CONCLUSION 
Peripheral neuropathy is more common in childhood mitochondrial disease due to a nuclear gene 
mutation when compared to mitochondrial genome mutations. The identification of a peripheral 
neuropathy and definition of its characteristics may help classify the mitochondrial syndrome 
and direct genetic testing. SURF1 mutations are associated with a demyelinating neuropathy 
while PDHc deficiency is associated with an axonal neuropathy. POLG mutations are associated 
with an axonal sensory neuropathy. In contrast to that seen with CMT, the neuropathy of 
mitochondrial disease is non-length dependent. Nerve conduction studies should be an integral 
component of the diagnostic evaluation of suspected childhood mitochondrial disease.
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Phenotype of Brown-Vialetto-Van Laere 
syndrome due to RFVT2 deficiency 
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INTRODUCTION 
This chapter describes a cohort of previously genetically unclassified families with a common 
phenotype suggestive of a mitochondrial disorder. Subsequent genetic testing revealed mutations 
in a gene (SLC52A2) encoding the neuronal transporter (Riboflavin transporter type 2) for a 
cofactor essential for mitochondrial metabolism and energy transport. I have characterised the 
phenotype of this disorder, the features that identify it as a mitochondrial disorder and the 
features that differentiate it from another riboflavin transporter disorder (RFVT3 deficiency due 
to mutations in SLC52A3). As hearing loss is an initial and characteristic feature of BVVL and 
has unique characteristics that aid early diagnosis, the audiological profile of my cohort is 
detailed separately in Chapter 3. 
 
Brown-Vialetto-Van Laere syndrome (BVVL) is a progressive inherited neurodegenerative 
disorder characterised by bilateral sensorineural deafness and pontobulbar palsy. The syndrome 
is named after Brown,
126
 Vialetto
127
 and Van Laere,
128
 who described individuals affected with 
the disorder. Onset is usually in childhood but may vary from infancy to the third decade of 
life.
129
   The course is often progressive, though episodic deterioration or long periods of stability 
have been described.
130
 Hearing loss is often the initial symptom, is progressive and ultimately 
severe. Affected individuals go on to develop lower (VII-XII) and less commonly upper (II-VI) 
cranial nerve abnormalities, neck, shoulder and limb muscle weakness and respiratory failure.
131
  
Associated features may include epilepsy, autonomic disturbances, cerebellar ataxia, retinitis 
pigmentosa and upper motor neuron signs. Sensory abnormalities have not been described as a 
feature of this disorder.
131
 Cognition is usually preserved. Electromyography shows chronic or 
active denervation in affected muscles. The onset of symptoms, or a clinical deterioration, may 
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occur in association with intercurrent illness.
132
 Spontaneous significant improvement in the 
clinical state has not been described. Mortality from the disease is usually from respiratory 
failure, occasionally precipitated by an intercurrent infection.
132
  
 
As elucidated in this chapter, the neuropathy associated with RFVT2 deficiency can be classified 
as a mitochondrial neuropathy. The biochemical defect in BVVL is an abnormality of 
mitochondrial fatty acid beta-oxidation and branched-chain amino acid catabolism, resulting in a 
deficiency in energy production. Affected individuals with BVVL have multisystemic 
involvement including optic atrophy and sensorineural hearing, similar to other mitochondrial 
diseases. The peripheral neuropathy is non-length dependent, as it is with other mitochondrial 
neuropathies, and the nerve biopsy shows a number of mitochondrial abnormalities. 
 
The Fazio-Londe syndrome has a very similar clinical profile to BVVL, but affected individuals 
do not have hearing loss.
133
 Madras motor neuron disease (childhood onset, sensorineural 
hearing loss, cranial nerve palsies, limb weakness), Nathalie syndrome (deafness, cataract, 
muscle weakness, hypogonadism, electrocardiographic abnormalities) and Boltshauser syndrome 
(hearing loss, vocal cord paralysis, distal muscular atrophy) share phenotypic similarities with 
BVVL.
134-136
  
 
Both familial and sporadic cases of BVVL have been described with the inheritance suggested to 
be autosomal recessive with reports of affected siblings in families with unaffected parents and 
occurrence in consanguineous families, though other modes of inheritance have occasionally 
been reported.
130,137,138
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Post-mortem examination of affected individuals shows neurogenic atrophy in the limb, neck 
and laryngeal muscles, which are clinically weak. The lower (VII-XII) cranial nerves, and 
sometimes the III, V and VI cranial nerves, show severe axonal loss with depletion of neurons 
and gliosis in the brainstem nuclei (including the tractus solitarius and nucleus ambiguus). The 
cochlear nucleus shows loss of neurons, and the lateral lemniscus and inferior colliculus show 
gliosis.
130,139
 The medial lemniscus and the gracile and cuneate nuclei also show degeneration.
139
 
The cerebral cortex, basal ganglia, thalami, white matter and corticospinal tracts are usually 
spared. The spinal cord shows loss of neurons in both the anterior and posterior horns with 
axonal loss and degeneration of the spinothalamic and spinocerebellar tracts, though pyramidal 
fibres are relatively spared.
139
 
 
Recently, autosomal recessive mutations in SLC52A3 (formerly C20orf54) and SLC52A2, 
encoding the riboflavin transporters RFVT3 (formerly RFT2) and RFVT2 (formerly RFT3) 
respectively have been identified in individuals with BVVL.
140,141
 The clinical and genetic 
profile, neurophysiology, biochemical abnormalities and histopathology of nine individuals from 
four families with homozygous and compound heterozygous mutations in SLC52A2 are 
described in this chapter.  
 
METHODS 
Ethics 
Patients were enrolled with informed consent from the patient and/or parental guardian.  This 
study had Ethics Committee/IRB approval from the Sydney Children’s Hospitals Network 
(10/CHW/45) and the University Of Miami Miller School Of Medicine. 
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Exome and Sanger Sequencing  
Families 3 and 4 were independently selected for exome sequencing as they had an undiagnosed 
familial neuropathy. There exists a research collaboration between the Peripheral Neuropathy 
Service at The Children’s Hospital at Westmead and the Center for Human Molecular Genomics, 
John P. Hussman Institute for Human Genomics University of Miami Miller School of Medicine 
(led by Prof. Stephan Zuchner). Exome sequencing was performed in family 3 (including 
patients 3.1 and 3.2) and family 4 (including patients 4.1, 4.2 and 4.3) at the  Center for Human 
Molecular Genomics, Miami and Western Sydney Genetics Program, The Children’s Hospital at 
Westmead respectively. Sanger sequencing of SLC52A2 was performed in the affected members 
of family 2 (including patients 2.1 and 2.2) at the Center for Human Molecular Genomics, Miami 
as their phenotype was similar to that recently described with SLC52A2 mutations.  Sanger 
sequencing for only the founder Lebanese mutation was performed in family 1 (including 
patients 1.1 and 1.2) at the Department of Molecular Genetics, The Children’s Hospital at 
Westmead, also based on the phenotypic resemblance to individuals with SLC52A2 mutations.  
 
The medical records, results of previous nerve conduction testing, medical imaging, hearing and 
ophthalmology assessments and histopathology of all individuals identified to have SLC52A2 
mutations were reviewed. The acylcarnitine profiles, including the level of medium-chain 
acylcarnitines, were also reviewed. Assessments were repeated at the time of diagnosis. These 
assessments included a clinical examination, nerve conduction testing and formal hearing 
assessment. The acylcarnitine profile and FAD levels were also measured at baseline. Newborn 
screening cards, where available, were tested for the level of medium-chain acylcarnitines. 
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Portions of this chapter have been modified from the previously published article (Foley AR, 
Menezes M et al. Brain 2014) on which I was a co-first author.  I was the treating neurologist for 
Families 1, 2 and 3, and shared care for family 4. I reviewed previous clinical notes and 
investigations (including nerve conduction studies) on all the study patients.  I performed 
baseline clinical assessments and nerve conduction tests on all the study patients, tabulated the 
nerve conduction results and acylcarnitine profile results and compared with age-matched and 
CHW laboratory norms respectively. I reviewed the biopsies of patients 3.1 and 4.2. I assisted 
with segregating the variants found in the exome sequencing of Family 3. The molecular genetic 
tests including exome sequencing and sanger sequencing and functional assays were performed 
by collaborators and I had no role in performing these tests. 
 
RESULTS 
Nine individuals from four families with either compound heterozygous or homozygous 
mutations in SLC52A2 were identified.  The pedigrees and genotype of the affected individuals is 
illustrated in Figure 2.1. Families 2, 3 and 4 have previously been reported as part of a published 
cohort of 18 children with SLC52A2 mutations.
142
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Figure 2.1:  Pedigrees and corresponding SLC52A2 mutations for affected patients 
 
Squares denote males, circles females and completely shaded shapes affected individuals. Half-shaded shapes indicate unaffected 
carriers.  
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SLC52A2 mutations  
The location of each published SLC52A2 mutation, including those in our cohort, is shown in 
Fig. 2.2A.    Both the SLC52A2 mutations identified in my cohort, p.G306R (c.916G>A) and 
p.L339P (c.1016T>C) have been reported previously 
140,143
 and have been predicted as not 
tolerated by the SIFT prediction program and as probably damaging by Polyphen-2. Both 
mutations alter amino acids evolutionarily conserved from humans to D. rerio and are also 
conserved in RFVT1 and RFVT3 (Fig. 2.2B). 
 
Array based genotyping 
Patients from families 1, 2 and 4, like the affected members of the family described by 
Megarbane et al. in 2000,
137
 are of Lebanese origin and all carry homozygous p.G306R 
SLC52A2 mutations.  Haplotype analysis was carried out by researchers at the Western Sydney 
Genetics Program using SNP based arrays or genotyping of SNPs around the SLC52A2 gene in 
patients from families 2 and 4 and patient L1 in the larger published cohort to determine whether 
this was a shared ancestral allele. All of them, as well as the two affected members of the family 
described by Megarbane et al., were found to be homozygous for the p.G306R mutation and all 
11 SNPs studied indicating that the mutation arose on a common haplotype within the Lebanese 
population as a founder mutation.  
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Figure 2.2:  Mutations in SLC52A2 in Brown-Vialetto-Van Laere syndrome   
A     
 
 
B
 
 (A) Predicted transmembrane domains in RFVT2, gene structure and location of mutations 
identified in SLC52A2, including those in this patient cohort.  (B) Structural conservation of 
relevant amino acid residues in RFVT2 across species and in RFVT1 and RFVT3.  Dark blue, 
medium blue and light blue colors correspond to amino acids conserved in ≥6, ≥5 or ≥3 out of 
the 7 sequences, respectively.   
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Clinical Phenotype  
Nine individuals from four families were found to harbour either compound heterozygous or 
homozygous mutations in SLC52A2.  The clinical and genetic features of these patients are listed 
in Table 2.1.  Three of the four families in my cohort were of Lebanese origin while the other 
was of English and Scottish descent. Three of the four families had a history of consanguinity.  
 
Affected children presented between 2 and 8 years of age with an ataxic gait due to a severe 
sensory ganglionopathy, sometimes associated with a sensorineural hearing loss.  
Hearing was normal on newborn screening (except in patient 1.1). The hearing loss had the 
characteristics of an auditory neuropathy and progressed rapidly after diagnosis. Hearing aids 
did not provide any benefit. A detailed description of the hearing loss associated with riboflavin 
transporter deficiency is available in Chapter 3. 
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Table 2.1: Clinical profile of affected individuals with SLC52A2 mutations  
  Family 1 Family 2 
Patient 1.1 1.2 2.1 2.2 
SLC52A2 mutations 
homozygous:         
c.916G>A 
homozygous:         
c.916G>A 
homozygous:         
c.916G>A 
homozygous:         
c.916G>A 
p. G306R p. G306R p. G306R p. G306R 
Sex F M F F 
Ethnicity Lebanese Lebanese Lebanese Lebanese 
Consanguinity yes yes yes yes 
First symptom ataxic gait  ataxic gait ataxic gait ataxic gait 
Age at first 
symptom 
hearing loss (1 month)             
ataxic gait (4 yrs) 
8 yrs 8 yrs 3 yrs 
Optic atrophy no NT no yes 
Sensorineural 
hearing loss 
yes NT yes yes 
Sensorimotor 
neuropathy 
sensory only NT sensory only yes 
Distribution of 
weakness 
none detected none detected none detected UL 
Overall maximal 
motor function  
independent 
ambulation 
independent 
ambulation 
independent 
ambulation 
independent 
ambulation 
Maximal motor 
function at the time 
of diagnosis  
independent 
ambulation 
independent 
ambulation 
independent 
ambulation 
independent 
ambulation 
Respiratory function normal normal normal normal 
Feeding by mouth by mouth by mouth by mouth 
Age at genetic 
diagnosis 
5 yrs 8 yrs 10 yrs 9 yrs 
 
UL – upper limb, NT – not tested, NA – not applicable, NIV – non-invasive ventilation 
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Table 2.1: Clinical profile of affected individuals with SLC52A2 mutations (continued) 
  Family 3 Family 4 
Patient 3.1 3.2 4.1 4.2 4.3 
SLC52A2 mutations 
compound 
heterozygous:                  
c.916 G>A; 1016T>C   
compound 
heterozygous:                  
c.916 G>A; 1016T>C   
homozygous:         
c.916G>A 
homozygous:         
c.916G>A 
homozygous:         
c.916G>A 
p.G306R; L339P p.G306R; L339P p. G306R p. G306R p. G306R 
Sex F F M M M 
Ethnicity English and Scottish English and Scottish Lebanese Lebanese Lebanese 
Consanguinity no no yes yes yes 
First symptom 
ataxic gait and UL 
weakness 
ataxic gait and 
hearing loss 
ataxic gait and 
hearing loss 
ataxic gait and 
hearing loss 
ataxic gait 
Age at first 
symptom 
2 yrs 5 yrs 3 yrs 3 yrs 3 yrs 
Optic atrophy no yes yes yes yes 
Sensorineural 
hearing loss 
NT yes yes yes yes 
Sensorimotor 
neuropathy 
yes yes yes yes yes 
Distribution of 
weakness 
UL UL; neck extension UL; neck extension UL; neck extension UL 
Overall maximal 
motor function  
independent 
ambulation 
independent 
ambulation 
independent 
ambulation 
independent 
ambulation 
independent 
ambulation 
Maximal motor 
function at the 
time of diagnosis  
NA 
independent 
ambulation 
non-ambulant non-ambulant 
independent 
ambulation 
Respiratory 
function 
decreased; on 
ventilator at the time 
of death 
decreased; nocturnal 
NIV recommended 
ventilator 
dependent 
nocturnal NIV normal 
Feeding by mouth by mouth by gastrostomy only by gastrostomy only by mouth 
Age at genetic 
diagnosis 
deceased (3.5 yrs) 15 yrs 16 yrs 16yrs 21 yrs 
 
UL – upper limb, NT – not tested, NA – not applicable, NIV – non-invasive ventilation 
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Sensory ataxia was noted in all patients at presentation. The gait ataxia, severe generalised 
large-fibre sensory loss, lack of regeneration on nerve biopsy (see below) and absence of a clear 
length-dependent abnormality on nerve conduction studies indicate that the sensory 
abnormalities were most likely due to a sensory ganglionopathy.  Upper limb strength was 
normal at first presentation but weakness was usually noticed in the second decade of life and 
then progressed rapidly. Patient 3.2 had an earlier onset of upper limb and respiratory muscle 
weakness at 2 years of age, which progressed rapidly resulting in death from acute on chronic 
respiratory failure. Older affected children had a combination of proximal and distal upper 
limb weakness with no movement in the small muscles of the hand, only a flicker of movement 
on shoulder abduction, and neck extension weakness. Strength in the lower limbs was normal or 
only mildly reduced with even those late in the disease course being able to walk on their heels 
and toes when supported, though they were confined to a wheelchair because of the sensory 
ataxia.   
 
Mild optic atrophy was identified in five of the eight children who had a formal 
ophthalmological evaluation. Respiratory failure developed in four children. Patient 3.2 died 
within 6 months of presentation due to rapidly progressive respiratory failure. In the others, 
respiratory muscle weakness was identified on polysomnography between 13-15 years of age 
and was associated with longer disease duration and paralleled the proximal upper limb 
weakness. Cognition appeared preserved but was difficult to test in the most severely affected 
children (patients 4.1 and 4.2) because of their speech, writing and visual deficits. Two children 
had evidence of severe bulbar weakness necessitating gastrostomy insertion at the age of 16 
years. 
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Biochemical Studies 
Plasma acylcarnitine profiles were performed in eight children after diagnosis and prior to high-
dose oral riboflavin therapy and were abnormal in five (Table 2.2). Acylcarnitine profiles 
previously performed in patients 3.1 and 4.2 were also reviewed and showed the mild increase in 
medium-chain acylcarnitines characteristic of this disorder. However, as these two profiles were 
performed six and nine years prior to recognition that these mild abnormalities were suggestive 
of riboflavin transporter deficiency, they had been reported normal at that time. Urine metabolic 
screens done just prior to high-dose riboflavin therapy, as well as previously, were all normal. 
FAD levels done just prior to high-dose riboflavin therapy were within the normal range for our 
laboratory. Medium-chain acylcarnitines were normal on newborn screening in all five 
individuals for whom this testing had been undertaken.   
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Table 2.2: Biochemical profile of affected individuals with SLC52A2 mutations 
    Family 1 Family 2 Family 3 Family 4 
Acylcarnitine 
species 
Reference 
range 
1.1 1.2 2.1 2.2 3.1 3.2 4.1 4.2 4.3 
Free Carnitine 13-56 14 20 16.8 25.6 38.8 30.2 21.9 18.3 27.3 
C2  2.8-22.5 3 4 4.1 3.7 9.5 11.1 3.1 3.4 5.1 
C4  0.12-0.67 0.37 0.23 0.35 0.24 0.65 0.6 0.1 0.03 0.28 
C5  <0.28 0.19 0.33 0.37 3.82 0 0.31 0.1 0.08 0.26 
C6  <0.13 0.42 0.11 0.58 0.31 0.12 0.27 0.04 0.04 0.07 
C8 <0.24 1.38 0.35 1.31 0.29 0.34 0.7 0.09 0.11 0.16 
C10:1  <0.5 1.23 0.36 0.79 0.68 0.19 0.53 0.1 0.13 0.08 
C10  <0.4 1.38 0.43 1.39 0.61 0.52 0.8 0.13 0.16 0.2 
C12  <0.62 0.09 0.05 0.12 0.79 0.16 0.09 0.01 0.03 0.02 
C14:1  <0.73 0.12 0.05 0.16 0.11 0.16 0.18 0.06 0.09 0.05 
C14  <0.34 0.02 0.02 0.03 0.12 0.06 0 0 0.04 0.01 
C16  <0.64 0.06 0.05 0.07 0.08 0.03 0.11 0.04 0.09 0.05 
Riboflavin 
level 
174-471 239 ND 267 253 ND 245 369 310 337 
UMS   ND ND Normal Normal Normal ND Normal Normal Normal 
Newborn 
screening 
  Normal Normal Normal Normal Normal NA NA NA NA 
 
Abnormal values indicated in bold. ND – not done, NA – not available 
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Neurophysiology 
Nerve conduction studies performed early in the disease course showed absent or very low 
sensory amplitudes in the upper and lower limbs and normal motor studies (Table 2.3). This 
pattern of generalised sensory abnormalities on nerve conduction studies, severe sensory ataxia 
and absent reflexes is consistent with a sensory ganglionopathy. Sequential studies showed a 
steady decline of upper limb motor amplitudes consistent with a motor axonal neuropathy.   
Lower limb CMAP amplitudes were normal or mildy reduced and did not show a clear 
progression with disease duration.  This overall pattern is in contrast to inherited sensorimotor 
polyneuropathies which are typically length-dependent, with sensory symptoms and weakness in 
the lower limbs preceding and progressing to a greater degree than in the upper limbs.
144
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Table 2.3: Nerve conduction studies in affected individuals with SLC52A2 mutations  
Patient 1.1 2.1 2.2 3.2 4.1 4.2 
Age at NCS 4 yrs 8 yrs 10 yrs 3 yrs 5yrs 9 yrs 8 yrs 16 yrs 15 yrs 16 yrs 16 yrs 
Motor   
         
  
Median Nerve   
         
  
CMAP (mV) 10.3 
 
9.3 11.1 8.2 3.1 5.1 NR NR NR 1.3 
CV (m/s) 53 
 
49 46 48 43 44 
   
51 
Ulnar Nerve   
         
  
CMAP (mV) 7.3 
 
8 7.7 6.7 4.6 12.3 NR 1 2.7 3.3 
CV (m/s) 65 
 
54 55 55 50 59 
 
59 59 56 
Peroneal Nerve   
         
  
CMAP (mV) 1.8 4.3 3.8 3.8 2.1 1.4 4.5 4.8 3.5 NR NR 
CV (m/s) 52 44 46 47 53 
 
52 44 42 
 
  
Tibial Nerve   
         
  
CMAP (mV) 12.5 
 
8 12.5 12.1 6.3 
 
13.2 6.8 9.6 10.4 
CV (m/s) 47 
 
45 47 44 42 
 
40 40 39 38 
Sensory   
         
  
Sural (µV) NR NR NR NR NR NR NR NR NR NR NR 
Median (µV) NR NR NR 2 NR NR 3 5 NR NR NR 
Ulnar (µV) NR 
NR     
(radial) 
NR NR NR NR 3   NR NR NR 
 
Abnormal values (< 2SD) indicated in bold. Reference values from Cai et al.
100
 CMAP – 
compound muscle action potential, CV – conduction velocity, NR – not recordable 
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Histopathology  
The histopathological characteristics, including electron microscopy, of sural nerve biopsies 
from 6 patients with BVVL have been reported in the published article, and showed a severe 
chronic axonal neuropathy with accompanying increase in connective tissue but no evidence of 
ongoing degeneration (Fig. 2.3).  Large myelinated fibres were more severely affected and 
regeneration was strikingly absent.  Unmyelinated fibres were generally better preserved.  There 
was no inflammation, pathological hypomyelination or demyelination. This included slides of 
sural nerve biopsies from patients 3.1 and 4.2 which I have reviewed. An adequately preserved 
sample was only available from the biopsy from patient 3.1, and electron microscopy was 
performed by Prof J-M Vallat at the Reference Centre for Peripheral Neuropathies, CHU 
Limoges, France and reviewed by me at the University of Sydney Nerve Laboratory (Fig. 2.4).  
This revealed a focal proliferation of microfilaments in myelinated axons, abnormal glycogen 
accumulation in axons, Schwann cells and fibroblasts, and abnormalities in the number and 
shape of mitochondria. These unique features have not been reported previously. 
 
Neuroimaging 
Brain magnetic resonance imaging (MRI) was performed in four patients and revealed no 
abnormality in the cerebral cortex, brainstem, internal auditory structures or cochlear nerve.   
This finding is in contrast to reports of hyperintensity of brainstem nuclei 
145,146
, atrophy of the 
brainstem 
139,146,147
 and atrophy of the cerebellum 
139,147
 in genetically undifferentiated cohorts of 
patients with BVVL and those with SLC52A3 mutations. This is consistent with the pure lower 
motor neuron phenotype of SLC52A2 mutations which contrasts with the upper motor neuron 
signs seen with SLC52A3 mutations and in genetically undifferentiated cohorts.  
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Figure 2.3: Sural nerve pathology with mutations in SLC52A2 
 
 
 
Resin-semithin section, stained with toluidine blue; x 40 magnification (A) in patient 3.1 at 3 years of age demonstrates a moderate 
loss of myelinated axons, preferentially of large diameters (8-12µm).  There is an increase of collagen in the endoneurium, and there 
are no inflammatory infiltrates. (B) Unaffected control. Scale bar represents 25nm. 
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Figure 2.4: Sural nerve pathology with mutations in SLC52A2: electron microscopy 
 
 
 
 
 
 
 
 
 
 
 
 
Electron microscopy examination of transverse (A, C, E and F) and longitudinal sections (B, D) of the sural nerve biopsy from patient 
3.2 at 3 years of age demonstrates focal proliferation of microfilaments in myelinated axons (A, B), mitochondrial abnormalities with 
an increased number of intra-axonal mitochondria (C), abnormally shaped mitochondria (black arrowheads, D), and abnormal 
accumulation of black glycogen granules in axons (E), Schwann cell cytoplasm and fibroblasts (F).  
 
 
A C 
E D F 
B 
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Functional Analyses of SLC52A2 mutations 
Seven SLC52A2 mutations [p.W31S (c.92G>C), p.Q234X (c.700C>T), p.A284D (c.851C>A), 
p.Y305C (c.914A>G), p.G306R (c.916G>A), p.L312P (c.935T>C) and p.L339P (c.1016T>C)] 
were analysed in an in vitro transient expression system at the
 
Department of Clinical 
Pharmacology and Therapeutics, Kyoto University Hospital (Kumiko Sugano, Kazuo Matsubara 
and Atsushi Yonezawa). This department has previously performed functional studies on other 
riboflavin transporter mutations and has a research collaboration with the Western Sydney 
Genetics Program, The Children’s Hospital at Westmead.148 [3H]riboflavin transport activity and 
protein expression of SLC52A2
92G>C
, SLC52A2
700C>T
, SLC52A2
851C>A
, SLC52A2
914A>G
, 
SLC52A2
916G>A
, SLC52A2
935T>C
 and SLC52A2
1016T>C
 were assessed (Fig. 2.5A).  
[
3
H]Riboflavin uptake by the SLC52A2 mutations p.W31S, p.Q234X, p.A284D, p.Y305C and 
p.L339P was completely abolished, and SLC52A2 mutations p.G306R and p.L312P showed a 
moderate but significant decrease in [
3
H]riboflavin transport activity compared with wild-type 
SLC52A2.  To determine whether the transport activity reduction was due to the decreased 
expression of transporter proteins in the plasma membranes, Western blot analysis was carried 
out using the crude membrane of HEK293 cells transiently transfected with these variants (Fig. 
2.5B).  The expression levels of SLC52A2
 
mutants except for p.W31S were decreased compared 
with wild-type SLC52A2, which are well correlated with the reduction ratios of the transport 
activity for these variants.  The p.W31S mutant was expressed in the plasma membrane but was 
dysfunctional as evidenced by completely abolished riboflavin uptake in vitro. 
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Figure 2.5:  Functional studies of SLC52A2 mutations
 
 
(A) Uptake of [
3
H]riboflavin by HEK293 cells transfected with empty vector (Vector), wild-type 
SLC52A2 (WT), SLC52A2
92G>C
 (W31S), SLC52A2
700C>T
 (Q234X), SLC52A2
851C>A
 (A284D), 
SLC52A2
914A>G
 (Y305C), SLC52A2
916G>A
 (G306R), SLC52A2
935T>C
 (L312P) and 
SLC52A2
1016T>C
 (L339P).  The cells were incubated with 5 nM [
3
H]riboflavin (pH 7.4) for 1 min 
at 37 ˚C.  Each bar represents the mean ± SEM, n=3.  Data were analyzed by Dunnett’s two-
tailed test after one-way analysis of variance (ANOVA).  *P<0.05, ***P<0.001, significantly 
different from vector-transfected cells.  #P<0.05, ###P<0.001, significantly different from 
SLC52A2
WT
-transfected cells.  
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Figure 2.5:  Functional studies of SLC52A2 mutations (continued)
  
(B) Western blot analysis performed using the crude membrane of HEK293 cells expressing 
empty vector, SLC52A2
WT
 and SLC52A2 variants.  The crude membrane fractions were 
subjected to Western blotting using antibodies against FLAG and Na
+
/K
+
-ATPase.  Na
+
/K
+
-
ATPase was used as an internal standard.  fmol = femtomole 
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DISCUSSION  
The unique clinical, neurophysiological, histopathological, biochemical and molecular genetic 
profile of nine cases of Brown-Vialetto-Van Laere syndrome due to mutations in the riboflavin 
transporter gene SLC52A2 has been characterised in this chapter. While the age of onset and 
severity of disease progression may vary among those affected, the phenotype is unique and 
striking.  Initial presentation is with sensory ataxia and hearing loss. Progressive upper limb 
weakness, optic atrophy, respiratory failure and bulbar weakness emerge with disease 
progression. The phenotype is caused by an early-onset generalised sensory ganglionopathy, a 
progressive upper limb motor axonal neuropathy and cranial neuropathy affecting II, VIII and 
bulbar cranial nerves. This unique phenotype may be described as a ‘child-in-the-barrel’, 
reminiscent of the ‘man-in-the-barrel’ phenotype, with severe weakness in the upper limbs and 
preserved strength in the lower limbs. A similar phenotype has been previously reported with the 
flail-arm variant of motor neuron disease and in the pharyngo-cervico-brachial variant of 
Guillain-Barre syndrome in children. 
149,150
  
 
The phenotype of SLC52A2 mutations has characteristic features distinguishing this condition 
from that previously described with genetically unclassified BVVL or with SLC52A3 mutations, 
another cause of riboflavin transporter deficiency (Table 2.4). My cohort of affected individuals 
with SLC52A2 mutations presented with sensory ataxia and had a generalised sensory 
ganglionopathy. Sensory loss and abnormalities in sensory nerve conduction studies are not a 
feature of SLC52A3 mutations and have only rarely been described with genetically unclassified 
BVVL.
131,141,151
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Table 2.4: Phenotypical and biochemical differences between RFVT2 and RFVT3 
deficiency 
Feature RFVT2 deficiency (SLC52A2 
mutations) 
RFVT3 deficiency (SLC52A3 
mutations) 
Sensory ataxia Presenting feature and 
universally present. Due to a 
generalised sensory 
ganglionopathy 
Not reported 
Motor 
weakness 
Predominantly involves the 
upper limb with relative sparing 
of the lower limbs, leading to 
the ‘child-in-the-barrel’ 
phenotype 
Generalised weakness 
Upper motor 
neuron 
features 
Not reported Brisk reflexes, ankle clonus and 
extensor plantar responses 
have been reported 
Urine organic 
acid profile 
Normal Abnormal. Resembles mild 
multiple acyl-CoA 
dehydrogenation defect 
(MADD) 
Plasma flavin 
levels 
Normal Reduced when compared to 
controls 
Tissue 
expression of 
encoded 
riboflavin 
transporter 
Mainly in brain and spinal cord. 
Responsible for the neuronal 
transport of riboflavin 
Mainly in small intestine. 
Responsible for intestinal 
absorption of riboflavin 
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The muscle weakness associated with SLC52A2 mutations predominantly affects the upper 
limbs and neck while that described with SLC52A3 mutations and genetically unclassified 
BVVL is generalised.
141,152
 Upper motor neurone signs such as brisk reflexes, clonus and 
extensor plantar responses and abnormalities on brain imaging have been described with both 
genetically unclassified BVVL and affected individuals with SLC52A3 mutations. 
131,141
 In 
contrast, SLC52A2 mutations appear to cause a pure lower motor neuron syndrome. One of 
the possible explanations for the different phenotypes of SLC52A2 and SLC52A3 mutations 
could be the differential tissue expression. It is known that RFVT3 and RFVT1, the riboflavin 
transporters encoded by SLC52A3 and SLC52A1, are predominantly expressed in the small 
intestine and responsible for intestinal transport of riboflavin. Preliminary human tissue 
studies of SLC52A2 encoded RFVT2 demonstrate a relatively higher expression in the brain 
and spinal cord than in the small intestine. 
153,154
 It is possible that there are further 
differences in the neuronal expression of RFVT2 in the anterior horn cells along the spinal 
cord. 
 
The initial description by C.H. Brown in 1894 captures the salient features of this disorder.
126
  
He described a fifteen-year-old boy in whom symptoms were first seen at 3 years of age and 
in whom  ‘the onset was rather rapid and grew more pronounced every day so that in a week 
he could not move his tongue, whistle or swallow without an effort’.  He also noted that ‘He 
grew hard of hearing and on least exertion he had difficulty in breathing’.  This description 
of an early childhood onset, rapidly progressive neurodegeneration characterised by hearing 
loss, pontobulbar weakness and respiratory failure is characteristic of the disorder 
subsequently known as Brown-Vialetto-Van Laere syndrome. However, it can be argued that 
the case described was likely to be specifically of RFVT2 deficiency, as Brown reports that 
the boy ‘found it difficult to button or unbutton his clothes, write or carry weights’ and was 
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‘an exceedingly emaciated boy, more markedly so, however, in the upper parts of the body’ 
and had ‘apparent paresis and atrophy of most of the arm muscles’. This description evokes 
the proprioceptive loss (contributing to difficulty in fine motor tasks), upper limb-
predominant weakness and ‘child-in-the-barrel’ phenotype that has described in association 
with RFVT2 deficiency. Interestingly, he notes previous description of similar cases by Fazio 
(1892) and Londe (1894), among others.
155,156
 He also recognised this was a neuronopathy, 
concluding his report by remarking on similarities with amyotrophic lateral sclerosis in 
adults.   
 
BVVL associated with SLC52A2 mutations is inherited as an autosomal recessive condition, 
which helps to differentiate it from other optico-acoustic neuropathies including autosomal 
dominantly inherited OPA1 or MFN2 mutations, X-linked PRPS1 mutations and 
mitochondrially inherited neuropathy due to mitochondrial DNA mutations (such as Leber 
hereditary optic neuropathy or the syndrome of neuropathy, ataxia and retinitis pigmentosa 
known as ‘NARP’).  While it is an inherited neuropathy, the prominent cranial nerve 
involvement, upper-limb predominance of motor weakness, sensory ganglionopathy and non-
length dependent nature of peripheral nerve involvement differentiate it from most types of 
Charcot-Marie-Tooth disease.
157
 In the past, hearing loss has been used to distinguish BVVL 
as a diagnostic entity from other forms of childhood onset motor neuron diseases including 
Fazio-Londe disease.
158
  It now appears that BVVL and Fazio-Londe disease are allelic 
conditions.
133,152
 Sequencing of all three riboflavin transporter genes in a cohort of patients 
with Madras motor neuron disease did not reveal a causative mutation, though the close 
similarity in the clinical phenotype suggests that the disease may share a common 
pathophysiological pathway with BVVL.
159
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While the phenotype associated with SLC52A2 mutations is relatively homogeneous, the rate 
of progression may vary, even within families. One affected individual in my cohort (patient 
3.1) had a rapid deterioration, dying from respiratory failure within nine months of onset of 
symptoms. A trial of intravenous immunoglobulin therapy was ineffective. Her elder sibling 
(patient 3.2), who shares the same SLC52A2 mutations, remains able to ambulate 
independently at 15 years of age and respiratory muscle weakness requiring non-invasive 
ventilation was first identified only at 15 years of age. Patient 4.3 shares the same SLC52A2 
genotype and similar age of onset as his more severely affected siblings (patients 4.1 and 4.2) 
but remains ambulant at 21 years of age with only mild weakness in the small muscles of the 
hand and no evidence of respiratory failure. His younger siblings have severe proximal and 
distal upper limb weakness, are wheelchair-bound and require assisted ventilation. This 
suggests that there may be other genetic or environmental factors that modulate disease 
severity.     
 
Nomenclature of riboflavin transporter disorders 
Because of the different names being used for the genes, transporters and diseases caused by 
mutations in the genes encoding riboflavin transporters, the group involved in reporting the 
large international cohort has made suggestions for a new nomenclature.
142
 Using the new 
protein nomenclature and aiming to achieve improved clarity, the group recommended that 
the term ‘riboflavin transporter deficiency, type 2’ be used to correspond to the SLC52A2 
encoded RFVT2 (formerly RFT3) and ‘riboflavin transporter deficiency, type 3’ to 
correspond to the SLC52A3 encoded RFVT3 (formerly RFT2). 
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Diagnostic pathway for riboflavin transporter deficiency 
Riboflavin is a precursor of flavin mononucleotide (FMN) and flavin adenine dinucleotide 
(FAD), and FAD acts as an electron acceptor for a number of acyl-CoA dehydrogenation 
reactions involved in mitochondrial fatty acid beta-oxidation and branched-chain amino acid 
catabolism. 
160
 Both FMN and FAD are required for normal mitochondrial respiratory chain 
function. Acylcarnitine profiles need to be carefully reviewed for the mild elevations of 
medium-chain acylcarnitines that are diagnostic of this disorder. While elevation of medium-
chain acylcarnitines on an acylcarnitine profile is a useful clue to the diagnosis, abnormalities 
were noted on this test in only 60% of patients in this study and in the larger cohort, showing 
that this test is not an adequately sensitive screening test.
142
 Unlike patients with SLC52A3 
mutations, patients with SLC52A2 mutations have normal urine organic acids on a urine 
metabolic screen and normal plasma FAD levels. 
152
 As the condition is potentially treatable, 
it is important that treating clinicians maintain a continued suspicion and consider genetic 
testing despite a normal acylcarnitine profile if the clinical profile is suggestive of SLC52A2 
mutations.  
 
The neuropathy associated with RFVT2 deficiency can be classified as a mitochondrial 
neuropathy. While the pathophysiological basis of the motor nerve dysfunction in this 
disorder remains to be explored, the biochemical defect is due to abnormalities of 
mitochondrial fatty acid beta-oxidation and branched-chain amino acid catabolism, resulting 
in an abnormality in energy production. BVVL also shares a number of phenotypic 
similarities with other mitochondrial diseases, especially with multisystemic involvement 
including optic atrophy and sensorineural hearing loss. As is characteristic of mitochondrial 
neuropathies (Chapter 1), the peripheral neuropathy is non-length dependent and 
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neuropathological examination of nerve biopsies in this disorder has revealed a number of 
mitochondrial abnormalities. 
 
Treatment of RFVT2 deficiency 
Functional studies have demonstrated that SLC52A2 mutations cause decreased riboflavin 
transporter expression and reduced riboflavin uptake.  This raised the possibility that therapy 
with riboflavin may be a useful therapeutic intervention in this group of patients for whom no 
disease-modifying therapy has previously been available.
131
 Doses of up to 25 mg/kg/day of 
riboflavin have been used in patients with SLC52A3 mutations, and treated individuals have 
shown improvement in muscle strength, motor function, vision and hearing, and a decrease in 
the amount of respiratory support required.
151
 However, the optimum dose and frequency of 
riboflavin administration has not yet been defined. The intestinal riboflavin transporters, 
RFVT1 and RFVT3, are expected to remain functional in patients with RFVT2 deficiency 
and further studies are required to define how to optimise riboflavin transport via these 
transporters as well as uptake via diffusion once these transporters are saturated. Similarly, 
the extent of potential improvement, especially in affected individuals with a significant 
sensory and motor neuronopathy, also needs to be established. 
 
Given the likely benefit of high-dose riboflavin in this otherwise progressive and often fatal 
disorder, clinicians need to be made aware of the phenotype of this rare disorder and institute 
riboflavin therapy in all individuals with a phenotype suggestive of riboflavin transporter 
deficiency, even while mutational analysis results are pending. Siblings of affected 
individuals should be promptly screened for the disorder, as benefit is likely to be the highest 
when treatment is started in the pre-symptomatic phase.   
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INTRODUCTION 
While the clinical phenotype of children with BVVL due to RFVT2 deficiency has been 
reported in detail, the characteristics of the hearing loss have not been explored, despite it 
being a presenting or early feature in affected individuals. Reports of individuals with RFVT2 
deficiency and of genetically undifferentiated cohorts of individuals with BVVL classify the 
hearing impairment as a ‘sensorineural hearing loss’ without a clear description of its 
characteristics.
131,142
 As this progressive neurodegenerative disorder is treatable, it is 
important that treating clinicians are able to diagnose and commence treatment early in 
children with riboflavin transporter deficiency. It is therefore important for clinicians to 
identify those children warranting further investigation, for possible riboflavin transporter 
deficiency, among the many children who present with new-onset hearing loss. 
 
Otoacoustic emissions 
The cochlea can generate several different kinds of sounds that reflect back into the middle 
ear, known as otoacoustic emissions (OAEs). Self-oscillation of the outer hair cells (OHCs), 
without a provoking stimulus, produces a pure tone sound called the spontaneous otoacoustic 
emission (SPOE). The transient evoked otoacoustic emission (TEOAE) is the cochlear echo 
that occurs after a transient sound is presented to the ear. Distortion product otoacoustic 
emissions (DPOAEs) are used for diagnostic purposes and are generated by presenting two 
tones simultaneously to the ear. These reflect function of the OHCs. DPOAEs are of low 
amplitude or absent when the OHCs are injured or destroyed. 
 
Auditory brainstem responses and cochlear microphonics 
The auditory brainstem responses (ABR) are evoked potentials from the auditory nervous 
system generated after the presentation of a transient sound, usually a click sound or a tone 
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burst. When recorded as the potential difference between a vertex electrode and a mastoid or 
earlobe electrode ipsilateral to the stimulus sound, the ABR typically consists of five to seven 
vertex positive waves. The ABR is commonly elicited by click stimulus presented to one ear 
at a time. Condensation clicks move the tympanic membrane inward initially, while 
rarefaction clicks cause the opposite movement. In simple terms, the ABR components are 
generated by the activity in sequentially activated structures along the auditory pathway. The 
cochlear microphonic (CM), recorded from an electrode at the round window, is the sum of 
potentials generated by the cochlear hair cells, mostly by the OHCs at the basal portion of the 
cochlea. 
 
Patients with auditory neuropathy spectrum disorder (ANSD) typically have abnormal or 
absent ABRs with preserved otoacoustic emissions. With an ANSD, a cochlear microphonic 
may be present at the beginning of the click recording without the presence of synchronous 
neural activity in the form of the normal ABR waves. While evaluating for ANSD, recordings 
from a click stimulus are used and responses are collected from one rarefaction and one 
condensation run. The cochlear microphonic should be in complete phase cancellation 
(‘ringing’ cochlear microphonic). To rule out a stimulus artefact, the earphone tubing is 
pinched; this should cause disappearance of all recorded responses. 
 
Auditory neuropathy spectrum disorder 
The hearing loss reported in most genetic conditions associated with a peripheral neuropathy, 
including Charcot-Marie-Tooth disease and Friedreich ataxia, is due to an auditory 
neuropathy spectrum disorder.
161
 Auditory neuropathy spectrum disorder (ANSD) is a term 
used to describe the type of hearing impairment in which OHC function (the cochlear 
amplifier) is normal but there is a disruption in afferent conduction along the auditory neural 
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pathway.
162,163
 The diagnosis of ANSD is based on a characteristic pattern of results on 
hearing assessments: absent or abnormal ABR with the presence of a CM. OAEs are often, 
but not always, present and acoustic reflexes may be elevated or absent.
164
 Depending on the 
underlying cause, the disruption could be at the level of the inner hair cells, the spiral 
ganglion fibres, the myelinated cochlear nerve fibres or the brainstem. Hearing thresholds on 
pure tone audiometry (PTA) in individuals with ANSD may vary from normal to levels 
indicating a profound hearing loss, and speech perception may be much worse than predicted 
from the pure tone audiogram.
165,166
 In addition, understanding speech in the presence of 
background noise has been reported to be especially difficult for individuals with ANSD.
167
 
Some of this difficulty in speech perception is due to temporal (rate and sequence of 
processing auditory information) disruption of the auditory signal.
168,169
 
 
This study explores the characteristics of the hearing impairment in seven children with 
BVVL due to RFVT2 deficiency, and the benefits of cochlear implantation in one affected 
child. 
 
METHODS 
Seven children (from four families) with RFVT2 deficiency due to homozygous or compound 
heterozygous mutations in SLC52A2 were enrolled in this study. I reviewed the results of 
previous hearing tests including OAE, PTA, ABR, impedance audiometry and speech 
perception tests, which had been performed at my hospital and in other centres. These tests 
were repeated at the time of genetic diagnosis and prior to the commencement of riboflavin 
therapy. Prospective audiological tests were performed by Katherine O’Brien, Department of 
Audiology, The Children’s Hospital at Westmead. Pre- and post-surgical audiological 
assessments on patient 2.2 were performed by Mandy Hill, Sydney Cochlear Implant Centre 
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and cochlear implantation was performed by A/Prof Catherine Birman, The Children’s 
Hospital at Westmead and The University of Sydney. I reviewed the pure-tone audiogram 
and ABR recordings and re-interpreted the results so that there was uniformity in the 
interpretation of the retrospectively reviewed and prospectively performed tests. When there 
was a discrepancy between the reported result and my interpretation, the test was discussed 
with audiologist Katherine O’Brien to develop a consensus. I did not perform any of the 
audiological assessments. 
 
Otoacoustic emissions (OAE) 
Distortion Product Otoacoustic Emissions (DPOAEs) were acquired using the Interacoustics 
Titan, Interacoustics OtoRead or the GSI Audera systems. Protocols were consistent between 
the three systems and as described. Two primary tones at frequency F1 and F2 with F2/F1 = 
1.22 and intensity levels of L1 and L2 = 60/50 dB SPL (SPL – sound pressure level) were 
delivered through an emission probe. DPOAE levels were recorded at F2 frequencies 
between 996.1 Hz to 8003.9 Hz. DPOAE was considered present if DPOAE level was 8 dB 
greater than the level of the noise floor at each tested F2 frequency. 
 
Audiometry  
Pure Tone Audiometry was conducted in a sound-attenuated test room with an ambient noise 
level of less than 30 dBA (decibels with an A scale filter). Pure tones were presented via 
THD39 head phones, EAR Tone 3A insert phones and B71 bone conductor using an 
Interacoustics AC33 Audiometer. Thresholds were obtained using the modified Hughson-
Westlake technique as described by Carhart and Jerger.
170
 Where masking was required, 
Hood’s plateau procedure was used.171 
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Impedance Audiometry 
Tympanometry and acoustic reflexes were obtained using the Interacoustics Titan or the GSI 
TympStar systems. Acoustic Reflexes were reported as absent if no repeatable threshold was 
obtained to a maximum stimulus of 100 dB. 
 
Electrophysiology 
ABRs were recorded using the Vivosonic Integrity evoked potential system. Acoustic click 
stimuli (100 µs) were presented to each ear individually at 80 dBnHL. Stimulus presentation 
rate was 37.7 Hz and EEG samples following at least 2000 clicks were averaged using 
Kalman Weighting to produce each test run. Initial assessment in each ear was carried out 
using rarefaction polarity clicks. In cases where an ABR could not be observed, the testing 
was repeated using condensation polarity stimuli to investigate the presence of the cochlear 
microphonic.  
 
Speech perception assessments 
At the baseline assessment prior to riboflavin therapy, speech audiometry was conducted 
using the NAL-AB Word Lists, which are based on the Consonant Vowel Consonant Words 
(CVC words) lists by Arthur Boothroyd and recorded by a native Australian speaker. 
Stimulus was presented via THD39 headphones or EAR Tone 3A insert phones.  Tests of 
expressive and receptive language ability were performed on one individual (patient 2.2) 
prior to cochlear implantation. The tests included the Peabody Picture Vocabulary test 
(PPVT) and Clinical Evaluation of Language Fundamentals – Fourth Edition (CELF-4).  
Speech production was assessed using the Diagnostic Evaluation of Articulation and 
Phonology (DEAP). Tests of speech perception performed on patient 2.2 prior to and 
following cochlear implantation included the Bench-Kowal-Bamford Sentence test (BKB 
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sentences), DeVault Common Phrases test, Manchester Junior Words test, CVC words and 
Glendonald Auditory Screening Procedure (GASP) Phoneme Detection and Imitation test. 
 
RESULTS 
The clinical profile, pedigree, and molecular genetic profile of all the individuals in this study 
is presented in Chapter 1, and that of six individuals (patients 2.1, 2,2, 3.2, 4.1,4.2 and 4.3) 
has been previously published.
142
 All individuals had homozygous p.G306R mutations in 
SLC52A2, except for patient 3.2 who had a compound heterozygous p.G306R/p.L339P 
genotype.  All patients had presented between the ages of three and eight years with either an 
ataxic gait or hearing loss. Upper limb weakness was identified in the early second decade of 
life. Patients 2.1, 2.2 and 4.3 had mild distal upper limb weakness while patients 3.2, 4.1 and 
4.2 had severe proximal and distal weakness with no movement at the shoulder or in the 
small muscles of the hand. Respiratory weakness requiring non-invasive ventilation (patients 
3.2 and 4.2) or tracheostomy (patient 4.1) and bulbar weakness requiring gastrostomy 
(patients 4.1 and 4.2) were seen with those more severely affected. Optic atrophy, usually 
mild, was seen in five of the seven individuals. 
 
Hearing loss  
Onset 
The median age of onset of hearing loss was 3 years (range 1
st
 month of life – 10 years) 
(Table 3.1). One child (patient 1.1), whose parents were consanguineous, had hearing loss 
identified in the first month of life. She had an older brother who also had congenital hearing 
loss but did not carry the homozygous SLC52A2 mutations. This raised the possibility that 
her hearing loss and its congenital onset were also influenced by another unidentified 
recessive genetic cause for hearing loss. Onset of hearing loss in infancy was also noted in 
RFVT2 Audiology 
 
 
97 
 
one individual in the cohort described by Vialetto.
127
 Hearing loss was the presenting feature 
in five of the seven affected children, and occurred two and six years after a presentation with 
gait ataxia in the other two. MRI imaging was normal without evidence of VIII nerve 
hypoplasia. 
 
Characteristics of hearing loss 
Hearing loss in BVVL due to RFVT2 deficiency had the characteristics of an ANSD. 
Otoacoustic emissions were present at onset in most individuals, consistent with normal outer 
hair cell (OHC) function. The ABR was abnormal or absent at onset with a large ringing 
cochlear microphonic that inverted with change in polarity of the click stimulus.  
 
Progression of hearing loss 
Hearing loss progressed rapidly in all affected individuals, with most progressing to severe or 
profound hearing loss, and lip reading, within 2 years of identification of the hearing loss.  
 
Interventions 
Hearing aids and FM amplification were used in all 6 individuals with poor speech 
discrimination but were of limited or no benefit. As described in Chapter 4, six of the 
individuals in this study (patients 2.1, 2,2, 3.2, 4.1,4.2 and 4.3) were treated with high-dose 
riboflavin (up to 1600 mg daily) and assessed after 24 months of therapy. Riboflavin therapy 
resulted in an improvement in auditory function in moderately affected patients (Table 5.1 
and Fig. 5.1 from Chapter 5).  
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Table 3.1: Characteristics of individuals with hearing loss in RFVT2 deficiency 
Patient 1.1 2.1 2.2 3.2 
Presenting feature 
hearing loss                 
(1 month)                  
ataxic gait (4 yrs) 
ataxic gait (8 years) ataxic gait (3 yrs) hearing loss  
Hearing loss  + + + + 
Age of onset of                                     
hearing loss 
1st month of life 10 yrs 9 yrs 5 yrs 
Audiological characteristics         
at initial hearing loss                    
diagnosis 
    
OAE absent B/L present B/L present B/L present B/L 
ABR abnormal ABR 
abnormal ABR                     
CM present 
abnormal ABR                                 
CM present 
abnormal ABR                     
CM present 
Audiometry - 
B/L mild low-
frequency HL 
R - moderate to 
severe HL                                                                   
L - severe to 
profound HL 
B/L mild to moderate 
HL 
Auditory discrimination tests 
(NAL AB word lists) 
- 
excellent speech 
perception  
poor discrimination 
without visual cues 
poor discrimination 
without visual cues 
MRI Brain and IAMS - - normal normal 
CT Petrous Temporal                            
bones 
- - - normal 
Audiological characteristics                      
prior to riboflavin therapy 
5 yrs 10 yrs 9 yrs 15 yrs 
OAE absent B/L present B/L present B/L present B/L 
ABR 
abnormal ABR                     
CM present in R ear 
abnormal ABR                     
CM present 
abnormal ABR                                 
CM present 
abnormal ABR                     
CM present 
Audiometry 
R - moderate HL                                  
L - moderate to 
severe HL 
B/L mild low-
frequency HL 
R - moderate to 
severe HL                                                       
L - severe to 
profound HL 
B/L moderate – 
severe HL 
Auditory discrimination tests 
(NAL AB word lists) - unaided 
- 
excellent speech 
perception  
poor discrimination 
without visual cues  
extremely poor 
speech discrimination 
even in aided 
condition 
Sensory ataxia present present present present 
Optic atrophy absent absent present present 
Previous treatment 
  
  
 
Hearing aids limited benefit - no benefit limited benefit 
FM device - - - some benefit 
 
OAE – otoacoustic emissions, ABR – automated brainstem responses, B/L – bilateral, R – 
right, L – left, HL – hearing loss, TROG - Test of Reception and Grammar, CM – cochlear 
microphonic, FM – frequency modulation, CT – computerised tomography, MRI – magnetic 
resonance imaging, IAMS – internal auditory meati. All audiology tests are performed 
unaided unless specified.  
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Table 3.1: Characteristics of individuals with hearing loss in RFVT2 deficiency 
(continued) 
Patient 4.1 4.2 4.3 
Presenting feature 
ataxic gait and hearing 
loss 
ataxic gait and hearing 
loss 
ataxic gait and hearing 
loss 
Hearing loss  + + + 
Age of onset of                                     
hearing loss 
3 yrs 3 yrs 3 yrs 
Audiological 
characteristics at            
initial hearing loss                    
diagnosis 
   
OAE R - present, L - absent absent B/L present B/L 
ABR abnormal ABR abnormal ABR abnormal ABR 
Audiometry 
B/L severe to profound 
HL 
B/L severe to profound 
HL 
R - moderate low-
frequency HL                                                              
L- moderate to mild HL 
Auditory discrimination 
tests (NAL AB word lists) 
- - 
(6 yrs) TROG - poor 
discrimination without 
visual cues 
MRI Brain and IAMS normal - normal 
CT Petrous Temporal                            
bones 
normal - normal 
Audiological 
characteristics                      
prior to riboflavin therapy 
15 yrs 15 yrs 20 yrs 
OAE reduced or absent B/L present B/L - 
ABR 
abnormal ABR                     
CM present 
abnormal ABR                     
CM present 
- 
Audiometry 
B/L profound to severe 
HL 
B/L profound to severe 
HL 
B/l severe to mild HL 
Auditory discrimination 
tests (NAL AB word lists) - 
unaided 
- - - 
Sensory ataxia present present present 
Optic atrophy present present present 
Previous treatment 
   
Hearing aids no benefit no benefit no benefit 
FM device - - no benefit 
 
OAE – otoacoustic emissions, ABR – automated brainstem responses, B/L – bilateral, R – 
right, L – left, HL – hearing loss, TROG - Test of Reception and Grammar, CM – cochlear 
microphonic, FM – frequency modulation. CT – computerised tomography, MRI – magnetic 
resonance imaging, IAMS – internal auditory meati. All audiology tests are performed 
unaided unless specified. 
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Cochlear implantation  
Patient 2.2 received a cochlear implant on the left side after 18 months of riboflavin therapy. 
Auditory assessment, six months prior to cochlear implant surgery, showed a mild – 
moderate hearing loss in the right ear and a severe to profound hearing loss in the left ear. 
OAEs were present bilaterally. The ABR was abnormal with a large ringing cochlear 
microphonic, absent ABR waveforms on maximum testing at 110dBHL and bilateral absent 
acoustic reflexes. Tests of receptive and expressive language ability were performed prior to 
cochlear implantation and showed poor speech perception, which correlated with the patient’s 
description that she could not understand what was said to her (Table 3.2).  
 
She received a Cochlear™ Nucleus CI422 implant on the left side.  The left side was chosen 
as it was the side with poor hearing and poorer speech perception. Intra-operative recordings 
of neural auditory function on the left side showed electrically-evoked auditory brainstem 
responses which were poorly formed but present. The cochlear implant was switched on two 
weeks after surgery. The results of audiometry and speech perception testing pre-, 6 months 
and 12 months post- implantation are in Table 3.3. These tests showed a significant and 
progressive improvement in her speech perception after cochlear implantation, enabling her 
to return to a normal class room and continue with verbal language. 
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Table 3.2: Speech and language, and speech production ability prior to cochlear 
implantation for patient 2.2 
Measure Percentile rank score 
Peabody Picture Vocabulary Test (PPVT) 14th percentile 
Clinical Evaluation of Language 
Fundamentals 4th edition (CELF-4) 
Concepts & following directions 
Recalling sentences 
Formulated sentences 
Word classes: 
Receptive 
Expressive 
Total language score: 
 
 
5th percentile 
25th percentile 
63rd percentile 
 
9th percentile 
63rd percentile 
23rd percentile 
Diagnostic Evaluation of Articulation & 
Phonology (DEAP) 
100% 
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Table 3.3: Audiometry and speech perception testing prior to and after cochlear implantation in patient 2.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI – cochlear implant, HA – hearing aid, NT – not tested, BKB sentences - Bench-Kowal-Bamford Sentence test, CVC words - Consonant 
Vowel Consonant Words, GASP – Glendonald Auditory Screening Procedure 
 
Speech Perception 
Pre-CI Pre-CI 6 months 
post-CI 
12 months 
post-CI 
12 months 
post-CI 
12 months 
post-CI 
Condition – Live Voice  Live Voice Live Voice Live Voice Live Voice Recorded Recorded 
Condition – Quiet  Quiet Quiet Quiet Quiet Quiet Quiet 
Device/s Left HA Right HA Left CI Left CI Left CI CI & HA 
DeVault Common Phrases 
- words correct   
BKB sentences 
- words correct   
 
35% 
 
0% 
 
NT 
 
46% 
 
85% 
 
78% 
 
NT 
 
94% 
 
NT 
 
70% 
 
NT 
 
82% 
Manchester Junior  
- words correct 
- phonemes correct 
CVC words 
- words correct 
- phonemes correct 
 
10% 
45% 
 
NT 
NT 
 
NT 
NT 
 
40% 
69% 
 
65% 
81% 
 
40% 
65% 
 
NT 
NT 
 
52% 
75% 
 
NT 
NT 
 
NT 
NT 
 
 
NT 
NT 
 
72% 
89% 
GASP Phoneme Detection and 
Imitation 
- vowel detection  
- consonant detection  
- vowel identification  
- consonant identification 
 
 
100% 
66% 
18% 
16% 
 
 
 
100% 
100% 
66% 
50% 
 
 
 
100% 
100% 
100% 
58% 
 
 
 
100% 
100% 
100% 
83% 
 
 
 
NT 
NT 
NT 
      NT 
 
 
NT 
NT 
NT 
NT 
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DISCUSSION 
This study has evaluated the characteristics of the hearing loss in seven children with BVVL 
due to RFVT2 deficiency and shown that this hearing loss is due to an ANSD. To date, 29 
individuals from 17 families have been reported with BVVL due to RFVT2 deficiency 
(including families 2, 3 and 4 in this study). 
137,140,142,143,172,173
 In this group, hearing loss was 
present in all affected individuals, with an earliest reported age of onset of two years, and was 
the presenting feature in five of the 17 probands. The hearing loss was rapidly progressive 
with many children progressing to severe deafness and communicating via lip reading within 
two years of identification of the hearing loss.  
 
ANSD is not uncommon and makes up approximately 8% of newly diagnosed cases of 
hearing loss in children per year.
174
  ANSD was identified in 15% of children with severe 
hearing loss identified through a universal newborn screening program and approximately 
13% of children aged 6-32 months with severe to profound hearing loss.
162,163
   Auditory 
neuropathy may be caused by acquired or genetic factors. Acquired causes and risk factors 
include hyperbilirubinemia, sepsis, prematurity, low birth weight, ototoxic drug exposure and 
hypoxic-ischaemic encephalopathy.
175,176
 Hereditary causes include primary non-syndromic 
genetic causes of auditory neuropathy and genetic disorders in which auditory neuropathy is 
an associated feature. The non-syndromic genetic causes of auditory neuropathy include 
genes with an autosomal dominant (AUNA1, PCDH), autosomal recessive (OTOF/DFNB9, 
Pejvakin/DFNB59) and X-linked (GJB2, AUNX1) inheritance.
161
 ANSD may be a feature of 
Charcot-Marie-Tooth disease,
177
 Friedreich ataxia,
178
 autosomal dominant optic atrophy due 
to OPA1 mutations,
179
 Refsum disease,
180
 Mohr-Tranebjaerg syndrome,
181
 ARTS 
syndrome,
182
 Leber hereditary optic neuropathy
183
 and other mitochondrial disorders.
184
 
Interestingly, like BVVL, many of these disorders have an associated peripheral neuropathy 
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and optic neuropathy and are often referred to as optico-acoustic neuropathies. Clinicians 
must now consider BVVL due to riboflavin transporter mutations in the differential diagnoses 
of any child who presents with new-onset auditory neuropathy, as this progressive 
neurodegenerative disorder is treatable with high-dose riboflavin and response to therapy is 
best with early treatment.   
 
Otoacoustic emissions may reduce or disappear over time in a small number of individuals 
with auditory neuropathy, as was the case in patient 4.1. Their retention should not be 
considered the only marker of auditory neuropathy, and individuals with acquired hearing 
loss should also be assessed with ABR.
185
 All children with new-onset ANSD should 
undergo testing of their serum acylcarnitine profile as part of their baseline assessment. In 
addition, as medium-chain acylcarnitines are raised on acylcarnitine profiles in only 60% of 
those with RFVT2 deficiency,
142
 genetic testing for SLC52A2 mutations may need to be 
considered despite a negative acylcarnitine profile when an alternative explanation for the 
hearing loss has not been identified.  It has been shown previously that the p.G306R mutation 
in SLC52A2 is a founder mutation in those of Lebanese heritage, and genetic testing for 
riboflavin transporter mutations should be considered in children of Lebanese origin who 
present with ANSD.
142
 Details of laboratories in Australia and overseas offering SLC52A2 
sequencing is provided in the recommendations section in the Summary and 
Recommendations chapter. The emergence of other signs of BVVL, such as gait ataxia, 
should encourage the commencement of riboflavin therapy while waiting for the results of 
genetic testing. 
 
It is not yet clear if BVVL due to riboflavin transporter deficiency can present with 
congenital (present at birth) hearing loss. Patient 1.1 in my cohort had hearing loss identified 
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soon after birth, though its early occurrence may have been caused by a different recessive 
genetic cause of hearing loss prevalent in the family. Of the children in this cohort, there is 
definite evidence of a normal ABR at birth only in siblings 2.1 and 2.2. As it is a low-cost 
test, and the benefits of early treatment are significant, an acylcarnitine profile should be 
considered even in those with congenital-onset ANSD. 
 
As with other forms of sensorineural hearing loss, hearing aids, FM systems and cochlear 
implants are some of the technologies available for the management of children with ANSD. 
While most children with ANSD, especially those younger than a year of age, will be initially 
managed with hearing aids, these are often of limited benefit as they do not address the 
underlying temporal processing deficits. 
164,186
 There is increasing evidence that children with 
ANSD may achieve greater benefit with cochlear implantation, especially when the cochlear 
nerves are normal on imaging.
187-189
 In addition, children who do not respond to amplification 
may benefit from cochlear implantation when this is done at a young age.
190-192
 Hearing aids 
were tried in six of the children in this cohort with limited or no benefit.   
 
The benefits of cochlear implantation have also been demonstrated in patients with ANSD 
associated with other inherited peripheral neuropathies.
179
 These good results in ANSD are 
possibly due to the ability of cochlear implants to improve auditory processing by aiding 
synchronous firing of the auditory nerve.
193
 Studies on children with pre-lingual deafness 
indicate that those implanted prior to 24 months of age and before the development of a 
substantial delay in language development show a greater benefit when compared to those 
implanted after 24 months of age.
194,195
 A similar benefit with implantation before 12 months 
of age has been seen with children with ANSD.
196,197
 There has been only a single previous 
report regarding the use of cochlear implantation in a family with genetically unclassified 
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BVVL, in which no benefit had been derived from hearing aids.
198
 In that kindred, cochlear 
implantation at the age of 38 and 45 years, 29 years after onset of hearing loss in both 
siblings, did not result in an improvement in speech perception. My study describes the first 
patient with BVVL reported in the literature to benefit from a cochlear implant. She was 
treated early in the disease course, within two years of identification of the hearing loss, and 
has had excellent speech perception outcomes.  
 
There is little experience of cochlear implant surgery for children with BVVL due to RFVT2 
deficiency and impaired speech perception. The success of patient 2.2 may be aided by the 
continued use of riboflavin therapy, possibly slowing or halting auditory nerve damage.  
Hearing aids are often tried initially for ANSD, and for some there is limited benefit. Mild 
low-frequency loss may recover completely with high-dose riboflavin therapy. Cochlear 
implant surgery should be performed early in children with BVVL due to RFVT2 deficiency, 
based on their impaired speech perception results, when PTA still shows moderate to severe 
hearing loss. In addition, I recommend continued use of riboflavin therapy. 
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Chapter 4 
 
Pathophysiology of motor nerve 
dysfunction in Brown-Vialetto-Van Laere 
syndrome due to RFVT2 deficiency 
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INTRODUCTION 
Brown-Vialetto-Van Laere (BVVL) syndrome is a progressive neurodegenerative disorder 
characterised by pontobulbar palsy and sensorineural hearing loss.
131
 Recently, a significant 
number of patients with BVVL have been shown to harbour homozygous or compound 
heterozygous mutations in SLC52A2 and SLC52A3.
140,141
 The SLC52A1, -A2 and -A3 genes, 
encoding the riboflavin transporters RFVT1, RFVT2 and RFVT3, are members of the solute 
carrier family 52 and are localised within the cytoplasm and endosomal vesicles. While the 
riboflavin transporters RFVT1 and RFVT3 are highly expressed in the small intestine, 
RFVT2 expression is most pronounced in foetal brain and spinal cord.
153
 Patients with 
RFVT2 deficiency develop a motor and sensory neuronopathy characterised by childhood-
onset pontobulbar palsy, sensory ataxia, upper limb weakness, respiratory insufficiency, 
sensorineural deafness and optic atrophy.
140
 This rare neurodegenerative disorder has a poor 
prognosis, resulting in loss of ambulation, respiratory failure requiring ventilation and early 
death.
142
  
 
Functional studies have demonstrated that SLC52A2 mutations reduce both riboflavin uptake 
and riboflavin transporter expression.
142,143
 Riboflavin is critical for the biosynthesis of flavin 
mononucleotide (FMN) and flavin adenine dinucleotide (FAD), important cofactors for 
carbohydrate, amino acid and lipid metabolism. FAD acts as an electron acceptor in acyl-
CoA dehydrogenation reactions in mitochondrial fatty acid oxidation and branched chain 
amino acid catabolism. Untreated patients with BVVL exhibit an increase in blood medium-
chain acylcarnitine levels, which normalizes rapidly after riboflavin supplementation. In 
addition, supplementation with riboflavin may exert a neuroprotective effect by slowing the 
disease course and improving motor function.
140,142,152
 While identification of mutations in 
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the riboflavin transporters have opened the way to therapy for BVVL, the pathophysiological 
basis of motor neuron dysfunction in this condition remains unclear.  
 
 
Figure 4.1: Severe distal upper limb weakness in BVVL due to RFVT2 deficiency. There 
is clawing of the hands and prominent wasting of the lumbricals and interossei, including the 
first dorsal interosseous muscle. 
 
 
The development of sensory and motor neuronopathy is a common clinical feature of BVVL. 
Nerve conduction studies in BVVL due to RFVT2 deficiency reveal a severe axonal sensory 
neuronopathy at presentation, followed by the development of a progressive motor 
neuronopathy.
142
 Pathological studies in BVVL have disclosed degeneration of sensory and 
motor neurons, in keeping with the neurophysiological findings.
139,142
 Novel 
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neurophysiologic tests of axonal excitability have been recently applied to various 
neurodegenerative disorders, including motor neuron disease, and have identified significant 
abnormalities in axonal ion channel function in these conditions.
199-203
 In contrast to 
conventional nerve conduction studies that explore the conduction of an impulse along a 
segment of a motor or sensory nerve, axonal excitability studies explore the properties at one 
point of the motor nerve. While conventional studies seek to classify peripheral nerve 
involvement as axonal or demyelinating, these classifications are not associated with 
characteristic findings on nerve excitability studies. Rather, nerve excitability studies 
investigate the changes in membrane potential and ion channel function that result in the 
motor nerve dysfunction. The aim of the present study was to use these novel means of 
testing axonal excitability to better characterise the pathophysiological basis of motor axon 
dysfunction in BVVL. The studies were repeated after 12 months to determine the extent to 
which any identifiable abnormalities of axonal excitability might respond to treatment with 
riboflavin and hence be included as one of the outcomes in the study evaluating the benefit of 
high-dose riboflavin therapy in BVVL due to RFVT2 deficiency. 
 
METHODS 
Patients with BVVL due to mutations in the SLC52A2 gene were prospectively recruited 
from a specialised neuropathy clinic. Henceforth, the term BVVL will be used for this group.   
The nerve excitability tests were performed by me along with Dr Michelle Farrar, and both of 
us are co-first authors on the resulting publication (Menezes MP et al. Clin Neurophysiol 
2015). All patients or their parent guardian gave informed consent for the procedures which 
were approved by the South Eastern Sydney and Illawarra Area Health Service (SCH/08/215) 
and The Children’s Hospital at Westmead Human Research Ethics Committees (11/CHW/7). 
Assessments were undertaken at baseline, at the time of initiation of riboflavin treatment, and 
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after 12 months of treatment. All patients were treated with 1000mg/day of oral riboflavin 
(Herbs of Gold, Riboflavin 200mg tablets, Kirrawee, Australia), equating to a dose of 20-
26mg/kg/day.  
 
Nerve excitability studies 
The nerve excitability studies were performed by me along with Dr Michelle Farrar, Sydney 
Children’s Hospital, Randwick, Australia and data analysis was performed under the 
supervision of Dr Michelle Farrar, Prof Steve Vucic, Westmead Hospital and The University 
of Sydney and Prof Matthew Kiernan, Brain and Mind Research Institute, University of 
Sydney. Nerve excitability studies were undertaken according to a previously described 
protocol.
200
 Stimulus current was applied at the wrist to the median nerve, recording over the 
abductor pollicis brevis muscle (APB). Skin temperature was measured at the site of 
stimulation and was stable at or above 32 °C. The studies were undertaken using TRONDNF 
protocol of the multiple nerve excitability QTRACs software (Institute of Neurology, 
London, England).  
Multiple nerve excitability variables were recorded and measured, including: 
 
1. Stimulus-response relationship 
To commence the protocol, a stimulus-response curve was generated by increasing the 
stimulus intensity in a stepwise fashion from zero, until a maximal CMAP amplitude was 
achieved. Threshold (current) refers to the stimulus current required to evoke a compound 
potential that was 40% of the maximum. 
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2. Strength-Duration relationship 
Strength-duration time constant (SDTC), a surrogate biomarker of nodal persistent sodium 
(Na
+
) conductances,
204,205
 was calculated according to Weiss’s formula.206 The rheobase, 
defined as the threshold for stimuli of infinitely long duration, 
207
 was also calculated. 
 
3.  Threshold Electrotonus (TE) and current/threshold (I/V) relationship 
Threshold electrotonus (TE) provides information about internodal membrane properties and 
conductances in addition to an estimate of resting membrane potential.
207,208
 In this protocol, 
threshold tracking was used to record changes in excitability in response to prolonged 
(100ms) subthreshold polarising currents, set to ±40% of the control threshold current.
200,207
 
The changes in threshold at different time intervals before, during and after the subthreshold 
polarising (±40% of threshold) conditioning stimuli were measured. For example, 
depolarising TE was assessed at 10 and 20ms (TEd 10- 20ms) and 90 and 100ms (TEd 90-
100ms). The parameter accommodation half-time was defined as the time from the start of 
the 40% depolarising current until the threshold reduction returned to half-way between the 
peak and plateau levels. The threshold change to hyperpolarising subthreshold conditioning 
current was assessed at 10 and 20ms (TEh 10-20ms) and 90 and 100ms (TEh 90-100ms).  
 
With the onset or offset of the polarising current, there is a fast change in threshold due to 
rapid depolarisation or hyperpolarisation at the node of Ranvier, followed by a slower change 
in threshold in the same direction, due to slower change in the potential across the internodal 
axonal membrane affecting the nodal membrane potential. Activation of the slow K
+
 
channels at the node then brings the threshold slowly back to baseline. A third slow 
component, due to the activation of the inward rectifier channel by hyperpolarization, results 
in excitation. The membrane potential is the most important variable affecting the threshold 
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electrotonus, and the threshold electrotonus can hence be used as a marker of the membrane 
potential.
207
 For example, ischemia inhibits the Na
+
 pump, resulting in membrane 
depolarization and a fall or ‘fanning in’ of the threshold electrotonus. Release of the ischemia 
results in hyperpolarization and an increase or ‘fanning out’ of the threshold electrotonus. 
 
The current-threshold relationship, a biomarker of inward and outward rectifying axonal 
currents, was also assessed.  Long duration (200ms) polarising conditioning current was 
altered in 10% steps, from +50% (depolarising) to -100% (hyperpolarising) of the threshold 
stimulus, and the change in threshold was measured 200ms after the onset of the conditioning 
current. The hyperpolarising I/V gradient was calculated from polarising current between -80 
and -100% while the resting I/V slope was calculated from polarising currents +10% to -10%. 
 
4. Recovery cycle 
The recovery cycle was determined utilising a paired pulse paradigm with a supramaximal 
conditioning stimulus preceding a test stimulus at decreasing interstimulus intervals from 200 
to 2ms.
200,209
 The following parameters were measured from the recovery cycle: (i) relative 
refractory period (RRP, ms), defined as the first intercept at which the recovery curve crosses 
the x-axis. Refractoriness is primarily due to Na
+
 channel inactivation and the RRP is a 
biomarker of transient Na
+
 channel function; (ii) superexcitability (%), defined as the 
minimum mean threshold change of three adjacent points. Superexcitability correlates well 
with the depolarising afterpotential, caused due to long-lasting passive depolarisation of the 
internodal axon by the action potential, and  is a biomarker of paranodal fast K
+
 channel 
conduction; (iii) late subexcitability (%), defined as the largest increase in threshold in three 
adjacent points following the superexcitability period. The late subexcitability correlates with 
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the late hyperpolarising afterpotential due to the slow turn-off of slow K
+
 channel and 
represents a biomarker of nodal K
+
 channel conduction.
210
  
 
Mathematical model of nerve excitability 
To model the excitability changes in motor axons in patients with BVVL, and the functional 
effects of altered axonal conductances and passive membrane properties in these subjects, 
mathematical simulations were undertaken using a model of the human axon.
199,211-214
 
Transient Na
+
 channels were modelled using the voltage-clamp data,
215
 and persistent Na
+
 
currents were added.
205
 The equations for a single node and internode, representing a 
spatially uniform axon, were assessed by integration over successive small time steps 
(Euler’s method).153,216 At times corresponding to those in human nerve excitability 
recordings, the excitability of the model nerve was tested repeatedly to determine threshold 
with an accuracy of 0.5%. The discrepancy between the thresholds determined for the model 
and those determined from a sample of real nerves was scored as the weighted sum of the 
error terms: [(xm-xn)/sn]
2
, where xm is the threshold of the model, xn the mean and sn the 
standard deviation of the thresholds for the real nerves. The weights were the same for all 
threshold measurements of the same type (e.g. recovery cycle), chosen to give an equal total 
weight to the different types of threshold measurement: current/threshold relationship, 
threshold electrotonus and the recovery cycle. The standard model was obtained by 
minimising the discrepancy between the model and the normal control data with an iterative 
least squares procedure, so that alteration of any of the above parameters would increase the 
discrepancy. 
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Statistical analysis 
Nerve excitability and grip strength dynamometry on the CMTPedS were used as the primary 
outcomes to evaluate the clinical and pathophysiological impact of 12 months of riboflavin 
therapy on motor nerve function in subjects with BVVL. The grip strength item was chosen 
as it is the subscale on the CMT Pediatric Scale (CMTPedS) corresponding best with distal 
upper limb motor nerve function. Measurements from BVVL patients at baseline were 
compared to the 95% confidence intervals (CI) of healthy controls (and considered significant 
if outside this range). Control data was obtained from 17 age-matched participants (nine 
males, eight females; age range 9-18 years, mean 12.4 years). This control data was sourced 
by including all those in the age range of 9-18 years from previously collected control data 
from a larger healthy cohort. Paired Student t-tests were used to determine differences 
between BVVL patients before and after treatment. A p-value of <0.05 was considered 
statistically significant. Results in BVVL patients are expressed as mean ± standard error of 
the mean (SEM). The results in healthy controls are expressed as mean and 95% confidence 
interval (CI), as the patient sample size was small. 
 
RESULTS 
Clinical features  
A total of six patients, aged between 10 and 21 years, from 3 different families (patients 2.1 
and 2.2 from family 2, 3.2 from family 3, and 4.1, 4.2 and 4.3 from family 4) were recruited 
for this study.  All patients were homozygous for the p.G306R mutation in SLC52A2, except 
for patient 3.2 who had a compound heterozygous p.G306R/p.L339P genotype. The clinical 
phenotype  in this patient cohort was typical of BVVL and characterised by sensory ataxia, 
progressive upper limb, axial and respiratory weakness along with cranial neuropathy 
affecting cranial nerves II (optic atrophy) and VIII (sensorineural hearing loss).
142
  Hearing 
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deteriorated rapidly, with patients progressing to lip-reading within 2 years of onset of 
hearing loss. Upper limb weakness and wasting was not present at onset but was identified in 
the early second decade of life and progressed rapidly. The weakness involved both the 
proximal and distal upper limb and was ultimately severe, resulting in a flail-arm phenotype.  
Bulbar symptoms included dysarthria, tongue weakness and dysphagia.  Respiratory 
weakness requiring invasive or non-invasive respiratory support was present in 2 patients. 
Cognition was preserved in all patients. 
 
Baseline nerve excitability 
Conventional neurophysiological testing disclosed the presence of an axonal sensorimotor 
polyneuropathy in subjects with BVVL (Table 2.3 from Chapter 2).  Nerve excitability was 
assessed in three patients with recordable median CMAP responses (patients 2.1, 2.2 and 4.3) 
2, 6 and 16 years after symptom onset respectively. The other three subjects exhibited absent 
or significantly reduced median motor responses, such that axonal excitability studies could 
not be undertaken on these patients. In the tested group, the CMAP amplitude was similar to 
healthy controls (BVVL, 5.4 ± 1.2mV; controls, 6.3 mV [95% CI 4.1 – 8.4]). The threshold 
currents required to elicit a response were similar in BVVL patients and controls (BVVL, 2.6 
± 1.2mA; controls, 3.2mA [95% CI 1.2 – 5.2]). The strength duration time constant (BVVL, 
0.42 ± 0.03ms; controls, 0.40ms [95% CI 0.36 – 0.44]) and rheobase (BVVL, 1.9 ± 1.1mA; 
controls, 2.2 mA [95% CI 0.04 – 4.4]) were also similar. A “fanned out” appearance of 
threshold electrotonus was evident in the BVVL patients, signifying greater threshold change 
to both depolarisation and hyperpolarisation (Table 4.1, Fig. 4.2A). Specifically, TEd 90-
100ms (BVVL, 56.1 ± 2.3%; controls 42.6% [95% CI 40.6 – 44.6]) and TEh 90-100ms 
(BVVL, -151.7 ± 10.2%; controls -107.8% [95% CI -116.6 – -99.0]) were significantly 
increased when compared to controls. The changes in TE were accompanied by abnormalities 
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of the I/V gradient, whereby the resting I/V gradient was significantly reduced in BVVL 
patients (BVVL, 0.44 ± 0.03; controls 0.68 [95% CI 0.64 – 0.72], Fig 4.2B). 
 
Table 4.1: Results of motor nerve excitability testing    
 
 Normal 
BVVL  
baseline 
BVVL on 
riboflavin 
  n = 17 n = 3 n = 3 
CMAP amplitude 6.3 [4.1-8.5] 5.4 ± 1.2 5.1 ± 1.1 
Strength duration time constant (ms) 0.40[0.36-0.44] 0.42 ± 0.03 0.41 ± 0.02 
Threshold electrotonus    
  Depolarizing TE peak (%) 65.1 [62.6-67.7] 76.2 ± 0.4 76.2 ± 2.6 
  Depolarising TE 40-60ms (%) 50.6[48.6-52.6] 61.5 ±  0.3 58.4 ± 1.7 
  Depolarising TE 90-100ms (%) 42.6[40.6-44.6] 56.1 ± 2.3  49.3 ± 1.3 
  Hyperpolarising TE 10-20ms (%)  -70.8[-74.5--67.1] -88.8 ± 4.6 -77.9 ± 1.9 
  Hyperpolarising TE 90-100ms (%)  -107.8[-116.6--99] -151.7 ± 10.2 -129.9 ± 5.5 
Current-voltage relationship    
  Resting I/V slope  0.68 [0.64-0.72] 0.44 ± 0.03 0.54 ± 0.03 
Recovery cycle    
  Refractoriness at 2.5ms (%)  23.8[13.4– 34.2] -4.8 ± 4.8 15.8 ± 12.3 
  Superexcitabilty (%)  -26.2[-28.2--24.2] -37.5 ± 1.7 -32.4 ± 2.1 
  Late subexcitability (%) 13.9[12.7-15.1] 11.8 ± 3.1 11.4 ± 0.9 
Results in BVVL patients are expressed as mean ± standard error of the mean (SEM) and in 
healthy controls as mean and 95% confidence intervals (CI). p-values comparing BVVL 
baseline to BVVL on riboflavin. Significant results (p < 0.05) in bold.  
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Figure 4.2: Nerve excitability measures in BVVL patients and normal controls 
 
 
Comparison of multiple measures of nerve excitability in median motor nerves in BVVL 
patients at baseline (filled circles) and normal controls (dashed lines) plotted as mean and 
standard errors of mean or 95% confidence intervals respectively. Riboflavin therapy resulted 
in significant modulation of excitability with partial reversibility of baseline changes (open 
circles = BVVL patients ON riboflavin therapy; filled circles = BVVL patients baseline). 
(A) Threshold electrotonus, depicting TEh 90–100 ms and TEd 90–100 ms. 
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Figure 4.2: Nerve excitability measures in BVVL patients and normal controls 
(continued) 
 
 
Comparison of multiple measures of nerve excitability in median motor nerves in BVVL 
patients at baseline (filled circles) and normal controls (dashed lines) plotted as mean and 
standard errors of mean or 95% confidence intervals respectively. Riboflavin therapy resulted 
in significant modulation of excitability with partial reversibility of baseline changes (open 
circles = BVVL patients ON riboflavin therapy; filled circles = BVVL patients baseline). 
(B) Current threshold relationship. 
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Figure 4.2: Nerve excitability measures in BVVL patients and normal controls 
(continued) 
 
Comparison of multiple measures of nerve excitability in median motor nerves in BVVL 
patients at baseline (filled circles) and normal controls (dashed lines) plotted as mean and 
standard errors of mean or 95% confidence intervals respectively. Riboflavin therapy resulted 
in significant modulation of excitability with partial reversibility of baseline changes (open 
circles = BVVL patients ON riboflavin therapy; filled circles = BVVL patients baseline). 
(C) Recovery cycle of excitability, demonstrating reduced refractoriness and increased 
superexcitability at baseline.   
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The recovery cycle of axonal excitability curves was markedly shifted downwards in BVVL 
patients when compared to controls (Fig. 4.2C). Specifically, there was a significant 
reduction in refractoriness at 2.5 ms (BVVL, -4.8 ± 4.8%; controls, 23.8 [95% CI 13.4 – 
34.2]) and an increase in superexcitability (BVVL, -37.5 ± 1.7; controls -26.2 [95% CI -28.2 
– -24.2], Table 4.1, Fig 4.2C) in subjects with BVVL. Late subexcitability was similar 
between the groups (BVVL, 11.8 ± 3.1; controls 13.9 [95% CI 12.7 – 15.1]).  
 
Mathematical modeling of abnormal excitability properties  
To assist in interpreting the complex changes observed in clinical nerve excitability 
measures, a mathematical model of the human motor axon was adjusted to provide a close 
match to the age-matched control group. The model was then used to explore whether 
changes in any membrane parameter could reproduce the changes seen in BVVL patient 
recordings (3 patients).  Alterations in membrane conductances or potential, in isolation, 
could not account satisfactorily for the changes seen in subjects with BVVL. Membrane 
hyperpolarisation reduced the discrepancy by 67%, yet did not support similarities in late 
subexcitability, ΤSD and threshold between BVVL patients and controls. Rather, increasing 
the Barrett and Barrett conductance (GBB) from 35.2 to 50.5 units reduced the discrepancy 
by 76.7% (Fig. 4.3). The GBB refers to passive membrane property related to applied 
currents accessing and crossing the internodal compartment of the axon.
207
 An increase in 
GBB may be caused by abnormal myelin permeability, secondary to thin or leaky myelin, or 
by a loosening of paranodal seal. Modeling of changes in two parameters improved the fit to 
77.1% by means of increasing GBB from 35.2 to 47.5 units and reducing leak conductances 
from 1 to 0.82 units. Consequently, the mathematical modeling suggested that an increase in 
myelin permeability may account for the abnormalities of axonal excitability in BVVL.
214
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Figure 4.3: Simulation of the excitability changes in clinical nerve excitability in BVVL patients using the mathematical model 
 
 
 
 
Open circles represent the model generated by the normal control group. Black lines were generated by the model by increasing GBB from 35.2 
units to 50.5 units, which reduced the discrepancy by 76.7%. (A) Threshold electrotonus for 100-millisecond polarising currents ±40% of the 
resting threshold. (B) Current-threshold relationship. (C) Recovery cycles.   
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ASSESSMENTS AFTER 12-MONTHS OF RIBOFLAVIN THERAPY 
Improvement in motor nerve function  
Treatment with riboflavin was accompanied by partial normalisation of motor nerve function 
(Table 4.1, Fig. 4.2).  Specifically, there was a significant improvement in threshold 
electrotonus, with reduced TEd (90-100ms) and TEh (90-100ms) (TEd90-100ms: 
BVVLbaseline, 56.1 ± 2.3, BVVLon riboflavin, 49.3 ± 1.3, p<0.05, TEh90-100ms: BVVL baseline, -
151.7 ± 10.2; BVVLon riboflavin, -129.9 ± 5.5, p<0.05). There was also an increase in resting I/V 
slope (BVVL baseline, 0.44 ± 0.03; BVVLon riboflavin, 0.54 ± 0.03, p<0.05). Prominent changes 
were also noted in the recovery cycle of nerve excitability, with reduction in superexcitability 
(BVVL baseline, -37.5 ± 1.7; BVVLon riboflavin, -32.4 ± 2.1, p<0.05) and an increase in 
refractoriness at 2.5ms (BVVL baseline, -4.8 ± 4.8; BVVLon riboflavin, 15.8 ± 12.3, p=0.06). The 
excitability changes suggested that riboflavin therapy exerted a stabilising effect on myelin 
permeability in BVVL patients. Similarly, there was an improvement in absolute scores for 
grip strength on dynamometry (Table 5.2 from Chapter 5), contrasting with the natural 
history outcomes in untreated BVVL patients, who typically experience progressive upper-
limb weakness. This was paralleled by improvement on audiometry in the younger affected 
individuals, and stable or improved respiratory function in all six individuals. 
 
DISCUSSION 
Utilising the axonal excitability technique, the present study established that abnormalities of 
passive membrane properties were a feature of BVVL.  Specifically, an increase in 
depolarising and hyperpolarising threshold electrotonus, termed the ‘fanned-out’ appearance, 
was evident in BVVL.  The changes in TE were accompanied by a reduction in the current–
threshold slope and refractoriness, along with an increase in superexcitability.  Mathematical 
modeling suggested that abnormalities of axonal excitability were best explained by 
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alteration in passive membrane properties, namely an increase in the Barrett and Barrett 
conductance (GBB), while axonal ion channel function and resting membrane potential were 
maintained. The increase in GBB could be attributed to an increase in myelin permeability, 
either due to thin or leaky myelin or an increased permeability of the paranodal region, a 
pathophysiological process that may be secondary to riboflavin deficiency.    
 
Pathophysiological mechanisms underlying BVVL neuropathy  
Although riboflavin deficiency secondary to SLC52A2 gene mutations is postulated to 
underlie the BVVL phenotype, the pathophysiological processes mediating this condition 
have not yet been fully elucidated.  Importantly, BVVL is characterised by a sensorimotor 
axonal neuropathy.
142
  Given that riboflavin is an important co-factor in the synthesis of 
myelin,
217
 abnormalities of myelin permeability may account for the development of the 
BVVL neuropathy.  Schwann cells are critical in maintaining axonal integrity, and axonal 
degeneration due to primary Schwann cell and myelin dysfunction has been demonstrated in 
other inherited neuropathies.
218-221
  
 
Myelin adheres to axons at the paranodal junction, an axonal region that is permeable to 
small molecules, thereby forming a pathway to ‘short-circuit’ the nodal currents.222  The 
paranodal currents may traverse three possible pathways including (i) along the paranodal 
periaxonal space, (ii) through the obliquely-oriented transverse bands and (iii) between 
adjacent lamellae of myelin sheaths.
223
 While structural changes in peripheral nerve 
myelination have not been previously described in BVVL, the findings in the present study 
would suggest that dysfunction at the paranodal region, particularly loosening of the 
paranodal seal, may lead to an increase in GBB and superexcitability in this condition. The 
changes demonstrated here are due to functional alteration in the myelin (increased 
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permeability) rather than demyelination.  Consequently, significant changes in motor 
conduction velocity would not be expected, a notion underscored by the nerve conduction 
study findings in the BVVL cohort (Table 5.1 from Chapter 5). It should be highlighted that 
the axonal excitability abnormalities evident in BVVL are different from those previously 
described in dysmyelination of maturing nerves,
214,224,225
 mitigating against the possibility 
that the abnormalities evident in the present study are relate simply to delayed nerve 
maturation.  Underscoring this notion are pathological studies in riboflavin-deficient animal 
models which develop a similar neuropathy to BVVL patients, disclosing abnormalities of 
myelin with dissociation of both the inner and outer spirals of the myelin lamellae.
226,227
  In a 
mouse model of mitochondrial dysfunction, cerebroside depletion was shown to interfere 
with the maintenance of Schwann cell-axon contacts on electron microscopic analysis, with 
enlarged nodal gaps and axons that had pulled away from their myelin sheaths.
125
  
 
It could be argued that age was a confounding factor in the present study, particularly given 
that GBB changes with nerve maturation.  This seems unlikely given that an age-matched 
reference model was used and that maturational changes in axonal excitability reach a plateau 
between 8-15 years, the very age range of two of the patients modeled (1.1 and 1.2). 
Separately, it may be expected that an increase in GBB should also lead to reduction in ΤSD, 
although this was not observed in the current study.  ΤSD depends on many membrane 
parameters and a possible explanation may relate to subtle differences in these (for example 
leak conductance, nodal capacitance, nodal K
+
 and Na
+
 conductances or nodal width).
206
 This 
notion is supported by the mathematical simulations of excitability changes in the present 
study, as a reduction in leak conductance should lead to an increase in ΤSD, opposing the 
effect of increasing GBB.   
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Progress with riboflavin therapy 
The natural history of BVVL is of progressive neurodegeneration together with decline in 
motor amplitudes. 
142
 Previous excitability studies in motor neuron disease have 
demonstrated progressive axonal dysfunction paralleling clinical impairment and also 
established the reproducibility of demonstrated abnormalities of axonal excitability. 
199,228
 
The longitudinal improvement in nerve excitability profiles with riboflavin treatment in all 
BVVL patients in this series, which was accompanied by improvement in grip strength and 
stable motor amplitudes (Chapter 5), appears incongruous with the natural history, 
suggesting that riboflavin exerts positive effects on peripheral nerve function with 
modulation of myelin dysfunction.   Stabilisation of the myelin sheath would in turn be 
expected to prevent further axonal degeneration and promote recovery, which is supported by 
the motor amplitudes remaining stable. In my cohort, the established and severe sensory 
neuronopathy did not improve with therapy. In contrast, neuropathy of more recent onset 
(motor neuropathy of onset in early 2
nd
 decade and mild in the younger siblings, VIII nerve 
involvement hearing loss in the younger children) improved significantly with therapy. This 
emphasises the need for clinicians to diagnose and commence therapy early in children with 
the disorder. 
 
Taken together, findings from the present study suggest that abnormalities of myelin function 
are a feature of BVVL and these may be partially normalised with riboflavin therapy.  These 
findings also suggest that nerve excitability studies may be further developed in larger 
cohorts as a potential biomarker, to identify and monitor treatment response and to guide 
more specific and tailored treatment strategies for BVVL patients.
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Chapter 5 
 
Outcome after therapy with riboflavin in 
Brown-Vialetto-Van Laere syndrome due 
to RFVT2 deficiency
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INTRODUCTION 
Brown-Vialetto-Van Laere (BVVL) syndrome due to riboflavin transporter type 2 (RFVT2) 
deficiency is a neurodegenerative disorder with a poor prognosis in which disease 
progression results in loss of ambulation, respiratory failure and early death. 
142
  Nerve 
excitability studies (Chapter 4) suggest that motor dysfunction may be more amenable to 
therapy commenced early in the course of BVVL. The sensory deficit is due to an early-onset 
ganglionopathy which is already established at diagnosis and unlikely to improve with 
disease-modifying therapy. In contrast, strength and motor amplitudes on nerve conduction 
studies may be normal at presentation and subsequently deteriorate. Early evidence from a 
small number of patients on short-term treatment demonstrates that supplementation with 
riboflavin may be beneficial in slowing disease progression and may improve motor 
function.
140,142,152
 The possible pathophysiology of motor nerve dysfunction and partial 
recovery with riboflavin therapy has been discussed in Chapter 4. The variable progression 
and lack of a sensitive and relevant assessment scale remains a challenge in objectively 
evaluating efficacy of treatment in BVVL.  
 
While the phenotype of BVVL due to RFVT2 mutations is unique, there is significant 
variability in age of onset and rate of progression.
140,142,143,172,173
  The age of onset ranges 
from infancy to late childhood. While some patients become non-ambulant in early 
childhood, others continue to ambulate independently into early adulthood. Developing a 
robust clinical and functional scale that can characterise the heterogeneity in disease severity 
and course, including sensory and motor deficits, is critical to mapping the natural history of 
neurodegeneration in this disorder.  A sensitive scale is also necessary to evaluate the 
efficacy of therapeutic interventions.  
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The aim of the present study was to define the baseline motor and sensory deficits in a 
diverse cohort of patients with BVVL due to RFVT2 deficiency using the Charcot-Marie-
Tooth Pediatric scale (CMTPedS).
96
 The study also aimed to monitor progression of disease 
on riboflavin therapy using the CMTPedS and other clinical assessments.  
 
METHODS 
Patients with BVVL due to mutations in the SLC52A2 gene were prospectively recruited 
from a specialised neuropathy clinic. Clinical (CMTPedS, respiratory function testing and 
audiometry) and biochemical (acylcarnitine profile) assessments were combined with 
conventional and specialised neurophysiological tests. Clinical and functional retrospective 
data were utilised, to enable comparison with untreated patients. Research assessments on the 
CMTPedS scale were part of a study approved by The Children’s Hospital at Westmead 
Human Research Ethics Committee (11/CHW/7). I performed and interpreted all the clinical 
assessments, nerve excitability tests and CMTPedS assessments that are detailed in Chapters 
4 and 5, both at baseline as well as after 12 and 24 months of therapy. The nerve excitability 
tests were performed by me along with Dr Michelle Farrar, and both of us are co-first authors 
on the resulting publication.  I performed the CMTPedS assessments under the supervision of 
Prof. Joshua Burns, Pediatric Gait Analysis Service, The Sydney Children’s Hospital 
Network and The University of Sydney.   
 
Assessments were undertaken at baseline, at the time of initiation of riboflavin treatment, and 
compared with those after 12 and 24 months of treatment. All patients were treated with 
1000mg/day of oral riboflavin (Herbs of Gold, Riboflavin 200mg tablets, Kirrawee, 
Australia), equating to a dose of 20-26mg/kg/day, for the first 12 months, and with 1600mg 
of riboflavin (32-42mg/kg/day) for the next 12 months. The results of axonal nerve 
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excitability testing at baseline and after 12 months of therapy with riboflavin are reported in 
Chapter 4.  
 
Clinical and functional grading  
All patients were clinically assessed using the Charcot-Marie-Tooth Pediatric Scale 
(CMTPedS), an 11-item linearly weighted scale that has been validated as a reliable and 
sensitive global measure of disability in children with a variety of CMT types from the age of 
3 years, including those genetic types that are more severe than CMT1A.
96
 The CMTPedS 
was chosen as it includes subscales that evaluate upper limb and lower limb strength (grip, 
ankle dorsiflexion and plantarflexion), sensation (vibration and pinprick) and function (upper 
limb - functional dexterity and 9-hole peg tests, lower limb – balance, gait manoeuvres, long 
jump and 6-minute walk test). According to the original publication, raw scores for each item 
(seconds, Newtons, metres) are converted to dimensionless z-scores based on age- and sex-
matched normative reference values. The z-scores for each item are then categorised into 
individual point scores of 0 (normal) to 4 (severe). Summation of individual scores generates 
a total score from 0 (normal) to 44 (severe disability). While more severely affected subjects 
with BVVL are non-ambulant, and hence unable to attempt some items, the range of items 
covered by the CMTPedS and their contribution to the total score make both the total score 
and comparison separately on various items a useful mode of monitoring those affected. The 
CMTPedS has also been shown to be sensitive to change over a 1-year period in children 
with CMT.
97
 
 
RESULTS 
As described in Chapter 4, a total of six patients, aged between 10 and 21 years, from three 
different families (patients 2.1 and 2.2 from family 2, 3.2 from family 3, and 4.1, 4.2 and 4.3 
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from family 4) were recruited for this study.  Patients from family 4 were only assessed at 12 
months as their care was transitioned to an adult facility after this time. All patients were 
homozygous for the p.G306R mutation in SLC52A2, except for patient 3.2 who had 
compound heterozygous p.G306R/p.L339P genotype. Overall, there was a broad spectrum of 
clinical severity, ranging from mild to profound weakness and functional impairment, as 
reflected by the variation in baseline CMTPedS scores, respiratory function testing and 
audiometry. At baseline before riboflavin therapy, two patients were wheelchair-bound while 
four patients continued to walk despite being unsteady due to severe sensory ataxia.  
 
Neurophysiological features 
All patients demonstrated a sensorimotor axonal neuropathy with relative preservation of 
conduction velocities (Table 5.1). Historical data for patient 2.2 demonstrated a progressive 
decline in distal median CMAPs over a period of seven years (11.1mV at 3 years of age to 
3.1mV at 9 years of age).   
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Table 5.1: Comparison of assessments in patients with BVVL at baseline and after 12 and 24 months of riboflavin therapy 
Patient 2.1 2.2 3.2 
Gender F F F 
Disease duration (yrs) 2 6 10 
Ambulation independently ambulant independently ambulant independently ambulant 
 
Previous Baseline 12m 24m Previous Baseline 12m 24m Previous Baseline 12m 24m 
Age at assessment (yrs) 8 10 11 12 8 9 10 11 
 
16 17 18 
CMTPedS total score 
 
18 21 16 19 27 25 26 
 
33 31 30 
Nerve conduction 
studies     
5 yrs 
   
8 yrs 
   
Median motor (APB) 
            
CMAP (mV) 
 
9.3 6 
 
8.2 3.1 4.2 
 
5.1 NR NR 
 
CV (m/s) 
 
49 47 
 
48 43 49 
 
44 
   
Tibial motor (AH) 
            
CMAP (mV) 
 
8 9.8 
 
12.1 6.3 4.3 
  
13.2 13.1 
 
CV (m/s) 
 
45 47 
 
44 42 45 
  
40 42 
 
Median SAP (µV) NR NR NR 
 
NR NR NR 
 
3 5 3 
 
Sural SAP (µV) NR NR NR 
 
NR NR NR 
 
NR NR NR 
 
Audiology 
    
8 yrs 
   
8 yrs 
   
Pure tone audiometry 
 
B/L mild 
low-
frequency 
normal -
normalised 
at 6 
months 
B/L mild 
low-
frequency 
normal 
R - 
moderate-
severe                          
L - severe-
profound 
R - mild-
moderate                          
L - severe to 
moderate 
R - mild-
moderate                          
L - severe 
to 
moderate 
B/L 
moderate 
B/L 
moderate-
severe 
B/L 
moderate-
severe 
B/L 
moderate-
severe 
Respiratory function 
testing (% predicted)  
6 months 
of therapy   
8 yrs 
   
13 yrs 
6 months 
of therapy   
FEV1 
 
98 93 113 93 ND 89 84 76 66 63 69 
FVC 
 
95 93 103 93 ND 97 90 79 66 68 73 
BiPAP/Ventilation 
pressure (cm of H2O)             
Acylcarnitine profile 
 
abnormala normal normal 
 
abnormala normal abnormala 
 
abnormala normal ND 
FAD level (nmol/L) 
 
267 385 (407) 356 
 
253 211 (383) 271 
 
245 293 (324) ND 
 
M - male, F - female, CMTPedS - CMT pediatric scale, CMAP - compound muscle action potential, SAP - sensory action potential, NR - not 
recordable, ND - not done, L - left, R - right, FAD - flavin adenine dinucleotide, B/L – bilateral, aelevated medium chain acylcarnitines, 
b
baseline data not available. Abnormal nerve conduction values (< 2SD) indicated in bold.
100
  Riboflavin levels at 6 weeks in parentheses.
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Table 5.1: Comparison of assessments in patients with BVVL at baseline and after 12 and 24 months of riboflavin therapy (continued) 
Patient 4.1 4.2 4.3b 
Gender M M M 
Disease duration (yrs) 13 13 16 
Ambulation non-ambulant non-ambulant independently ambulant 
 
Previous Baseline 12m Previous Baseline 12m Baseline 12m 
Age at assessment (yrs) 
 
16 17 
 
16 17 20 21 
CMTPedS total score 
 
35 37 
 
36 38  28 
Nerve conduction 
studies 
15 yrs 
     
 
 
Median motor (APB) 
      
 
 
CMAP (mV) NR NR NR 
 
1.3 1.4  6 
CV (m/s) 
    
51 41  
 
Tibial motor (AH) 
      
 
 
CMAP (mV) 6.8 9.6 8.3 
 
10.4 11.9  
 
CV (m/s) 40 39 44 
 
38 41  
 
Median SAP (µV) NR NR NR 
 
NR NR  
 
Sural SAP (µV) NR NR NR 
 
NR NR  
 
Audiology 11 yrs 
  
11 yrs 
  
 
 
Pure tone audiometry 
B/L severe to 
profound 
B/L profound to 
severe 
B/L profound 
R - severe-
profound                            
L - profound 
B/L profound to 
severe 
R - profound to 
severe                       
L- profound 
B/L severe to 
mild 
B/L profound to 
mild 
Respiratory function 
testing (% predicted) 
ventilated nocturnal BiPAP 
 
FEV1 
      
 71 
FVC 15 yrs 
  
15 yrs 
  
 77 
BiPAP/Ventilation 
pressure (cm of H2O) 
16/5 16/5 12/5 10/5 20/8 18/8  
 
Acylcarnitine profile 
 
normal normal 
 
normal normal  normal 
FAD level (nmol/L) 
 
369 336 (396) 
 
310 455 (380)  324 
 
M - male, F - female, CMTPedS - CMT pediatric scale, CMAP - compound muscle action potential, SAP - sensory action potential, NR - not 
recordable, ND - not done, L - left, R - right, FAD - flavin adenine dinucleotide, B/L – bilateral, aelevated medium chain acylcarnitines, 
b
baseline data not available. Abnormal nerve conduction values (< 2SD) indicated in bold.
100
  Riboflavin levels at 6 weeks in parentheses.
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Table 5.2: CMT Pediatric Scale (CMTPedS) in patients with BVVL at baseline and 
after 12 and 24 months of riboflavin therapy 
Patient 2.1 2.2 
  Baseline 12m 24m Prev Baseline 12m 24m 
Age at assessment 
(years) 
10 11 12 7 9 10 11 
Functional dexterity 
test (sec) 
26.3 34.97 26.5 32.47 62.27 48.49 48.25 
Point score 1 4 1 1 4 4 4 
Nine-hole peg test 
(sec) 
27.1 28.63 25.87 32.18 32.88 31.19 34.74 
Point score 3 3 4 4 4 4 4 
Grip (Newtons) 118 174 204 47.3 72 82 89.3 
Point score 0 0 0 1 1 1 2 
Ankle plantarflexion 
(Newtons) 
276 204 238.3 172.3 210 215 183.3 
Point score 0 0 0 0 0 0 0 
Ankle dorsiflexion 
(Newtons) 
74 77.67 124.7 80 72.3 80.3 86 
Point score 3 3 1 1 3 3 3 
Pinprick (point score) 0 0 0 0 0 0 0 
Vibration (point score) 4 4 4 4 4 4 4 
BOT-2 score (raw) 8 8 18 2 1 4 3 
Point score 4 4 2 4 4 4 4 
Gait (point score) 0 0 0 1 2 0 0 
Long Jump (cm) 70 71 105 49 51 50 58 
Point score 2 2 1 2 3 3 2 
6-minute walk test 
(metres) 
555 570 507 467 500 510 450 
Point score 1 1 3 1 2 2 3 
Total score 18 21 16 19 27 25 26 
 
Balance BOT-2- Bruininks Oseretsky test of Motor Proficiency 2
nd
 Edition, 
b
baseline data not 
available 
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Table 5.2: CMT Pediatric Scale (CMTPedS) in patients with BVVL at baseline and 
after 12 and 24 months of riboflavin therapy (continued) 
Patient 3.2 4.1 4.2 4.3
b
 
  Baseline 12m 24m Baseline 12m Baseline 12m 12m 
Age at assessment 
(years) 
15 16 17 16 17 16 17 21 
Functional 
dexterity test (sec) 
150 150 150 150 150 150 150 44.16 
Point score 4 4 4 4 4 4 4 4 
Nine-hole peg test 
(sec) 
150 150 150 150 150 150 150 43.72 
Point score 4 4 4 4 4 4 4 4 
Grip (Newtons) 0.7 0 0 20 24 0 36 326.7 
Point score 4 4 4 4 4 4 4 2 
Ankle 
plantarflexion 
(Newtons) 
248.7 244.3 243.7 234.3 182.3 194.7 146.7 221.7 
Point score 0 0 0 0 1 1 2 0 
Ankle dorsiflexion 
(Newtons) 
75 109 106.7 101.3 108.3 98.7 105 113.7 
Point score 4 2 2 3 4 3 4 2 
Pinprick (point 
score) 
0 0 0 0 0 0 0 0 
Vibration (point 
score) 
2 3 2 4 4 4 4 4 
BOT-2 score (raw) 1 2 2 0 0 0 0 0 
Point score 4 4 4 4 4 4 4 4 
Gait (point score) 3 2 2 4 4 4 4 0 
Long Jump (cm) 43 26 44 0 0 0 0 0 
Point score 4 4 4 4 4 4 4 4 
6-minute walk test 
(metres) 
350 365 350 0 0 0 0 0 
Point score 4 4 4 4 4 4 4 4 
Total score 33 31 30 35 37 36 38 28 
 
Balance BOT-2- Bruininks Oseretsky test of Motor Proficiency 2
nd
 Edition, 
b
baseline data not 
available 
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CMTPedS  
Total CMTPedS scores at baseline ranged from 18-36, with two individuals (2.1, 2.2) being 
moderately affected (CMTPedS score between 15-29) and three (3.2, 4.1, 4.2) severely 
affected (CMTPedS score between 30-44). Review of the CMTPedS subscales (Table 5.2) at 
baseline confirms many of the unique features of the RFVT2 phenotype. Affected individuals 
had worse scores on the subscales that measure sensation (vibration, BOT-2) and functional 
scales that rely predominantly on normal proprioception (functional dexterity, nine hole peg 
test), irrespective of disease duration, consistent with their clinical presentation with early-
onset severe ataxia and absent sensory responses in the upper and lower limbs on nerve 
conduction studies (Table 5.1) .  
 
The sensory loss associated with RFVT2 deficiency is consistent with a large-diameter fibre 
sensory neuronopathy (ganglionopathy). The early-onset sensory ataxia and positive 
Romberg sign, absent reflexes in the upper and lower limbs early in disease course and non-
length dependent pure sensory abnormalities on nerve conduction studies with none or 
limited motor involvement at disease onset are all consistent with a sensory 
ganglionopathy.
229
 The finding is also consistent with the severe proprioceptive abnormality 
causing difficulty with functional tasks like the functional dexterity test and nine hole peg test 
in the younger affected individuals despite preserved grip strength. The preserved sensation 
to pinprick, irrespective of disease duration, shows that small-fibre sensory nerves remain 
unaffected even late in disease course. 
 
In contrast, motor involvement showed differential involvement of the upper and lower limbs 
and progression of upper limb weakness with disease duration.  Those early in the disease 
course had normal grip strength or only mild weakness while those with advanced disease 
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had only minimal movement of the upper limbs. In contrast, ankle dorsiflexion and 
plantarflexion strength were preserved even late in disease course. This parallels the change 
in motor amplitudes on nerve conduction studies (Table 5.1) with normal upper and lower 
limb CMAPs at presentation, and a progressive decline in upper limb CMAPs with disease 
progression. 
 
Change with riboflavin therapy 
The mean change in the CMTPedS total score after treatment with riboflavin was a 
deterioration of 0.66 points (range +3 to -2, n=5) after 1 year and an improvement of 1.66 
points (range -1 to -2, n=3) after 2 years. Interpreting the magnitude of this change is difficult 
due to the lack of natural history data in large cohorts of subjects with this condition. The rate 
of progression in CMT1A, a more common but less severe neuropathy, is +0.6 points/year.
97
 
In addition, BVVL is a progressive neurodegenerative condition in which improvement 
without therapy has not previously been described. 
131
 Historical CMTPedS data was 
available for patient 2.2 and showed that her total CMTPedS score had deteriorated from 19 
to 27 over the preceding 12 months prior to riboflavin therapy, with worsening in functional 
dexterity, ankle dorsiflexion strength, long jump distance and six-minute walk test (6MWT) 
distance. 
 
Scores on the subscales measuring sensory function showed no change over the two year 
period of treatment. In contrast, absolute scores for grip strength improved, especially in the 
less severely affected, consistent with the improvement in motor nerve function on axonal 
excitability studies (Chapter 4). Absolute scores for ankle dorsiflexion and plantarflexion  
varied, but Z-scores were stable. Similarly, long jump distance improved or remained stable, 
both on absolute as well as Z-scores, in those who were able to attempt the test. However, the 
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6MWT distance, a functional performance measure that requires both balance and strength, 
deteriorated in the second year of therapy. 
 
Audiology 
Riboflavin therapy resulted in significant improvement in auditory function in moderately 
affected patients (Table 5.1 and Fig. 5.1). Patient 2.1 had low frequency hearing loss 
identified at baseline which resolved after a year of riboflavin therapy. The hearing loss was 
identified again when evaluated after 24 months of therapy; this apparent relapse may have 
related to poor compliance with riboflavin. Patient 2.2 had moderate to severe hearing loss in 
the right ear and severe – profound hearing loss in the left ear, which improved after a year of 
riboflavin therapy and then remained stable.   
 
Respiratory function testing 
Respiratory function testing was possible in 3 patients at baseline (Table 5.1). Forced vital 
capacity (FVC) remained normal in the 2 patients in whom baseline studies were normal, and 
remained stable in patient 3.2 during the period of observation, after deteriorating in the 2 
years prior to therapy initiation. In those patients who required ventilation, pressures 
decreased significantly in patient 3.1 and stabilised, after a year of significant increase, in 
patient 3.2. 
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Figure 5.1: Audiometry in BVVL patients before and after riboflavin therapy 
 
Audiometry in patient 1.2 (A,B,C) and 1.1 (D,E) showing deterioration during disease course, and improvement following riboflavin therapy. 
Patient 1.2 progressed from normal (A) to severe hearing loss (B) over 12 months with improvement after 12 months of riboflavin therapy (C). 
Patient 1.1 was diagnosed with low frequency hearing loss at baseline (D), returning to normal after 12 months of riboflavin therapy (E).   
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Biochemical profile 
Untreated patients with BVVL have an elevation of medium-chain acylcarnitines which 
normalises rapidly after riboflavin supplementation. Elevation of medium chain 
acylcarnitines was evident in 60% of BVVL patients at baseline. Riboflavin therapy led to 
normalisation of medium-chain acylcarnitine levels within six weeks of commencement of 
treatment (Table 5.1). No significant adverse effects were reported during the two years of 
riboflavin therapy.  
 
Patients 2.1 and 2.2 reported poor compliance with the riboflavin during the second year of 
therapy due to the need to take large doses (three capsules three times a day). This was 
reflected in recurrence of mild abnormalities in the acylcarnitine profile of patient 2.2. 
 
DISCUSSION 
In this study, the CMTPedS has been used as an effective tool in characterising disease 
burden in affected individuals with RFVT2 deficiency. As CMTPedS has subscales that 
evaluate strength, sensation and function, it is useful in defining baseline deficits and 
monitoring progression in BVVL, particularly as each of these domains may be differentially 
involved at different stages of the disease. The individuals studied in this series showed wide 
variation in disease severity as measured by the CMTPedS, partly related to disease duration, 
though there were outliers to this rule; patient 4.3 had less severe disease when compared to 
his twin brothers (patients 4.1 and 4.2) who carried the same mutation, indicating that there 
are other genetic, epigenetic or environmental factors moderating disease severity in BVVL. 
 
Evaluation of the CMTPedS at baseline characterised the unique features of BVVL due to 
RFVT2 deficiency: differential motor and sensory involvement, severe large fibre sensory 
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ganglionopathy early in disease course and progressive upper limb muscle weakness with 
relative sparing of the lower limbs. At baseline, the CMTPedS was sensitive to increased 
upper limb weakness and development of restrictive lung disease and hence could be used to 
identify when surveillance for restrictive lung disease should begin. The CMTPedS appears 
sensitive to baseline disability and progression of disease in BVVL and further studies 
formally validating it for clinical trials in BVVL are warranted. This study does provide 
face/content validation and shows that the CMTPedS does hold promise as a useful way to 
monitor disease progression in this group and in related motor and sensory neur(on)opathies. 
 
Long-term effects of riboflavin 
To date, 29 patients from 17 families have been reported with BVVL due to RFVT2 
deficiency.
140,142,143,172,173
 A poor prognosis may be expected, with 20% (6 patients) patients 
dying between the ages of three and 22 years, most commonly due to respiratory failure.  
Approximately half of the remaining patients required respiratory support and half had lost 
independent ambulation by the age of 21 years.  In the present study, riboflavin therapy 
stabilised or improved clinical, biochemical and neurophysiological parameters in subjects 
with BVVL, in contrast to the progressive neurodegeneration seen in untreated patients.  
 
Following a two year therapeutic course with high-dose riboflavin, there were improvements 
in total CMTPedS score, and the items of grip strength and long jump distance.  The youngest 
patients demonstrated significant improvement in their hearing and older patients showed 
stabilisation or improvement in their respiratory function, both aspects in which clinical 
deterioration was relatively recent and hence reversible. This is consistent with earlier reports 
of short-term (up to seven months) riboflavin therapy, where greater gains in gross motor 
functions were seen in younger patients.
142
  In contrast, clinical deficits related to underlying 
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neuronal death (sensory ataxia linked to dorsal root ganglionopathy) were irreversible. As 
expected, all patients received maximal scores for those components of the CMTPedS relying 
on large fibre sensory function (vibration, balance) and these did not change during the 
treatment trial. This places responsibility on the treating physician to recognise the early 
clinical features of BVVL (sensory ataxia and sensorineural hearing loss) and initiate 
riboflavin therapy as early as possible. There was sustained improvement in the biochemical 
parameters and no significant side effects were reported. Taken together, this suggests that 
outcome measures focusing on motor dysfunction and audiology tests monitoring change in 
hearing may be the most sensitive and relevant to include in future treatment trials. 
 
While this was a prospective study, its findings are to some extent limited by the small 
patient numbers and by the lack of historical data and of an untreated patient group. Most 
patients with a suggestive clinical phenotype are commenced on riboflavin prior to genetic 
confirmation, due to the lack of a sensitive biochemical test (the acylcarnitine profile is 
abnormal in only two-thirds of those affected) and difficulty in accessing genetic testing. It 
would also be unethical to have a trial with a placebo arm in this ultimately fatal rapidly 
progressive disorder while a low-cost treatment with no side-effects is available. While this 
study has shown that therapy with high-dose riboflavin is beneficial in BVVL due to RFVT2 
deficiency, a multicentre dose-escalating cohort study including recruiting children recently 
diagnosed and early in their disease course will be required to better delineate the benefits of 
riboflavin therapy. 
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SUMMARY 
The studies contained in this thesis have explored the neurophysiological characteristics of a 
broad group of childhood mitochondrial diseases, and specifically studied the clinical, 
neurophysiological, biochemical and histopathological profile, pathophysiology and response 
to disease-modifying therapy in affected children with Brown-Vialetto-Van Laere syndrome 
due to riboflavin transporter -type 2 (RFVT2) deficiency. These studies demonstrate the 
enormous progress made over the last three years in understanding this disorder, commencing 
with the identification of the causative gene mutations and extending onto the evaluation of a 
disease-modifying therapy. BVVL remains one of the few inherited neuropathies to have an 
effective treatment. 
 
Peripheral neuropathy in childhood mitochondrial disease 
Peripheral nerve involvement is seen in a number of childhood mitochondrial diseases but is 
often under-recognised due to the clinical prominence of the signs of central nervous system 
involvement. The study detailed in Chapter 1 investigated the neurophysiological features of 
the peripheral neuropathy associated with the common genetic childhood mitochondrial 
diseases and showed that the results of nerve conduction studies may help direct genetic 
testing.  
 
In those who were investigated as part of the study, a peripheral neuropathy was uncommon 
with mitochondrial genome mutations causing mitochondrial disease. In contrast, large-fibre 
peripheral nerve involvement was frequently identified in those with nuclear gene mutations 
affecting mitochondrial function. Of the nuclear genes associated with Leigh syndrome, 
SURF1 mutations were associated with a demyelinating neuropathy while PDHc deficiency 
was associated with an axonal sensorimotor neuropathy. Individuals with POLG mutations 
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had a generalised sensory axonal neuropathy with variable motor involvement. Overall, the 
neuropathy associated with mitochondrial disease was not length-dependent, in contrast to 
Charcot-Marie-Tooth disease, and clear progression with age or disease duration was not 
identified in this study.   
 
BVVL due to RFVT2 mutations 
In addition to studying this group of children with varying genetic causes of mitochondrial 
disease, studies also specifically evaluated a cohort of children with a clinical profile that 
closely resembled that seen with mitochondrial disease, and who had homozygous and 
compound heterozygous mutations in SLC52A2, a gene that encodes the transporter 
responsible for riboflavin transport in the nervous system. This very variable phenotype has 
been previously described as Brown-Vialetto-Van Laere syndrome (BVVL), and recently 
mutations in SLC52A2 and SLC52A3, encoding the riboflavin transporters RFVT2 and 
RFVT3 respectively, have been described in a subset of individuals with BVVL. Riboflavin 
is a precursor of FMN and FAD, important cofactors for oxidative phosphorylation and 
energy transport. FAD is also a cofactor for mitochondrial fatty acid β-oxidation and 
branched-chain amino acid catabolism. 
 
Examination of this cohort of children with BVVL due to RFVT2 deficiency revealed a 
unique and striking phenotype. These children were normal at birth and had normal newborn 
hearing tests. The most common presenting features were sensory ataxia and hearing loss, 
which often developed in early childhood. Weakness involving the proximal and distal 
muscles of the upper limbs was usually seen during the late first decade or early second 
decade of life and was rapidly progressive, while strength in the lower limbs was relatively 
preserved, resulting in the ‘child-in-the-barrel’ phenotype. Bulbar weakness and optic atrophy 
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were part of the phenotype and progressive respiratory weakness required assisted 
ventilation. There was wide variability in the rate of disease progression even within families. 
 
Evaluation of the audiological tests of this cohort of children revealed that the hearing loss 
was due to an auditory neuropathy spectrum disorder (ANSD) with the defect expected to be 
along the auditory pathway (involving the inner hair cells, cochlear nerve and brainstem 
cochlear nucleus). Automated brainstem responses were abnormal or absent with a present 
cochlear microphonic. Unlike the common forms of sensorineural hearing loss, otoacoustic 
emissions (also derived from outer hair cells like the cochlear microphonic) were usually 
present. Pure tone audiometry did not always correspond well with the severe impairment in 
speech perception. Hearing aids did not provide a benefit. Therapy with high-dose riboflavin 
resulted in improvement in hearing thresholds in those early in the disease course and with 
recent-onset hearing loss.  One child underwent cochlear implantation with a significant 
improvement in her speech perception.  
 
Nerve conduction studies showed that BVVL due to RFVT2 causes both a sensory 
ganglionopathy of early onset and a progressive motor axonal neuropathy affecting the upper 
limbs. There was a progressive decline in upper limb motor potential amplitudes in the early 
second decade of life, paralleling the rapidly progressive upper limb weakness. Examination 
of sural nerve biopsies shows a chronic axonal neuropathy without evidence of regeneration.  
 
The acylcarnitine profile was a useful but not sensitive marker of RFVT2 deficiency with 
only 60% of our cohort showing a characteristic elevation of medium-chain acylcarnitines. 
The urine metabolic screen, plasma flavin levels and acylcarnitine profiles on newborn 
screening cards were all normal. Both FMN and FAD are required for normal mitochondrial 
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respiratory chain function. While the other known riboflavin transporters, RFVT3 and 
RFVT1, are primarily involved in the intestinal absorption of riboflavin, RFVT2 is 
predominantly expressed in the brain. The SLC52A2 mutations identified in affected 
individuals either abolish or significantly diminish riboflavin uptake in an in vitro model.  
Overall, BVVL due to RFVT2 mutations had clinical (multisystemic disease with non-length 
dependent neuropathy, optic atrophy and auditory neuropathy), biochemical (defect in energy 
transport) and neuropathological defects that would classify it as a mitochondrial disease. 
While the metabolic abnormality caused by RFVT2 deficiency has been identified, the 
pathophysiology of neuronal dysfunction is not yet clearly understood and was hence 
explored using novel nerve excitability techniques. Abnormalities at baseline, prior to 
riboflavin therapy, included greater threshold change to depolarisation and hyperpolarisation 
with a ‘fanning out’ of the threshold electrotonus, reduction in refractoriness and an increase 
in superexcitability. Modeling on a mathematical model of a human motor axon suggested 
that the abnormality was due to an increase in the Barrett and Barrett conductance (GBB), 
due to an increase in myelin permeability at the paranode.  
 
Assessment on the CMT Pediatric scale (CMTPedS) at baseline showed differential motor 
and sensory involvement. There were poor scores on the subscales that measured sensation, 
irrespective of disease duration, consistent with the severe generalised sensory 
ganglionopathy. Scores on subscales that measured strength and motor performance revealed 
predominantly upper limb weakness consistent with the ‘child-in-the-barrel’ phenotype. 
Treatment with high-dose riboflavin for 12 months resulted in a partial normalisation of the 
axonal excitability findings. Following a 24 month therapeutic course with riboflavin, there 
were improvements in total CMTPedS score, specifically in the items of grip strength and 
long jump distance.  The youngest patients also demonstrated significant improvement in 
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their hearing and older patients showed stabilisation or improvement in their respiratory 
function, both being aspects in which clinical deterioration was relatively recent. In contrast, 
clinical deficits related to underlying neuronal death (sensory ataxia linked to dorsal root 
ganglionopathy) were irreversible.  
 
RECOMMENDATIONS ARISING FROM THIS THESIS  
 
 Nerve conduction tests should be an integral part of the initial evaluation of children 
with suspected mitochondrial disease. 
 
 It is essential that physicians and audiologists are made aware of the clinical 
phenotype of BVVL due to RFVT2 mutations so that appropriate therapy with high-
dose riboflavin can be commenced early in affected individuals. While elevation of 
medium-chain acylcarnitines on the acylcarnitine profile is a useful marker for the 
disorder, it is not a sensitive test, and genetic testing should be considered in those 
with a suggestive phenotype even if the acylcarnitine profile is normal. The disorder 
should be considered during the initial screening of those with a new-onset auditory 
neuropathy or those presenting with sensory ataxia. It is planned that the results 
detailed in thesis will be disseminated widely by publication in high impact peer-
reviewed journals and presentation at national and international paediatric neurology 
conferences. In addition to the Paediatric Neurology and Neurogenetics departments, I 
have also discussed these findings with our hospital  audiology staff and Hearing Loss 
Clinic staff so that affected children may be identified and treated early. 
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 There should be a low threshold for genetic testing for riboflavin transporter 
deficiency and commencing riboflavin. The rapid progress in next-generation 
sequencing technology has made genetic testing cheaper and more accessible. 
Previously available only at research laboratories, sequencing of the riboflavin 
transporter genes SLC52A1, -A2, -A3 is now available on a number of diagnostic 
multi-gene metabolic and neuromuscular panels, including the latest version of the 
Neuromuscular (NM) Gene Panel at PathWest in Western Australia. Sequencing for 
the SLC52A2 p.G306R mutation, a founder mutation in those of Lebanese heritage, is 
also available through the Molecular Genetics Department at The Children’s Hospital 
at Westmead. It is my practice to sequence affected children of Lebanese ethnicity for 
this mutation before referring for a multi-gene panel or whole exome sequencing. A 
list of international laboratories offering sequencing of SLC52A2 is available at 
www.genetests.org (accessed 1
st
 October 2015). In those with suspected BVVL, 
consideration should also be given to commencing riboflavin prior to the availability 
of genetic testing results, especially if sequencing is expected to take time. 
 
 In addition to therapy with riboflavin, cochlear implantation should be considered 
early in affected children with ANSD and impaired speech perception. 
 
 Prior to commencing riboflavin, affected individuals should have a detailed clinical 
examination including accurate strength and sensory assessments, hearing assessment 
including an ABR, ophthalmology review, respiratory function testing, nerve 
conduction tests and evaluation on the CMTPedS scale. The CMTPedS scale is 
sensitive to the baseline deficits in motor and sensory modalities and is a useful tool 
in measuring the response to riboflavin. Nerve excitability studies hold promise as an 
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effective outcome measure in research studies involving affected children with 
riboflavin transporter mutations, as well as other anterior horn cell disorders. 
 
 
FUTURE DIRECTIONS 
The initial presentation of children with riboflavin transporter mutations is with hearing loss 
or sensory ataxia and hence likely to be to a hearing clinic or paediatric neurologist. The 
initial assessment of children with a new-onset ANSD does not currently include an 
acylcarnitine profile. Though the disorder is rare, it is one of the few treatable causes of an 
ANSD. In addition, the audiological management of children diagnosed with RFVT2 
deficiency is likely to change, with those whose speech perception does not respond 
adequately to riboflavin therapy being considered early for cochlear implantation. It is 
therefore necessary to determine if testing of all children with a new-onset ANSD using an 
acylcarnitine profile is a useful way of identifying those very early in the disease course. This 
will also determine if RFVT2 deficiency can present with infantile or even congenital hearing 
loss. A prospective evaluation of acylcarnitine profiles in all children diagnosed with ANSD, 
including those with congenital hearing loss, will provide an answer to these questions.   
 
While the benefits of riboflavin therapy are evident, the optimal dose of riboflavin therapy 
has not yet been determined. Initial doses were extrapolated from trials of riboflavin in 
migraine (up to 400mg/day), but as shown in my study, doses of 1600mg/day are safe and 
effective. Because of the progressive nature of BVVL due to RFVT2 deficiency and its poor 
ultimate outcome, it will not be possible to perform a randomised trial with a placebo arm to 
accurately determine the benefits of riboflavin therapy or optimum dose. Patient numbers at 
individual centres are likely to be small and an international randomised dose-escalation 
study remains the best way to identify the optimum dose of riboflavin in this disorder. 
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While progress has been made in understanding the biochemical and pathophysiological basis 
of BVVL due to riboflavin transporter mutations, including through the use of nerve 
excitability studies as reported in Chapter 4, the process through which riboflavin affects 
myelin permeability remains unexplored. Efforts to develop an animal model of this disease 
(in mice) are ongoing in a number of international centres and offer the best hope of further 
insights into the pathophysiology of BVVL. Understanding the pathophysiology of motor 
nerve dysfunction in BVVL would also enhance our understanding of the process of 
neurodegeneration in other inherited and metabolic neuronopathies. 
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PARENT INFORMATION SHEET 
 
 
 
 
The peripheral neuropathy in children with mitochondrial disease study 
 
Investigators: 
Dr Manoj Menezes, Paediatric Neurologist, The Institute for Neuroscience and Muscle Research 
Tel: (02) 9845 2652,  
Prof. John Christodoulou, Director, Western Sydney Genetics Program 
Tel: (02) 9845 3452 
 
We would like you to consider your child participating in a research study that will be conducted in The 
Institute for Neuroscience and Muscle Research at The Children’s Hospital at Westmead. 
 
What is the study about? 
The study investigates if the nerves that carry sensation and impulses to muscles are affected in different 
mitochondrial diseases.  The goal of this research is to improve diagnosis of children with mitochondrial 
disorders. The study is being conducted by investigators at The Institute for Neuroscience and Muscle 
Research (based at The Children’s Hospital at Westmead) in collaboration with the Western Sydney 
Genetics Program and The Children’s Hospital at Westmead Metabolic Clinic. You are invited to contribute 
your child’s personal details and medical history to the project, and enrol your child for a one-off medical 
examination and nerve conduction study. 
 
Who can participate in the study? 
Any child less than 18 years of age, who has been diagnosed with a mitochondrial disease, either on the 
basis of a positive genetic test, or after respiratory chain enzyme testing on a skin, muscle or liver biopsy, is 
eligible to participate in the study. 
 
Why should we look at peripheral nerve involvement in mitochondrial disease? 
While peripheral nerve involvement (neuropathy) is common in mitochondrial disease, the frequency with 
which it occurs in children in different mitochondrial diseases and the clinical features and nerve conduction 
findings of these mitochondrial diseases has not been well understood.  
 
Mitochondrial diseases are often difficult to diagnose. Similar clinical characteristics may be shared by 
different mitochondrial diseases, and reaching a diagnosis usually requires skin, muscle or liver biopsies. 
This study attempts to find out if the presence of a neuropathy and the characteristics of the neuropathy on 
nerve conduction studies differ among the different mitochondrial diseases, and if this information helps 
with identifying the mitochondrial disease and the underlying genetic abnormality without the need for 
invasive biopsies. Occasionally, children with mitochondrial disease may have difficulties because of the 
associated neuropathy, and this may manifest as weakness, abnormalities with sensation or difficulty with 
walking. In these cases, the identification of a neuropathy will help early rehabilitation. 
 
What does participating in the study involve? 
Your child was chosen to participate in this study as the records of the Metabolic Clinic identified him/her as 
having a mitochondrial disease. The study includes a medical assessment (looking for evidence of a 
neuropathy) and nerve conduction study that will usually be scheduled on a day you are visiting The 
Children’s Hospital at Westmead either for a clinic visit or to have another test done. One of the 
investigators will meet with you to talk to you about the study and answer any questions you may have. 
 
Corner Hawkesbury Road 
and Hainsworth Street 
 
Locked Bag 4001 
Westmead NSW 2145 
Sydney Australia  
 
DX 8213 Parramatta 
 
Tel +61 2 9845 0000 
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The investigator will ask you some personal details about your child, such as name, date of birth, address 
and diagnosis. The investigators require these details to access information from your child’s medical 
record and so that the report from the study is stored under the appropriate name. During the nerve 
conduction tests, small electrode dots are placed on the skin of an arm or a leg and a small electrical 
impulse is given by a probe over the skin. The doctor may also occasionally need to test a muscle by gently 
inserting a small needle (like an acupuncture needle) into the muscle.  
 
As some children find the nerve conduction study uncomfortable, they can be performed under sedation 
with nitrous oxide in children above one year of age. This pack contains separate leaflets that explain the 
nerve conduction study and nitrous oxide sedation. Both the medical assessment and the nerve conduction 
study will together take around 45 minutes. The study requires only a single visit and no further follow-up or 
repeat nerve conductions are required. The results of your child’s nerve conduction study will be sent to 
your child’s doctor at the Metabolic Clinic.  
 
The investigators thank you and your child for participating in this study. We expect 30 children to take part 
in this study. There is no external funding for the study and no payments or reimbursements will be made to 
participants. 
 
Are there any benefits for my child from participating in the study? 
We hope that information gained from the study will improve our knowledge about peripheral nerve 
involvement in mitochondrial disease, and help to improve our ability to diagnose mitochondrial disease 
and characterise the associated neuropathy. For some children, the early recognition of the neuropathy 
could help with early rehabilitation. In the short term however, there may be no direct benefit to you or your 
child from participating in the study. 
 
Are there any side-effects associated with the study? 
The nerve conduction study may be uncomfortable, and children over one year of age can be given nitrous 
oxide gas (laughing gas) through a mask to relax during the test. The needle, used occasionally during the 
nerve conduction test, may cause some bruising. There are no other risks from being involved in this study. 
 
Is the information collected during the study secure and confidential? 
To ensure that all information about your child is kept strictly confidential, access to the information 
collected as part of the study will only be available to the investigators of this project. Investigators will have 
a security password that will allow them to enter and access data. Data from the study will be stored for 15 
years after the completion of the study and will then be destroyed by shredding of paper documents and 
permanently erasing all computer files.  The information collected during this study could be used in reports 
or papers about the research. Your child will not be able to be identified in these reports or papers. The 
information collected during this study may be used in further ethics-committee approved studies. 
 
Other information 
Participation in this project is entirely voluntary and if you decide not to take part or decide to withdraw at 
any time this will not otherwise affect your child’s care at the Hospital.  
 
This copy of the Information Sheet is for you to keep. We will also give you a copy of the signed consent 
form. 
 
For questions about the study please call Dr Manoj Menezes at 02 9845 2652. This project has been 
approved by The Sydney Children’s Hospital Network Human Research Ethics Committee.  If you 
have any concerns about the conduct of this study, please do not hesitate to contact the Secretary 
of the Ethics Committee (02 9845 3017) and quote the approval code 12/SCHN/195. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
PARENT/GUARDIAN CONSENT FORM 
 
 
 
 
 
The peripheral neuropathy in children with mitochondrial disease 
study 
 
 
Investigators: 
Dr Manoj Menezes, The Institute for Neuroscience and Muscle Research, Tel: (02) 9845 2652,  
Prof. John Christodoulou, Western Sydney Genetics Program, Tel: (02) 9845 3452 
 
I have read and understood the Parent Information Sheet, the Nerve Conduction Study Fact Sheet and the 
Nitrous Oxide Fact Sheet, and give my consent for my child to participate in this research study, which has 
been explained to me by 
__________________________________________________________________________ 
 
 
 
I consent for the information about my child, collected during this study, to be used in further ethics-
committee approved research (Please tick appropriate box).         Yes                   No  
 
 
 
I understand that I am free to withdraw from the study at any time and this decision will not otherwise affect 
my child’s treatment at the Hospital. 
 
 
NAME OF CHILD: _________________________________________________ (Please print) 
 
 
NAME OF PARENT OR GUARDIAN: __________________________________ (Please print) 
 
 
SIGNATURE OF PARENT OR GUARDIAN: ____________________________ Date: _______ 
 
 
NAME OF WITNESS*: ______________________________________________ (Please print) 
 
 
SIGNATURE OF WITNESS*: ________________________________________ Date: _______ 
 
 
NAME OF INTERPRETER: _________________________________________ (Please print) 
 
 
SIGNATURE OF INTERPRETER: ____________________________________ Date: _______  
     
*Use when participant has had this consent form read to them (i.e., illiterate, legally blind, translated into 
foreign language). 
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ADOLESCENT INFORMATION FORM (Age 13-18 yrs) 
 
 
 
 
The peripheral neuropathy in children with mitochondrial disease study 
 
Investigators: 
Dr Manoj Menezes, Paediatric Neurologist, The Institute for Neuroscience and Muscle Research 
Tel: (02) 9845 2652,  
Prof. John Christodoulou, Director, Western Sydney Genetics Program 
Tel: (02) 9845 3452 
 
Why am I here?   
This is a research study. Only people who choose to take part are included in research studies. You are 
being asked to take part in this study because you have a mitochondrial disease. Please take time to read 
this form and understand what the study involves. Talk to your family about it and be sure to ask questions 
about anything you don’t understand. We expect that 30 children will take part in this study. 
 
Why are they doing this study? 
This study is being done to find out if the nerves that carry messages to muscles, and help one feel, are 
involved in mitochondrial disease. This may help us with reaching a diagnosis in other children with 
mitochondrial disease and start therapy earlier for children whose nerves are affected. 
 
What will I have to do if I take part? 
There will be two parts to your visit that will together take around 45 minutes to complete. The doctor will 
test your strength, walking ability and sensation. You will then have a nerve conduction test, where the 
small electrode dots are placed on the skin of an arm or a leg and a small electrical impulse is given by a 
probe over the skin. The doctor may also occasionally need to test a muscle by gently inserting a small 
needle (like an acupuncture needle) into the muscle. Some children feel these tests are uncomfortable, and 
we can give you some nitrous oxide or ‘laughing gas’ through a mask to help with the uncomfortable 
sensation, if this is what you would like us to do. You will need to have fasted, i.e. have had nothing to eat 
and drink, for 2 hours before having the nitrous oxide. There are no long term side effects from having the 
nerve conduction test or nitrous oxide. This test will only be performed once and no more involvement will 
be needed. 
 
Will the study help me? 
We cannot promise you that being in this research study will help you. The nerve conduction test will help 
identify if there is any nerve involvement as a part of your mitochondrial disease and this information will be 
sent to your doctor. Information from this study may help other people with similar health issues now or in 
the future. 
 
Do I have to take part in the research? 
No you don’t. You don’t have to be in this study if you don’t want to. Please discuss your decision with your 
parents and doctor. No one will be angry if you decide to stop being in the study. You will still be treated for 
your mitochondrial disease. 
 
 
Do my parents or guardians know about this?  
This study was explained to your parents/guardian and they said that you could be in it. You can talk this 
over with them. 
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What will happen to the information collected? 
The information you tell us and collected from the nerve conduction test will only be used by the 
investigators to help us reach a diagnosis in other children with mitochondrial disease and start therapy for 
children whose nerves are affected. No-one else will be allowed to use this information. The information 
could be used with information from other young people in reports or papers about the research. You will 
not be able to be identified in these reports or papers.  
 
The information you tell us will be stored securely in locked cupboards, or in password-protected computer 
files, at The Children’s Hospital at Westmead. It will be stored for 15 years and then destroyed. 
 
This sheet is for you to keep. 
 
For questions about the study please call Dr Manoj Menezes at 02 9845 2652. This project has been 
approved by The Sydney Children’s Hospital Network Human Research Ethics Committee.  If you 
have any concerns about the conduct of this study, please do not hesitate to contact the Secretary 
of the Ethics Committee (02 9845 3017) and quote the approval code 12/SCHN/195. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
